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Infectious and inflammatory diseases are a heterogeneous class of diseases that may be 
classified into infection, acute inflammation and chronic inflammation. They can affect 
multiple organs (systemic) or can be localized in one specific organ. Inflammatory diseases 
often relapse, invalidate and may require life-long treatment.
Clinicians often struggle with questions in patients dealing with presumed or established 
infectious or inflammatory disorders. The main questions of the clinicians are: Is there an 
infectious focus or an inflammatory sign? What is the size and the extent of the lesion? Is this 
the only lesion in the body or are there infectious metastases? When can I stop the treatment 
or should I continue?
From the clinical point of view, it is important to distinguish between an infection and sterile 
inflammation. If this is possible, it may lead to major changes in the treatment of patients. 
Nowadays, the goal is to distinguish the different phases of infection and to identify the type 
of inflammation, and the immune cells and mediators involved. 
Radiological imaging techniques—such as ultrasound, computed tomography (CT) and magnetic 
resonance imaging (MRI)—have, with the exception of functional MRI, in general high sensitivity 
but lack in specificity. Nuclear medicine techniques, in contrast, allow the in vivo detection of 
different physiological and pathological phenomena in humans. These noninvasive tools allow 
early detection of pathophysiological changes, i.e. before conventional radiological techniques 
show anatomical changes. Also, nuclear medicine techniques may detect changes even before 
the onset of disease symptoms. In the clinical setting, it is important to diagnose at an early 
stage occult infections and inflammatory diseases. Moreover, nuclear medicine offers a way to 
evaluate disease activity and efficacy of therapy, and has a role in monitoring relapse of disease. 
The progress in our understanding and knowledge of the pathophysiology of inflammatory 
diseases has led to the development of several new and specific radiopharmaceuticals, which 
can be used to answer most of the afore mentioned questions of clinicians.
In this introductory chapter, the pathophysiology of infection and acute inflammation will be 
discussed, followed by an overview of all existing radiopharmaceuticals in this field. After that, 
the focus will be on the features of chronic inflammation and the possible radiopharmaceuticals 
to image the different targets in these diseases.
Too many radiopharmaceuticals are presently available to describe them all in this thesis. 
Furthermore, they are all described in the papers mentioned on page 13. Therefore, only the 
working mechanisms and indications of the most commonly used tracers for the imaging of 
infectious and inflammatory diseases will be explained: labelled autologous white blood cells 
(WBC), labelled antigranulocyte monoclonal antibodies, 18F-fluorodeoxyglucose (18F-FDG), and 
99mTc-labelled Interleukin-2. This will be followed by an overview of the existing guidelines 








THE PATHOPHYSIOLOGY OF INFECTION AND ACUTE INFLAMMATION
First of all, inflammation is not synonymous with infection. An infection is caused by an 
exogenous pathogen, while inflammation is the response of the organism to the pathogen or 
tissue injury. Infection is often accompanied by an acute inflammation that may last for hours 
or days and is usually resolved without residual lesions; chronic inflammation can last from a 
few weeks to many years and usually causes late complications. There are several clinical and 
histopathological differences between infection/ acute inflammation and chronic inflammation 
that are mainly determined by the cause of the inflammation and its duration. We will now focus 
on the pathophysiology of infection and acute inflammation, the diseases characterized by acute 
inflammation and the radiopharmaceuticals for imaging infections. 
An infection starts with colonization of tissue or organs by pathogenic exogenous noxae. In 
many cases, microorganisms (bacteria, viruses, fungi, etc.) are considered to be the cause of 
an infection. Tissues (or organs) react to the injuries caused by the noxae with a response, in 
a way that is independent of the possible cause. This associated phenomenon is called acute 
inflammation. The presence of non-self antigens or tissue degradation products activates 
mechanisms, such as the release of histamine and serotonin, increase of vascular permeability, 
hyperexpression of adhesion molecules on endothelial cells and secretion of chemotactic 
factors. All of these phenomena induce leukocyte rolling along the endothelium and migration 
of these leukocytes through the capillary wall. Complement and antibody production together 
with the release of mediators amplify the local response by the continuous recruitment of 
cells from the peripheral blood, such as granulocytes, lymphocytes, monocytes, as well as 
several plasma proteins. The inflammation persists until elimination of the pathogenic noxae. 
Imaging targets in infection and acute inflammation are (1) the pathogens (bacteria, fungi), (2) 
the activated endothelial cells and the involved cytokines and mediators in this process, (3) the 
macromolecules that accumulate in inflamed tissues due to the increased vascular permeability 
and, (4) of course, the polymorphonuclear cells (leukocytes, granulocytes) that migrate to the 
injured tissue. Table 1 lists the diseases that are characterized by acute inflammation and Table 2 
summarizes the available radiopharmaceuticals for imaging infections and acute inflammation. 
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Imaging endothelial cell activation
99mTc-anti-E-selectin
111In-intercellular adhesion molecule-1 (ICAM-1)





Imaging infiltration of polymorphonuclear cells






Labelled monoclonal antibodies (MoAb)
99mTc-antigranulocyte IgG1 murine antibody
     BW250/183 (Besilesomab, Scintimun®)
99mTc-anti-stage specific embryonic antigen-1 murine
     antibody (anti-SSEA-1) (fanolesomab, LeuTech®)
99mTc-anti NCA-90 murine antibody Fab’fragment 
     (sulesomab, Leukoscan®)
   
Others             
18F-Fluorodeoxyglucose (FDG)
123I-Interleukin-1 receptor antagonist (IL1ra)
99mTc-Interleukin-8 (IL8)
99mTc-P483H (against platelet factor 4)
99mTc-EP1-HNE2 (neutrophil elastase inhibitor)
Other available radiopharmaceuticals
67-68Ga-citrate







































THE PATHOPHYSIOLOGY OF CHRONIC INFLAMMATION
After the phase of infection and acute inflammation, some diseases are characterized by 
apoptosis, a regulatory mechanism that is characterized by a programmed cell death. Some 
molecules, such as annexin-V are able to bind apoptotic cells and therefore can be considered 
for imaging purposes.
If the pathogenic noxae persist, a chronic type of inflammation arises. Two main types of 
chronic inflammation can be recognized: primary and secondary chronic inflammation. 
Primary chronic inflammation 
In this type of chronic inflammation, from the onset on a distinctive chronic reaction is 
observed with little increased vascularity and permeability and little or no neutrophil 
infiltration. This is usually observed in cell-mediated immune responses against cells of the 
body that become the target of the immune system. This immune response follows after 
infection from intracellular micro-organisms or viruses, after generation of autoimmunity and 
after cancer or transplantation. Autoimmune diseases can give rise to different histological 
characteristics ranging from a typical lymphocytic infiltration, as in thyroiditis, to a mixed cell 
population of T and B cells, plasma cells and neutrophils, as in rheumatoid arthritis. Tumors 
also show infiltration by lympho/mononuclear cells, and in graft rejection a typical infiltration 
by cytotoxic lymphocytes is observed. Imaging targets in this phase are T and B lymphocytes, 
as well as monocytes/macrophages and apoptotic cells.
Secondary chronic inflammation 
This type is due to the persistence of the stimulus that caused the acute inflammation. If 
an inflammatory agent persists, the character of the inflammatory lesion changes into 
chronic inflammation. Polymorphonuclear cells migrate out of the lesion; vasodilatation, 
vascular permeability and endothelial activation tend to normalize. The infiltration becomes 
predominantly mononuclear, consisting of lymphocytes and cells of the monocyte-macrophage 
series, and further progression of the process is mainly via proliferation of these infiltrating 
cells. Examples of this type of inflammation are chronic infections such as tuberculosis, leading 
to the formation of chronic granulomas, sarcoidosis and contact dermatitis. Imaging targets in 
this phase are predominantly T lymphocytes and monocytes. 
Table 3 lists the diseases that are characterized by chronic inflammation and Table 4 presents 
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Table 3 Diseases characterized by chronic 
inflammation
Atherosclerosis
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MOST COMMONLY USED RADIOPHARMACEUTICALS FOR INFECTION AND 
INFLAMMATION IMAGING
LABELLED AUTOLOGOUS WHITE BLOOD CELLS
Radiolabelled WBC are still considered the gold standard imaging technique in nuclear medicine 
to diagnose infections. Several methods for the labelling and imaging of granulocytes exist. 
The rationale, advantages and limitations of these methods will now be discussed.
Labelling autologous white blood cells ex vivo with 99mTc or 111In
Imaging using ex vivo labeled autologous leukocytes has already been developed in the 
1970s. A blood sample of approximately 50 ml is collected and leukocytes are separated in 
vitro from red blood cells. These leukocytes are then labeled with either 99mTc-exametazine/ 
hexamethylpropyleneamine oxime (HMPAO) or 111In-oxine and reinjected. Using the standard 
labeling procedures, only a few granulocytes are damaged by labeling, whereas most 
lymphocytes are damaged. The damaged cells are rapidly cleared from the circulation after 
reinjection or accumulate in the lungs (1). 
Autologous leukocytes are characterized by high specificity, because they only accumulate as 
a consequence of active migration into inflamed tissues (2, 3). After intravenous reinjection, 
radiolabelled WBCs show rapid clearance from the lungs and blood pool, with progressive 
migration into the spleen, liver, bone marrow and in sites of infection where a neutrophilic 
infiltrate predominates. Radiolabelled WBCs first adhere to the vascular endothelium and 
then migrate towards the infected area through the endothelium and basal membrane. Thus, 
radiolabelled WBCs are a specific indicator for leukocytic infiltration (4). 
99mTc-labeled leukocytes have replaced 111In-labeled leukocytes for most indications, because 
of the more optimal radiation characteristics and the cheaper generator-based production. 
111In has a long half-life of 67 h and radiation energy of 173 and 247 keV that increases the 
radiation burden, whereas 99mTc has a short half-life of 6 h and ideal gamma-radiation energy 
of 140 keV. However, a major advantage of 111In-leukocytes is that there is no major kidney, 
bladder or bowel excretion. In contrast, 99mTc-exametazine is released from the leukocytes, 
which starts within a few minutes after administration, and is excreted by kidneys up to 7% 
of the label per hour, but mainly by the liver and gut, thus disturbing the imaging of the 
abdomen after 3 h. Therefore, the use of 111In-leukocytes is preferred for evaluation of the 
kidneys, bladder, gall bladder and intestines. 
With regard to diagnostic accuracy, there is no need for a better imaging agent than 
radiolabelled leukocytes. However, the preparation of this radiopharmaceutical is laborious 
and must be performed in sterile conditions, involving a complicated and time-consuming 
procedure, which takes a trained technician approximately 3 h. In addition, the need to handle 
potentially contaminated blood can result in hazards to technicians and patients.
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Acquisition modes and image interpretation criteria
For image acquisition, a large-field-of-view gamma camera with a low-energy high-resolution 
collimator is usually preferred (140 keV using a 15–20% energy window). When 99mTc-labeled 
WBCs are used, early imaging of lungs for quality control is essential as well as of pelvis 
and abdomen, because normal bowel activity is seen in 20–30% of children at 1 h and in 
2–6% of adults at 3–4 h after injection. Lung images at 30 min are therefore suggested and 
whole-body images at 3-4 and 20-24 h are compulsory. In case of abdominal infections and 
inflammatory bowel diseases, images can only be acquired 30 min and 3 h after injection of 
99mTc-HMPAO-labelled WBC because 99mTc-HMPAO is released by WBC with time, taken up by 
the liver and excreted through the bowel, thus producing false-positive images at later time 
points. Images of the regions of interest must be obtained for at least 800,000 counts/large 
field of view or at 5–10 min/view. 
As evaluated in Chapter 2 and 3 of this thesis, a better acquisition protocol is to correct images 
for isotope decay and look at the images using the same count intensity. This method reduces 
operator interference in final image interpretation, and an objective increase in activity or size 
with time in infected sites can easily be identified, thereby increasing the diagnostic accuracy. 
This approach makes quantitative analysis also more accurate (5, 6).
 A limited study to evaluate a specific region of the body is acceptable in selected cases. SPECT 
or SPECT/CT images are mandatory in selected indications (e.g., endocarditis). Usually, SPECT 
or SPECT/CT scans at 3-4 h are acquired with a 15–20 s/step protocol with 64 x 64 matrix, and 
with a 30–40 s/step protocol at 20-24 h. 
Accumulation of labeled WBC in infection sites is a dynamic process (Figure 1). Accurate 
interpretation of labeled WBC scintigraphy requires knowledge of the normal (blood and bone 
marrow) and abnormal variants of WBC localizations. The diagnosis of infection is made by 
comparing early and delayed images. The images are classified as (a) negative if no uptake 
or a significant decrease in uptake from early to delayed images is present, (b) positive when 
uptake is seen in both early and delayed images and increases with time, and (c) equivocal 
when the uptake in early and delayed images is the same or slightly decreases. 
After visual assessment, semi-quantitative evaluation may also be performed to help 
differentiating between infection and non-specific uptake. Regions of interest (ROIs) are drawn 
over the hottest region and copied to presumed normal reference tissue. As we investigated 
in Chapter 2 of this thesis, the reference tissue best used is the contralateral side, except 
for osteomyelitis and infected osteosynthesis. For these indications, the contralateral bone 
marrow should be used as reference tissue (5). The mean counts per pixel in these ROIs are 
recorded to calculate lesion-to-reference (L/R) ratios both in early and delayed images. When 
the L/R ratio increases with time, the scan is considered positive for infection; when the L/R 
ratio is similar or decreases slightly with time, the examination is classified as negative for 
infection. If SPECT/CT images are used, the delineation of the site of increased uptake may 
be calculated by a 50% isocontour on a single transaxial slice with the hottest activity and 







Clinical indications for the use of radiolabelled autologous white blood cells
As stated earlier, radiolabelled WBC are still considered the ‘‘gold standard’’ method for 
imaging infections in nuclear medicine. The principal clinical indications include inflammatory 
bowel diseases, osteomyelitis, infected vascular and orthopedic prostheses, and soft tissue 
infections (7-9). In fever of unknown origin (FUO), years ago, high sensitivity and specificity 
values were reported for this technique. However, recently 18F-FDG-PET has emerged as a 
valuable tool that is helpful for diagnosis, especially when CT anatomical landmarks are added 
to PET findings (10). For the time being, the probability of infection remains the most useful 
criterion for chosing between FDG-PET/CT and radiolabelled WBC. In the presence of low and 
medium probability, FDG is the more indicated technique, whereas radiolabelled WBC imaging 
should be performed when the probability of infection is high (increased leukocyte count 
and/or an elevated erythrocyte sedimentation rate and C-reactive protein level) (11). 
High sensitivity and specificity values were reported for radiolabelled WBC scintigraphy with 
99mTc-exametazine for the assessment of activity in inflammatory bowel diseases (Crohn’s 
disease and ulcerative colitis). Some discussion has been raised about the best imaging time. 
Overall tendency is a high accuracy if imaging is performed within 3 h. Moreover, scanning 
after 1 and 3 h may be helpful as the pathologic accumulation in actively inflamed segments 
becomes more pronounced over time. On the other hand, false-positive findings may occur 
after 3 h, due to excretion of 99mTc-exametazine into the bowel. Leukocytes labeled with 111In-
oxine also have been used for inflammatory bowel diseases and shown to be suitable for the 
assessment of the presence and location of active inflammation (12). 
For acute osteomyelitis, radiolabelled WBC imaging is highly reliable with an overall accuracy of 
approximately 90% (13), see Figure 2. However, the performance of radiolabelled leukocytes 
is poor in spondylitis and spondylodiscitis: up to 50% of all patients with spondylodiscitis show 
photopenic lesions due to encapsulation of the infection and therefore relatively hampered 
migration of leukocytes (14). For this indication, 18F-FDG should be used. 
The role of radiolabelled leukocytes in diabetic foot infection has been extensively investigated, 
with reported sensitivities ranging from 72 to 100% and specificities ranging from 67 to 
100%. With this approach, poor spatial resolution and lack of bony landmarks make the 
differentiation of soft tissue from bone infection difficult; therefore, much better results are 
achieved using SPECT/CT (13). As shown in Chapter 4 of this thesis, diagnostic accuracy of WBC 
imaging in the diabetic foot was found to be higher than that of 18F-FDG-PET imaging (15).
Radiolabelled leukocyte imaging is currently the radionuclide imaging procedure of choice 
for diagnosing prosthetic joint infections, on account of its almost 90% accuracy (16, 17). 
Radiolabelled leukocytes also play an important role in various vascular diseases. Several 
studies have demonstrated the use of this technique for the detection of infectious endocarditis 
(18,19). High sensitivity (82–100%) and specificity (75–100%) rates also were reported for 
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Figure 1 The accumulation of labelled WBC in infection sites is a dynamic process
Figure 2 
Two examples of WBC scintigraphy. A, B delayed and late images of an osteomyelitis of the tibia. Increase in 
intensity and size with time, thereby indication positivity for an infection. C, D delayed and late image of an 
infection after placement of a left knee prosthesis. Diffuse increase in intensity and size around the prosthesis 








Labelling autologous white blood cells ex vivo with 18F-FDG 
WBC have also been labeled in vitro with 18F-FDG in an attempt to develop a more specific 
positron emitting tracer. Whole-body and organ dosimetry are comparable with the results 
for conventional doses of 111In-oxine-labeled leukocytes (20). The results of initial clinical 
investigations were encouraging. However, there are several disadvantages to this procedure. 
The labeling efficiency of FDG-labeled leukocytes is significantly less than that for 99mTc or 
111In, there is significant efflux of FDG from the labelled cells, and there is evidence that blood 
glucose levels and metabolic status of the cells affect the labelling efficiency of leukocytes 
using FDG (21). Moreover, the short half-life of 18F (110 min) means that it is technically not 
feasible to perform imaging much later than 4–5 h after injection. Consequently, because of 
the low labelling efficiency and the short half-life, the labelling process must be started using 
two or three times the amount of radioactivity (17). Furthermore, in most clinical situations, 
and certainly in e.g. prosthetic joint infections, imaging at late time points (24 h post injection) 
is mandatory because of the slow leukocyte accumulation in infected sites as compared to 
bone marrow. This delay between injection and imaging is not possible using 18F as radiolabel. 
LABELLED ANTI-GRANULOCYTE MONOCLONAL ANTIBODIES
Considerable effort has been devoted to develop in vivo methods for leukocyte labelling that 
could eliminate the limitations of in vitro labelled leukocytes and that could increase sensitivity 
and specificity. Most efforts have been made in investigating monoclonal antibodies (MoAbs) 
against specific surface receptors that are expressed in activated granulocytes during the 
infectious or inflammatory process. The use of these radiolabelled MoAbs has the advantage 
that it is easier, compared to the use of radiolabelled autologous white blood cells and 
does not need the handling of potentially hazardous biological specimens. Disadvantages, 
however, are their high molecular weight (resulting in slow diffusion into sites of infection), 
a long plasma half-life, low target concentration in the affected site and high uptake in the 
liver and bone marrow, due to clearance by the reticulo-endothelial system. A long interval 
is therefore required between the administration of labelled MoAbs and the acquisition of 
images in order to have a good target-to-background ratio (6-24 h). Furthermore, only a minor 
percentage of the injected antibody really binds directly to the cells. Most of it will concentrate 
in the inflamed areas, due to non-specific leakage as a result of increased permeability – 
independently of whether there is an infection or just a sterile inflammation. 
The use of antibody fragments (Fab’) of human antibodies could overcome the limitations 
of complete antibodies; theoretically, immunogenicity is lower, blood clearance is faster 
and penetration in infected areas is higher. However, the theoretical advantage of a higher 
accumulation in infected areas is also considered a limitation because of the high non-specific 
leakage in sterile but inflamed tissues as in loosening of prostheses. 
Radiolabelled MoAbs or their fragments are always injected in a tracer (non-pharmacological) 
dose for scintigraphic imaging, which rarely induces any clinical or side effects in patients. 
One of the side effects that has been described in some cases of repeated murine MoAb 
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foreign antibodies. If MoAbs are injected in patients with HAMA, their distribution may be 
affected, as well as image quality and clinical relevance of images. 
The commercially available 99mTc-labelled anti-granulocyte IgG1 murine antibody BW 250/183 
(Besilesomab, Scintimun®, molecular weight 150 kDa) binds to the cross-reacting antigen 
95 (NCA-95), expressed on human granulocytes. This antigen is non-specific, because it is 
also expressed on the epithelium of the lung, in the colon and on macrophages (22,23). 
The possibility of inducing HAMA, particularly in patients receiving repeated injections, is a 
limitation of the use of this radiopharmaceutical in follow-up studies (24). 
Another murine MoAb, anti-stage specific embryogen antigen-1 (Anti-SSEA-1, molecular 
weight 900 kDa), called 99mTc-fanolesomab (LeuTech®), binds with high affinity to the CD15 
antigen expressed on neutrophils, eosinophils and lymphocytes. The antibody binds to 
neutrophils in larger proportions than to any other cell type (25). It can be used at a low 
dose, thereby not inducing HAMA. The in vivo binding on polymorphonuclear cells exceeds 
50 %, suggesting involvement of more specific accumulation in infected sites, such as in vivo 
migration of leukocytes from the circulation to the focus (26). In 2005 it was withdrawn from 
the market because of reports of serious and life-threatening cardiopulmonary events; the 
precise explanation of these events has yet to be elucidated (21). 
99mTc-sulesomab (LeukoScan®) is a murine IgG1 antibody Fab’ fragment (molecular weight 90 
kDa) that binds to NCA-90 on granulocytes. It does not induce HAMA response and extravasates 
into infected sites non-specifically by increased vascular permeability. Nevertheless, it may be 
accumulating after local binding to primed granulocytes or binding to activated migrated 
extravascular granulocytes (27).
Image interpretation criteria
The uptake mechanism of radiolabelled MoAbs is probably twofold: migration of targeted 
cells to the infectious focus due to chemotaxis, but also non-specific uptake of free antibody 
due to an increased capillary permeability at the infectious focus, with subsequent binding to 
granulocytes (27). About 10 % of the injected activity is bound to the granulocytes at 45 min 
after injection, and 20 % of the activity is circulating freely in the blood. 
NCA-95, the antigen to which Scintimun® is directed, is found on granulocytes and mature 
bone marrow cells of the granulocytic lineage. These cells are present in major amounts in 
infectious lesions, but are also found in the hematopoietic bone marrow. The typical uptake 
patterns of anti-granulocyte MoAbs, therefore, includes focal uptake at sites of infection as 
well as staining of the hematopoietic bone marrow (28). 
The same concepts as described for WBC scintigraphy can be applied for the use of anti-
granulocyte MoAbs. Thus, early, delayed, and late images (30 min, 3-4 h and 20-24 h) should 
be acquired and SPECT/CT images provide a useful benefit for the localisation of infections, 
being mandatory in some circumstances. Late images at 20-24 h have been recommended 
to increase sensitivity (21). The image acquisition criteria and the image interpretation 







radiolabelled antibodies do bind more to the bone marrow than radiolabelled WBC, thereby 
making the use of bone marrow scintigraphy as a reference background difficult. Secondly, 
the anti-granulocyte monoclonal antibodies bind to circulating granulocytes (that will later 
migrate to infection site) but also to tissue infiltrating granulocytes, thus an infection site can 
be positive both at delayed time points (3-4 h) as well as late (20-24 h) time points. Moreover, 
antibodies, having a small molecular weight (antibody fragments), may accumulate in sites 
of sterile inflammation due to extravascular leaking with oedema, thus giving false positive 
results.
Clinical indications for the use of radiolabelled anti-granulocyte monoclonal antibodies
99mTc-besilesomab (Scintimun®) has been used successfully in the study of subacute infectious 
endocarditis (29), lung abscesses (30), diabetic foot infections (31) and septic loosening of hip 
(see Figure 3) and knee prostheses (32,33). Peripheral bone infections were also adequately 
visualized (30,34), but sensitivity decreased when the infection was located closer to the 
spine because of physiological bone marrow uptake. As a result, 99mTc-besilesomab is less 
suitable for diagnosis of vertebral osteomyelitis (35). In inflammatory bowel diseases, this 
method appeared to be less accurate than radiolabelled leukocytes partly due to non-specific 
bowel uptake (36,37). In fever of unknown origin (FUO), results are controversial (38,39). For 
detecting infectious foci in neonates and infants with FUO, 99mTc-besilosemab appeared to be 
a safe and reliable method (40). 
99mTc-fanolesomab (LeuTech®) was successfully used in patients with osteomyelitis, diabetic 
foot ulcers and postsurgical infections (41-43). It has also been proposed for diagnostic 
purposes in equivocal cases of appendicitis (44). 
Controversial results have been obtained using 99mTc-sulesomab (LeukoScan®). In bone and soft 
tissue infections, at first scintigraphy using LeukoScan® appeared to provide rapid localization 
of bone and soft tissue infections (45,46). In other studies, however, it was found to be less 
specific for the diagnosis of musculoskeletal infections than WBC scanning (47,48). In a large 
study in diabetic patients with foot ulcers, radiolabelled sulesomab showed a high sensitivity 
of 91%, but a specificity of only 56% (49). All these studies suggest that 99mTc-sulesomab 
could be used for imaging of acute orthopedic infections, with its greatest strength being 
a high negative predictive value. However, positive studies may require further correlative 
imaging. Promising results were obtained in the detection of endocarditis and appendicitis 
(50,51). In inflammatory bowel diseases, 99mTc-sulesomab proved to be no alternative for 
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Figure 3 
Transaxial and coronal view of 99mTc-besilesomab (Scintimun®) scanning with suspicion of an infection of the left 
hip (scanning time 20 h after injection)
 
18F-FLUORODEOXYGLUCOSE (18F-FDG)
18F-FDG is a well-established diagnostic tool in oncology, but it can also be used in infection 
imaging due to a high uptake in activated granulocytes. Moreover, it can also be used in chronic 
inflammation, which is mostly sterile and with little granulocytes. In chronic inflammation, 
FDG is largely taken up by macrophages.
The accumulation of FDG in infection and inflammation is based on the fact that these cells 
use glucose as an energy source only after activation resulting in a metabolic burst. Transport 
of FDG across the cellular membrane is mediated by the GLUT glucose transporter proteins. 
Intracellular FDG is phosphorylated to 18F-FDG6-phosphate by the enzyme hexokinase and 
remains trapped inside the cell. 18F is a PET isotope with a physical half-life of 110 min and 
therefore suitable for imaging 60 min after injection. However, 18F-FDG is a non-specific tracer. 
It shows uptake both in infection, inflammation and tumors (actually in any cell with high 
glycolytic activity) and differentiation between these diseases is difficult. Consequently, in 
infectious diseases the specificity is lower than that of labelled WBC. Another disadvantage 
is the relatively high cost of the procedure. Despite these limitations, this technique is being 
exploited more and more in the imaging of infections and inflammation and has now been 
increasingly replacing conventional scintigraphy.
Image interpretation
As for any other nuclear medicine imaging technique, when interpreting a 18F-FDG-PET scan 
the nuclear medicine physician is supposed to be familiar with the physiological distribution 
of the radiopharmaceutical used in order to be able to discriminate between physiological 
and pathological uptake. Physiological uptake of FDG includes brain, heart, kidneys, bladder 
and sometimes intestines. To minimize FDG uptake in normal tissue and increase the uptake 
in the lesion(s), patients must fast for at least several hours to reduce competition for glucose 
transporters. After the injection, patients must rest for an hour and limit physical activity to 
minimize muscle uptake of FDG. High-contrast images of infectious lesions can be obtained 
early (60 min) after radiopharmaceutical injection. Consequently, the diagnostic route can 
be completed with a single visit to the hospital, which makes 18F-FDG-PET a patient-friendly 
procedure. In addition, the intrinsic characteristics of PET make it a preferable imaging 







resolution and higher sensitivity, because image acquisition does not require the use of a lead 
collimator (53).
No physiological uptake should be seen in the bone itself, but – especially in patients with 
infections or inflammation – the bone marrow, at various levels, can show increased uptake. 
In patients with vascular or orthopaedic prostheses, as is the case with any other foreign 
material in the body, the problem is the generation of artefacts, characterised by artificial FDG 
uptake adjacent to the foreign body material (54). Furthermore, non-specific FDG uptake may 
be seen in healing tissues, up to 6 months after surgical intervention (55), bone fractures (56) 
and atherosclerotic lesions.
Clinical indications for the use of 18F-FDG in infectious and acute inflammatory diseases
Many recent studies of FDG accumulation in different infections and acute inflammatory 
lesions have demonstrated highly promising results for imaging. Its clinical indications are 
FUO, osteomyelitis, spondylodiscitis, vascular graft infections, and many other miscellaneous 
infectious diseases. In FUO, several recent studies—retrospective and prospective— have 
drawn attention to the added value of 18F-FDG-PET over conventional techniques, recorded 
in 40–70% of patients (57,58). Most studies also stress the high negative predictive value of 
the technique in the assessment of FUO. Good results were also reported in children, critically 
ill and mechanically ventilated patients and in patients with human immunodeficiency virus 
(10,59,60]. 
18F-FDG-PET has been reported to be valuable for guiding therapy in inflammatory bowel 
diseases by detecting disease activity and providing an objective assessment of the severity 
of bowel inflammation (61). Especially in children, it could be an excellent noninvasive tool for 
identifying and localizing active intestinal inflammation (62). However, some doubts remain 
about the usefulness of 18F-FDG-PET in inflammatory bowel diseases, due to the physiological 
uptake of FDG in the intestinal tract. 
In acute osteomyelitis, 18F-FDG-PET may have limited value in the diagnosis of uncomplicated 
cases; conversely, it may play an important role in patients with chronic osteomyelitis, 
particularly those with previously documented osteomyelitis and suspected recurrence (57). 
In spondylitis and spondylodiscitis, 18F-FDG-PET/CT gave much better results compared to 
radiolabelled WBC imaging with sensitivities ranging from 94 to 100% and specificities ranging 
from 87 to 100%. 18F-FDG-PET/CT had a strong impact on the clinical management of 52% of 
patients with infectious spondylitis (63). An example of 18F-FDG-PET/CT in spondylodiscitis is 
shown in Figure 4.
Theoretically, 18F-FDG-PET has the potential to detect infections in hip and, to a lesser extent, 
knee prostheses. However, non-infectious reactions around the neck of the prosthesis are 
common, months and even years after surgery, and these may influence the specificity 
and diagnosis (11). Increased 18F-FDG uptake around the neck and/or head should not be 
interpreted as a finding suggestive of infection. 18F-FDG-PET should not be routinely used 
for this indication in a clinical setting until the criteria for differentiation between septic and 
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Little literature regarding the role of 18F-FDG-PET in the assessment of vascular graft infections 
is available, but what is available suggests that this modality is a reliable tool in the clinical 
setting and also indicates that CT is mandatory for the correct localization of FDG accumulation 
(64). It is not uncommon for 18F-FDG-PET to detect infection of vascular grafts even when the 
CT angiography results are negative. In Chapter 5 of this thesis, the accuracy of 18F-FDG-PET/
CT in the diagnostic work-up of patients with suspected vascular prosthetic graft infection 
was evaluated. 18F-FDG PET showed a better accuracy than CT for the detection of a vascular 
prosthetic infection (65).
 The role of 18F-FDG-PET in several other miscellaneous infectious diseases has been reported 
as well. In patients with echinococcosis, a serious parasitic infection, 18F-FDG-PET correctly 
identified the active lesions and appeared to be helpful in assessing response to treatment 
(66). The successful use of 18F-FDG-PET in the detection of infected liver and renal cysts in 
patients with polycystic kidney disease has been reported (67). 18F-FDG-PET also appears to be 
a promising technique in the early detection of complications and for the differential diagnosis 
of central nervous system lesions in patients with HIV or AIDS, despite the high physiological 
brain uptake (68). 
Figure 4 
Coronal 18F-FDG PET slice and fused sagittal 18F-FDG-PET/CT slice of a patient with spondylodiscitis with expansion 








Clinical indications for the use of 18F-FDG in chronic inflammatory diseases
In the evaluation of large-vessel vasculitis, this modality has proven validity, with sensitivity 
values ranging from 77 to 92% and specificities ranging from 89 to 100% (for an example, 
see Figure 5a). 18F-FDG-PET/ CT has proven utility in the initial diagnosis of patients suspected 
of having vasculitis, particularly those who present with non-specific symptoms, in the 
identification of areas of increased FDG uptake requiring biopsy and in the evaluation of the 
extent of disease (69). 
In sarcoidosis - a multisystem granulomatous disease that affects predominantly the lungs 
and associated lymph nodes, but may involve any organ - 18F-FDG-PET has extensively been 
studied on a relatively large number of patients. 18F-FDG-PET provides valuable information in 
evaluating pulmonary and extrapulmonary sarcoidosis. There is a high uptake of 18F-FDG by 
sarcoid granulomas, which typically appear as active lymph nodes in the mediastinum and 
hilar regions (see Figure 5b). 18F-FDG-PET was found to be more accurate than 67Ga-citrate 
and was also found to be superior for detecting extra-pulmonary lesions (70). The metabolic 
activity measured with 18F-FDG-PET reflects the disease activity in sarcoidosis in quantitative 
terms. 18F-FDG-PET has also a role in evaluating therapy. Glucose uptake in granulomas 
decreased after corticosteroid therapy (71). 18F-FDG uptake was also described in cases of 
sarcoid lesions involving the brain, bones, bone marrow, muscles and the skin (see Figure 
5c). A disadvantage of this technique is that 18F-FDG uptake patterns in sarcoidosis can mimic 
lymph node involvement by malignancy. As a consequence, 18F-FDG-PET may not be that 
useful as a definitive tool for the initial diagnosis of this disease, but has good potential for 
monitoring therapy efficacy and detecting disease relapse. 
Studies that have evaluated the role of 18F-FDG-PET in patients with rheumatoid arthritis (RA) 
are scarce. The degree of uptake and the number of affected joints correlated with clinical 
and laboratory parameters of disease activity (72). The degree of 18F-FDG uptake could be an 
indication of the severity of the inflammatory process. Pain in the joints due to inflammation 
was associated with increased metabolic activity as seen on 18F-FDG-PET. The quantification 
of metabolic changes in joint inflammation with 18F-FDG-PET was comparable to volumetric 
changes visualized with MRI, but 18F-FDG uptake was not associated with treatment outcome 
(73). No data support the use of 18F-FDG-PET for the routine study of RA, so further studies are 
warranted to determine the clinical usefulness of this technique (74). An example is shown 
in Figure 5d.
18F-FDG-PET/CT holds great promise for assessing atherosclerosis in large arteries. 18F-FDG is 
retained within plaque macrophages more avidly than within other plaque elements (75). 
A good reproducibility was reported in a group of patients who underwent carotid artery 
and aortic imaging, with high inter- and intra-observer agreement and low variability of 
18F-FDG uptake over 2 weeks (76). Results in the iliac and femoral arteries were also highly 
reproducible; however, 18F-FDG uptake in the carotid arteries was significantly higher than in 
both iliac and femoral vessels. Large prospective studies are necessary to determine if the 
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Figure 5
Examples of 18F-FDG-PET. A Giant cell arteritis, B Sarcoidosis of the mediastinal and hilar lymph nodes, 
C Sarcoidosis of the lungs and skin, D Rheumatoid arthritis
 
LABELLED INTERLEUKIN-2
Interleukin-2 (IL2) is a single-chain glycoprotein of 133 amino acids with a molecular weight 
of 15.5 kDa, which is synthesized and secreted, in vivo, by T lymphocytes after specific 
antigen stimulation. IL2 has a very high affinity for IL2 receptors (IL2R, hetero trimers of 
α, β, and Υ subunit, named CD25, CD122 and CD132, respectively) expressed by activated 
lymphocytes during inflammation. IL2 maintains the inflammatory response by inducing 
long-term proliferation of activated T lymphocytes and the proliferation and differentiation 
of natural killer cells, B cell lymphocytes and macrophages. While in physiological conditions 
the expression of ILR is negligible, during inflammation activated lymphocytes highly express 
IL2R thereby becoming a target for radiolabelled IL2. As a consequence, there is a low 
binding of radiolabelled IL2 to circulating lymphocytes resulting in low levels of background 
activity. Radiolabelled IL2 allows the visualization of both lymphocytic infiltration and T-cell 
lymphocyte activation. IL2 has been labeled with 35S, 123I, 131I and 99mTc, but clinical studies 
on patients have been performed only using 123I and 99mTc. Recently, IL2 labelled with a PET 
tracer (18F) was already proven stable, biologically active, and allowed the in vivo detection 
of activated lymphocytes in animal studies (78). Imaging with labelled IL2 is one of the best 
approaches to image chronic infiltration.
The use of radiolabelled IL2 in chronic inflammatory diseases
Both 99mTc- and 123I-labelled IL2 have been successfully used for imaging lymphocytes in several 
autoimmune and inflammatory diseases characterized by a chronic lymphocytic infiltration, 
such as Takayasu’s arteritis, diabetes mellitus, celiac disease, Crohn’s disease, melanoma 







The first scintigraphy with radiolabelled IL2 was performed in 1994, where an abnormal 
uptake in the area of the left subclavian artery and at the origin of the left common carotid 
artery was found, indicating the presence of an active process of lymphocytic infiltration in 
the arterial wall, in a patient known to have Takayasu’s arteritis. After therapy, a new 99mTc-IL2 
scintigraphy showed no signs of chronic inflammation anymore (79). 
In several rat models of autoimmune diabetes, 123I-IL2 adequately detected areas of lymphocytic 
infiltration. Specific accumulation of 123I-IL2 has been confirmed by ex vivo autoradiography 
(80,81). 123I-IL2 has also been used successfully in patients with type 1 diabetes. 99mTc- IL2 was 
able to identify a subgroup of patients with type 1 diabetes with persistent inflammation at 
the time of diagnosis that might benefit from the use of immunomodulating drugs to preserve 
β cell function (82). A recent study showed that in such patients treated with nicotinamide, 
insulin requirement and pancreatic inflammation after 1 year were significantly reduced 
suggesting that IL2 scintigraphy may be of potential use for assessing the autoimmune 
phenomena in the endocrine pancreas (83). 
Scintigraphic results using 123I-IL2 in patients with celiac disease were consistent with the 
histologically determined number of infiltrating IL2 receptor-positive cells in the jejunal 
mucosa (84). In patients with ileal Crohn’s disease (CD), intestinal uptake of IL2 was higher 
than in volunteers and the uptake positively correlated with the CD activity index. IL2 uptake 
significantly decreased in patients with CD in steroid-induced remission (85). Compared to 
radiolabelled white blood cells, both provided a high negative predictive value but a weak 
positive predictive value. However, 99mTc-IL2 scintigraphy was found useful in selecting CD 
patients in clinical remission who could benefit from preventive therapy to avoid disease 
relapse (86). IL2 scintigraphy can be an important step in the noninvasive imaging in patients 
with CD and could also be useful to monitor the efficacy of therapies in a more objective way 
(12). 
Cutaneous melanoma is often characterized by the presence of tumor-infiltrating lymphocytes. 
The degree of such infiltration and cell activation are considered significant prognostic factors 
reflecting the host’s immune response to the tumor. Thirty patients with cutaneous lesions 
suspected of being melanoma were studied. At final histology, 21 lesions were found to be 
melanoma; in 15 (71%) uptake of IL2 was found. In the remaining nine patients with benign 
cutaneous lesions, two (22%) showed uptake of IL2. The calculated tumor-to-background 
ratios correlated significantly with the number of IL2R-positive cells. 99mTc-IL2 thereby provides 
a means of in vivo measurement of the extent of tumor infiltration of IL2R-positive cells, 
thereby providing valuable prognostic information for selection of patients who may benefit 
from IL2 immunotherapy (87). 
99mTc-IL2 also strongly accumulates in the thyroid glands of patients with Hashimoto’s thyroiditis 
and Graves’ disease (88). In asymptomatic Sjögren syndrome patients, 99mTc-IL2 scintigraphy 
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Finally, radiolabelled IL2 was successfully used to detect inflamed atherosclerotic carotid 
plaques: those most vulnerable to rupture and prone to cause stroke. 99mTc-IL2 accumulated in 
vulnerable carotid plaques and the accumulation correlated with the amount of IL2R-positive 
cells within the plaque (measured ex vivo by histology) (90). In Chapter 6 of this thesis, the 
specificity of 99mTc-IL2 to image the lymphocytic infiltration in carotid plaques in vivo by planar 
and SPECT-CT imaging and ex vivo by microSPECT and autoradiography is evaluated.
GUIDELINES
Until a couple of years ago, no guidelines existed for the radiolabelling, acquisition protocols 
and image interpretation for the different existing radiopharmaceuticals that are suitable for 
the imaging of infectious and inflammatory diseases. As a consequence, variations in used 
labelling protocols, differences in acquisition protocols and differences in interpretation criteria 
made comparisons between publications difficult and led to variable reported sensitivities, 
specificities and diagnostic accuracies. 
In 2010, the Inflammation/Infection Task Group of the European Association of Nuclear 
Medicine (EANM) published guidelines for WBC labelling (both for 99mTc-HMPAO and for 111In-
oxine), which besides the indications and practical aspects, also included quality control and 
safety procedures (91,92) and are written in accordance with the current European Union 
regulations and International Atomic Energy Agency (IAEA) recommendations.
Recently, a joint force of the EANM and the Society of Nuclear Medicine and Molecular Imaging 
(SNMMI) led to the publication of guidelines for the use of 18F-FDG-PET in inflammation and 
infection. Based on cumulated reported accuracies > 85%, these guidelines state that the 
major indications for the use of 18F-FDG-PET/CT in infection and inflammation are: sarcoidosis, 
peripheral bone osteomyelitis, spondylodiscitis, evaluation of fever of unknown origin and the 
primary evaluation of vasculitis. Other well-described applications, however at this moment 
without sufficient evidence-based indications, are the evaluation of potentially infected liver 
and kidney cysts, suspected infection of intravascular devices, AIDS-associated opportunistic 
infections, and the assessment of metabolic activity in tuberculosis lesions. For diabetic foot 
infections, joint prosthetic infections, vascular prosthetic infections, inflammatory bowel 
diseases, and endocarditis, it is presently unclear if 18F-FDG imaging offers any significant 
advantage over radiolabelled WBC or anti-granulocyte monoclonal antibodies.
This thesis wants to emphasize the major importance of these and future guidelines. When 
performing imaging procedures in accordance with these guidelines, multicenter studies are 
possible and published results between studies comparable. The Infection and Inflammation 
Committee of the EANM is now working on guidelines describing the correct image acquisition 
protocols and interpretation criteria for WBC imaging. Chapter 2 and 3 of this thesis may help 
to develop these guidelines, since different acquisition protocols and interpretation criteria are 








As stated earlier, many radiopharmaceuticals are available to image the different phases 
of infection and inflammation and this also reflects the need to have several different 
radiopharmaceuticals to diagnose different stages of diseases and, possibly, different 
infections and inflammatory diseases. A single agent capable to satisfy all these diagnostic 
needs is not available and will for sure never be developed.
Nowadays, we have many radiopharmaceuticals available for many targets. Several different 
radiopharmaceuticals are necessary to show which kind of infection or inflammation is 
involved, which targets play a role in the process and with pathophysiological process is the 
cause. Our modern molecular imaging techniques use highly specific radiopharmaceuticals for 
imaging different events and targets: we call that the in vivo characterization of the process. 
The clinician, in cooperation with the nuclear medicine specialist, has to determine if a 
radiopharmaceutical is needed to image an infection or to image a chronic inflammation 
or autoimmune disease, has to look carefully to the suspected cause of the infection/
inflammation, and also has to determine if the tracer has to target the cause non specifically 
or has to target more specifically the cells that are thought to be involved in this process. 
As we will see in Chapter 9 of this thesis, the decision to specifically image a target cell or 
molecule in the process, will not only help for the diagnosis, but also in the decision making 
of which therapy would be suitable for the individual patient and even for follow-up and 
therapy evaluation.
THE OUTLINE OF THIS THESIS
This introduction chapter provided an overview of all the nuclear medicine possibilities in 
the field of infectious and inflammatory diseases. An attempt was given to show that many 
radiopharmaceuticals are available, but that there is still a lack of guidelines how to use these 
radiopharmaceuticals correctly and of evidence which tracer is best suitable for which disease. 
This thesis aims to give more insights in how to perform diagnostic procedures in infection 
and inflammation, compares different nuclear medicine techniques with each other and with 
conventional radiological imaging techniques, evaluates specific radiopharmaceuticals for 
the use in specific diseases, and tries to develop new strategies when to use which nuclear 
medicine technique in which part of the diagnostic pathway. This is our aim for the future: 
to provide to the medical world, in cooperation with the clinicians, evidence based nuclear 
medicine imaging techniques and to make it clear for the clinician when to ask for it and 
where to locate it in the diagnostic and therapy evaluating pathways.
This thesis, therefore, comprises two parts. The first part (Chapter 2-5) consists of nuclear 
imaging methods in infectious diseases, the second part (Chapter 6-8) is based on the use of 
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In Chapter 2 and 3, different acquisition protocols and interpretation criteria in WBC 
scintigraphy are evaluated in a large single-centre study and in a multicenter study, leading to 
a flow-chart for the correct acquisition and image analysis of WBC scanning.
Chapter 4 compares two nuclear medicine techniques (WBC imaging and 18F-FDG-PET) in 
the difficult diagnostic pathway to diagnose osteomyelitis of the diabetic foot. The debate of 
which tracer is best to image the diabetic foot is still continuing.
Chapter 5 compares the diagnostic accuracy of 18F-FDG-PET with computed tomography (CT) 
and the added value of fused 18F-FDG-PET/CT in diagnosing vascular prosthetic graft infections, 
leading to the conclusion that 18F-FDG-PET is a useful tool in the work-up for diagnosis in this 
indication.
Intermezzo 1 provides a short overview of the available nuclear medicine techniques 
to image atherosclerosis. This is further elaborated in Chapter 6, in which 99mTc-hynic-
Interleukin-2 is evaluated in vivo by planar and SPECT/CT imaging and ex vivo by microSPECT 
and autoradiography to confirm the specificity for imaging lymphocytic infiltration in plaques 
of the carotid artery.
After this, a switch is made to another inflammatory disease, amyloidosis, a disease 
characterized by extracellular depositions of fibrils composed of low molecular weight subunits 
of a variety of serum proteins (amyloid). The characteristics of this relative uncommon 
disease and the nuclear medicine possibilities to image amyloid depositions are described in 
Intermezzo 2. In Chapter 7, the utility of 18F-FDG-PET to differentiate between patients with 
localized and with systemic amyloidosis is evaluated. Furthermore, the findings on 18F-FDG-
PET are compared to the findings of 123I-Serum Amyloid P (123I-SAP) scintigraphy, which is part 
of the routine diagnostic work-up in patients with amyloidosis. 
One of the major problems in the diagnosis of amyloidosis is the early recognition of amyloid 
depositions in the heart. Chapter 8 evaluates if bone scintigraphy allows this early diagnosis 
of cardiac amyloidosis in patients with a specific type of amyloidosis, the transthyretin-derived 
amyloidosis.
At the end of this thesis, future perspectives and conclusions are described in Chapter 9. 
This chapter emphasizes four important concepts that have to be investigated in the next 
years: (1) extending the role of 18F-FDG-PET in therapy evaluation and searching for new 
applications to diagnose, (2) the potential tool of nuclear medicine to specifically target 
the infectious or inflammatory process, thereby providing a rationale for individual therapy, 
(3) the future expectations of new hybrid imaging techniques, the PET/MRI, and (4) the 
importance to develop strategies for the diagnostic pathway and therapy monitoring. One 
example of this strategy, in prosthetic joint infections, is described. These strategies have 
to be further elaborated in other infectious and inflammatory indications and have to be 
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The diagnosis of infection is often based on clinical, pathological and microbiological results. 
However, these investigations lack specificity. White blood cell (WBC) scintigraphy is considered 
the gold standard nuclear imaging technique for diagnosing infections in bone and soft 
tissues (except spondylodiscitis). However, image acquisition and interpretation criteria differ 
amongst centres throughout the world, leading to differences in reported results. The aim of 
this study was to identify the most accurate WBC scintigraphy acquisition and interpretation 
protocols for diagnosis of bone and soft tissue infections.
Methods
Included in this retrospective study were 297 patients with suspected bone or soft tissue 
infection who underwent WBC scintigraphy with 99mTc-HMPAO-labelled leucocytes between 
2009 and 2012. Sensitivity, specificity, accuracy, and positive and negative predictive values 
of WBC scintigraphy were determined for two different dual time point acquisition protocols 
(fixed-time acquisition and time decay-corrected acquisition) and five image interpretation 
methods (visual and semiquantitative with four different reference regions of interest). Final 
diagnosis was based on pathological and microbiological reports, and when these were not 
available, on clinical follow-up of at least 6 months.
Results
The best acquisition protocol was 4 h and 20 – 24 h dual time-point acquisition with 
time decay-corrected acquisition. When using this acquisition protocol, visual qualitative 
interpretation led to a sensitivity of 85.1 %, a specificity of 97.1 %, a diagnostic accuracy of 
94.5 %, a positive predictive value of 88.8 % and a negative predictive value of 95.9 %. For 
semiquantitative analysis, the best results were found when lesion-to-reference ratios were 
calculated with the contralateral side as the reference tissue, except for osteomyelitis and 
infected osteosynthesis, for which the contralateral bone marrow was found to be the best 
reference tissue. Results of the semiquantitative analyses per se were not better than for 
visual analysis. In the optimal analysis protocol, scans are first visually evaluated, and if this 
gives equivocal results, semiquantitative analysis is performed. This strategy resulted in an 
improved sensitivity of 97.9 %, a specificity of 91.8 % and a diagnostic accuracy of 93.1 %.
Conclusion
WBC scintigraphy for bone and soft-tissue infection is best performed using a dual acquisition 
protocol at 4 h and at 20–24 h after injection, in which the acquisition time of the scans is 
corrected for decay. In most patients, visual analysis is sufficient and leads to high diagnostic 
accuracy. When interpretation by visual analysis is inconclusive, semiquantitative analysis 









White blood cell (WBC) scintigraphy with leucocytes labelled with either 99mTc-HMPAO or 111In-
oxine is considered the best nuclear imaging technique for diagnosing infections in the bone and 
soft tissue (except spondylodiscitis) (1–4). High sensitivities and specificities (approximately 
90 %) have been found in various studies (2,5,6), but lower values have also been reported. 
WBC scintigraphy combined with bone scintigraphy and/or bone marrow scintigraphy has 
been recommended to increase diagnostic accuracy (3,5). The variable diagnostic accuracy 
reported for WBC scintigraphy, however, can largely be ascribed to variations in labelling 
procedures, differences in acquisition protocols and differences in interpretation criteria (2,7). 
In 2010, the Inflammation/Infection Task Group of the European Association of Nuclear 
Medicine (EANM) published guidelines for WBC labelling, quality controls, and safety 
procedures (8,9). However, guidelines describing the correct image acquisition protocols and 
interpretation criteria are not yet available. 
In this study, we evaluated retrospectively a large number of WBC scans and compared two 
acquisition protocols, both of which were dual time-point imaging, one with a fixed acquisition 
time and the other with time decay correction acquisition, and five analysis methods, one of 
which was visual and four were semiquantitative methods using different reference regions 
of interest (ROIs). Sensitivity, specificity, diagnostic accuracy, and positive and negative 
predictive values were calculated for both acquisition protocols and all five analysis methods 
for the whole population and for specific types of infections in the bone and soft tissue. Based 
on our results, we propose an algorithm for WBC scintigraphy acquisition and analysis that 
leads to the highest diagnostic accuracy. 
MATERIALS AND METHODS
Patients
The local hospital information system was reviewed for all patients in whom scintigraphy with 
99mTc-HMPAO labelled WBC had been performed between January 2009 and July 2012. In total, 
315 patients were eligible for inclusion. All indications for WBC scintigraphy were related to 
possible musculoskeletal infections. For abdominal and vascular infections and for fever of 
unknown origin we routinely perform 18F-FDG PET in our hospital. We collected all reports with 
regard to all other imaging investigations that were performed in the included patients. We 
also collected all available measured infection parameters in the blood (C-reactive protein, 
erythrocyte sedimentation rate and leucocyte count) and known medication use that might 
have influenced the results of the WBC scintigraphy (antibiotics, NSAIDs and (cortico)steroids). 
The final diagnosis of an infection or exclusion of an infection was based on pathological and 
microbiological reports, and when these were not available, on clinical follow-up of at least 6 
months (looking at all correspondence and all further investigations that had been performed). 
When clinical follow-up revealed no signs of an infection, final diagnosis was considered 
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Of the 315 patients, 18 were excluded because a final diagnosis could not be made (3 patients), 
the scans were not interpretable (15 patients), only single time-point image acquisition 
had been performed (9 patients), there were artefacts in the images (2 patients), or the 
patient’s position was different in early and late image acquisitions (4 patients). Therefore, 
297 patients (147 women, 150 men) with a mean age of 58 years (range 12–91 years) 
were included. These 297 patients were evaluated in total, but were also divided into several 
groups according to the indication for WBC scintigraphy. The patient characteristics and clinical 
indications are shown in Table 1.  
WBC scintigraphy and acquisition protocols
Radiolabelling of WBC (mixed leucocytes) with 99mTc-HMPAO was performed according to 
present guidelines of the EANM (8). 
Two dual time-point acquisition protocols were used, both with static images acquired 4 h 
(delayed images, 145 s) and 20–24 h (late images) after intravenous injection of 500 MBq 
99mTc-HMPAO-labelled WBC. In the first protocol, late images were acquired with a standard 
acquisition time of 10 min; decay of the radionuclide was not taken into account (fixed-time 
acquisition, 80 patients). In the second protocol, late images were acquired with acquisition 
times that were corrected for decay of the radionuclide between injection time and the late 
scan (Table 2, time decay-corrected acquisition, 217 patients). Since radioactive decay is 
compensated for by extension of the acquisition time, the signals in the delayed and late 
images can be compared directly. All images were acquired on a SPECT/CT gamma camera 
system (Symbia T; Siemens Medical Systems, Knoxville, TN). 
Visual analysis
Scans were visually classified as negative for infection if no uptake was seen both in delayed 
and late images, when the uptake was the same in both images, or when the uptake decreased 
over time. Scans were classified as positive for infection when the uptake showed an increase 
between delayed and late images, or when the size of the area with enhanced uptake showed 
an increase (Figure 1). Another important criterion for positivity was the change in shape over 
time, e.g. in the case of a fistula. When a patient was considered positive for infection, the 
location of the infection (defined only on planar images, and in some cases by SPECT/CT) and 
the type of infection were determined. The interpretation criteria were the same for the fixed-
time acquisition and the time decay-corrected images. 
The time decay-corrected images were displayed using a total counts intensity scale, and the 
same intensity threshold was used to visualize both the delayed and late images, thereby 
avoiding observer bias. 
Semiquantitative analysis
In all scans, semiquantitative analysis was performed by drawing a ROI over the suspected 
infectious foci. Whenever possible, this ROI was mirrored automatically on four presumed 
normal reference tissues: (1) contralateral tissue, (2) contralateral bone marrow, (3) ipsilateral 
bone marrow and (4) anterior superior iliac crest. The mean counts per pixel in these ROIs 







and late images for all four reference areas. When L/R ratios per reference tissue area 
were similar or decreased in the late scan compared to the delayed scan, the patient was 
considered negative for infection. If the L/R ratio showed an increase over time the patient 
was considered positive for infection. 
Table 1
Characteristics of the 297 included patients.
Age (years) Mean 58
 Range 12-91
Sex, n (%) Female 147 (49)
 Male 150 (51)
Indicationa
Osteomyelitis Suspected     61       
 Final diagnosis 15
Infected hip prosthesis Suspected 67
 Final diagnosis 10
Infected knee prosthesis Suspected 71
 Final diagnosis 11
Infected prosthesis, other regionsb Suspected 5
 Final diagnosis 0
Infected osteosynthesis Suspected 49
 Final diagnosis 10
Soft tissue infection Suspected 22
 Final diagnosis 21
Infected neuropathic foot Suspected 10
 Final diagnosis 0
Vertebral infection Suspected 5 
 Final diagnosis 0
Infections in head and neck regionsc Suspected 7
 Final diagnosis 4
Blood tests 
WBC count  No.performed 233
 No. increased (>10x109/L) 44
C-reactive protein  No.performed 172
 No. increased (>5 mg/L) 133
Erythrocyte Sedimentation Rate  No.performed 233 
 No. increased (>15 mm/h) 95
Known medication during scan, n Antibiotics 143
 NSAID 70
 Prednisone 98
Acquisition method, n (%) Fixed time 80 (27)
 Time decay correction  217 (73)
Semi-quantitative analysis, n (%) Contralateral side 285 (96)
 Contralateral bone marrow 177 (60)
 Ipsilateral bone marrow 169 (57)
 Anterior superior iliac crest 73  (25)
a Final diagnosis based on pathological, microbiological and clinical results
b Including shoulder (2), elbow (2) and toe (1) prosthesis
c Including dental infections (5), sinusitis (1) and ear infection (1)
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Sensitivity, specificity, diagnostic accuracy, and negative and positive predictive values were 
calculated using SPSS (version 20.0; SPSS, Chicago, IL). All values are expressed as medians 
and range, as is customary for nonparametric data. 
Table 2
Time decay-corrected.
Time after  Acquisition












WBC scintigraphy in a 64-year-old patient complaining of pain and redness after fracture of the right lower leg; 
time decay-corrected acquisition: A-D delayed images, anterior (A), posterior (B), and lateral (C, D) views; E, 
F late images, anterior (E) and posterior (F). Note the increase in uptake and size between delayed and late 









In total, 297 patients who had received 99mTc-HMPAO-labelled WBC scintigraphy for suspected 
infection were included. Based on pathological and microbiological reports, or (when these 
reports were not available) on clinical follow-up of at least 6 months, 71 infections were found 
(23.9 %). These confirmed infections were divided into different groups as shown in Table 1. 
Visual analysis
The results of the visual analysis in relation to the final diagnosis are shown in Table 3. 
Taking all patients together (fixed-time and time decay-corrected acquisition together), the 
sensitivity was 82.0 %, specificity 94.9 %, diagnostic accuracy 91.9 %, positive predictive 
value 81.0 % and negative predictive value 94.9 %. For all indications except diabetic foot, 
the specificity was higher than 90 %. 
Table 3
Results of visual analysis of all patients (fixed-time and time decay-corrected acquisition) in relation to the final 
diagnosis based on pathological, microbiological or clinical results. The values shown are percentages.
    Positive Negative
Indication group (n) Sensitivity Specificity Diagnostic predictive predictive
   accuracy value value
All patients (297) 82,0 94,9 91,9 81,0 94,9
     
Osteomyelitis (61) 85,7 98,1 96,7 85,7 98,1
All prostheses together (143) 76,2 91,7 89,4 61,5 95,7
Infected hip prosthesis (67) 80,0 93,0 91,0 66,7 94,4
Infected knee prosthesis (71) 81,8 90,0 90,0 60,0 96,4
Infected osteosynthesis (49) 100 97,4 98,0 90,9 100
Soft tissue infection (22) 75,0 100 72,7 100 14,3
Infected neuropathic foot (10) - 60,0 60,0 - 100
Vertebral infection (5) - 100 100 - 100
Head and neck infection (7)  75,0 100 85,7 100 75,0
Semiquantitative analysis
In 12 patients, semiquantitative analysis of the contralateral side was not possible since the 
infectious focus was located in the vertebral column (no contralateral or ipsilateral analysis 
possible) or in the head and neck region (no image made of the contralateral tissue). 
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Furthermore, semiquantitative analysis of the other three ROIs were not possible in all patients 
since, for example, bone marrow was not always visible or the anterior superior iliac crest was 
not visualized. In total, L/R ratio calculation was possible in 285 patients for the contralateral 
tissue, in 169 patients for the ipsilateral bone marrow, in 177 patients for the contralateral 
bone marrow and in 73 patients for the anterior superior iliac crest as reference tissue. 
The best results were when L/R ratios were calculated using the contralateral tissue as reference 
tissue (sensitivity 91.9 %, specificity 82.1 %, diagnostic accuracy 84.2 %, positive predictive 
value 58.7 % and negative predictive value 97.3 %; see Table 4). For most subgroups the 
contralateral area was also the best reference area for semiquantitative analysis. In patients 
with osteomyelitis and osteosynthesis, however, the highest sensitivity and specificity were 
obtained when the contralateral bone marrow was used as the reference tissue (100 and 85.7 
%, and 100 and 93.3 %, respectively). 
Semiquantitative vs. visual analysis
Visual analysis performed better than all semiquantitative calculations. Visual analysis 
provided optimal sensitivity and specificity, as is shown in the ROC curves in Figure 2, which 
are based on the results shown in Tables 3 and 4. 
Semiquantitative analysis of equivocal scans
A priori, we classified scans that showed decreased or stable uptake between the delayed and 
late images as negative for infection. However, some equivocal scans (stable or minimally 
increased or minimally decreased uptake over time) generated false-negative or false-positive 
results. We therefore decided to look at this group of patients separately. We hypothesized 
that there could be added value in semiquantitative analysis of equivocal scans. An example 
is shown in Figure 3. In patients with equivocal scans, semiquantitative analysis using the 
contralateral tissue as reference achieved a higher sensitivity (87.5 %) than visual analysis 
only (82 %), but a lower specificity (89.5 % vs. 94.9 %), as shown in Table 5. 
Visual analysis, fixed-time acquisition vs. time decay-corrected acquisition
Visual analysis results of both fixed-time and time decay-corrected images were compared 
with the final diagnosis. As is shown in Table 6, the results were markedly better for the 
time decay-corrected acquisition (sensitivity 85.1 %, specificity 97.1 %, diagnostic accuracy 
94.5 %, positive predictive value 88.8% and negative predictive value 95.9 %) compared to 
the fixed acquisition time (sensitivity 56.3 %, specificity 89.1 %, diagnostic accuracy 82.5 %, 
positive predictive value 56.3 %, negative predictive value 89.1 %). The time decay-corrected 
acquisition was also better in all subgroups separately except the osteosynthesis group (Table 








Semiquantitative analysis of all patients compared to the final diagnosis based on pathological, microbiological 
or clinical results. The values shown are percentages.
    Positive Negative
Reference tissue (n) Sensitivity Specificity Diagnostic predictive predictive
   accuracy value value
Contralateral tissue (285) 91,9 82,1 84,2 58,7 97,3
Ipsilateral bone marrow (169) 78,4 82,6 81,7 55,8 93,2
Contralateral bone marrow (177) 78,9 76,3 76,8 47,6 93,0
Anterior superior iliac crest (73) 72,7 83,9 82,2 44,4 94,5
Visual analysis (297) 82,0 94,9 91,9 81,0 94,9
Table 5
Semi-quantitative analysis of scans with equivocal results on visual analysis. The values shown are percentages.
    Positive Negative
Reference tissue (n) Sensitivity Specificity Diagnostic predictive predictive
   accuracy value value
Contralateral tissue (131) 87,5 89,5 88,5 27,6 99,0
Ipsilateral bone marrow (75) 83,3 81,1 81,3 27,8 98,2
Contralateral bone marrow (82) 83,3 75,0 75,6 20,8 98,2
Anterior superior iliac crest (37) 100,0 83,3 83,8 14,3 100,0
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ROC curves for WBC scintigraphy comparing visual analysis and semiquantitative analysis using four different 
reference regions ( 1 visual analysis, 2 contralateral tissue, 3 ipsilateral bone marrow, 4 contralateral bone 








WBC scintigraphy in a 62-year-old patient complaining of pain in the left knee after placement of a prosthesis 
4 years previously; time decay-corrected acquisition time for the late scan: A, B delayed images, anterior 
(A) and posterior (B); C, D late images, anterior (C) and posterior (D). Images are doubtful/equivocal. E, F 
semiquantitative analysis using the contralateral tissue as reference region shows an increase in L/R ratio 
(delayed 1.18, late 1.43), indicating the patient is positive for infection. Revision of the knee prosthesis showed 
inflammatory cells (pathology) and Staphylococcus aureus (microbiology).
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Visual analysis in patients with fixed-time acquisition and patients with time decay-corrected acquisition. The 
visual findings were compared to the final diagnosis based on pathological, microbiological or clinical results. 
The results in the two acquisition groups are significantly different (p < 0.000001, Mc Nemar’s test; p=0.02, 
Fisher’s exact test).
Indication group: Fixed-time acquisition
    Positive Negative
Indication group (n)  Sensitivity Specificity Diagnostic predictive predictive
   accuracy value value
All patients (80) 56,3 89,1 82,5 56,3 89,1
     
Osteomyelitis (16) - 93,3 87,5 - 93,3
All prostheses together (46) 57,1 84,2 80,0 40,0 91,4
Infected hip prosthesis (28) 33,3 88,0 82,1 25,0 91,7
Infected knee prosthesis (17) 75,0 76,9 76,5 50,0 90,9
Infected osteosynthesis (12) 100,0 100,0 100,0 100,0 100,0
Soft tissue infection (6) 50,0 - 50,0 100,0 -
Infected neuropathic foot (0) - - - - -
Vertebral infection (0) - - - - -







Indication group: Time decay-corrected acquisition 
    Positive Negative
Indication group (n)  Sensitivity Specificity Diagnostic predictive predictive
   accuracy value value
All patients (217) 85,1 97,1 94,5 88,8 95,9
     
Osteomyelitis (45) 100,0 100,0 100,0 100,0 100,0
All prostheses together (97) 85,7 95,2 93,8 75,0 97,5
Infected hip prosthesis (39) 85,7 96,9 94,9 85,7 96,9
Infected knee prosthesis (54) 85,7 93,6 92,6 66,7 97,8
Infected osteosynthesis (37) 87,5 96,6 94,6 87,5 96,6
Soft tissue infection (16) 80,0 100,0 81,3 100,0 75,0
Infected neuropathic foot (10)  - 100,0 100,0 - 100,0
Vertebral infection (5) - 100,0 100,0 - 100,0
Infection head and neck (7)  75,0 100,0 85,7 100,0 75,0
DISCUSSION
Diagnostic tests for an infection can be used to demonstrate the presence or absence of an 
infectious focus. Demonstrating the presence of the microorganism is often crucial for effective 
clinical management (10). However, the organism is not always detected and pathology and/
or microbiology are not always feasible, or may show false-negative results, for example 
due to sampling errors or the use of antibiotics. Other diagnostic tests, such as infection 
parameters in the blood and conventional radiological imaging are not sufficiently specific 
(11-14). Nuclear medicine offers various imaging techniques to diagnose infections, and WBC 
scintigraphy is considered the gold standard nuclear imaging technique for osteomyelitis, soft-
tissue infection, infected prostheses and the infected neuropathic foot (5,8,15,16). 
Many studies have investigated the value of WBC scintigraphy in diagnosing infectious and 
inflammatory diseases. Accumulation of labelled WBCs in infection sites is a dynamic process, 
and adequate interpretation of the scan results requires knowledge of normal (blood and 
bone marrow) and abnormal variants of WBC localizations in different tissues and organs and 
the changes in WBC uptake over time under different conditions (2). For example, infections 
(chronic and acute) show an increase in WBC accumulation over time, whereas uptake in the 
blood decreases. Bone marrow imaging has been suggested to equalize images, using bone 
marrow as a sort of reference tissue. However, we emphasize that bone marrow activity is 
not stable but may change over time. The image acquisition and interpretation criteria for 
WBS scintigraphy differ significantly among the studies. In general, agreement exists that at 
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least two time points (delayed and late imaging) are necessary for good interpretation of the 
scan; early images (1 h after injection) may also be acquired, but are not strictly necessary. 
With visual analysis, images are classified as negative for infection when the images show no 
uptake, or when the late images show a decrease in uptake or stable uptake compared with 
the delayed images. Images are considered positive when the uptake increases over time or 
in size between the delayed and late images. However, one could easily criticize this visual 
analysis method since in most cases fixed acquisition times are used. As a consequence, visual 
analysis is observer dependent and the results may differ significantly among observers using 
different contrasts and backgrounds. 
Therefore, this study analysed two different acquisition protocols, one with fixed-time 
acquisition (therefore observer dependent) and one with time decay-corrected acquisition, 
in which images were displayed with the number of counts and the same intensity scale, 
making comparisons between images possible without observer bias. Diagnostic accuracy by 
visual analysis was markedly higher for the time decay-corrected images (diagnostic accuracy 
94.5 % versus 82.5 % for the fixed-time images). Taking all patients together, our results are 
comparable with existing previously reported results. Sensitivity (82.0 %) in our study was 
slightly lower, but specificity (94.5 %) was somewhat higher than most previously reported 
results. The lower sensitivity may be explained by the variety of clinical indications in our 
study, and not focusing purely on one clinical indication, e.g. orthopaedic infections. 
In most patients, the longer scanning time for the late images is not a limiting factor. However, 
in very ill patients one may choose to perform delayed and late imaging with a fixed-time 
acquisition and multiply the counts on the late images by a decay-correction factor. It is 
important to realize that this method will result in a decrease in signal-to-noise ratio (the 
noise counts are also multiplied), and this may influence diagnostic accuracy. 
In previous studies WBC scintigraphy has often been performed in conjunction with bone 
marrow scintigraphy to maximize accuracy (5,6,17,18), but it is also considered that delayed 
and late images on WBC scintigraphy should be equalized according to bone marrow uptake 
(5). However, considering bone marrow activity on WBC scintigraphy is not a good option, since 
bone marrow activity may change over time and is therefore difficult to use as a reference. By 
performing visual analysis of WBC scintigraphy with time decay-corrected acquisition, bone 
marrow activity is less important as a reference for positivity, and similarly bone marrow 
scintigraphy is almost always avoided and diagnosis is settled after just one nuclear imaging 
study. 
Semiquantitative analysis may be helpful in the interpretation of WBC scintigraphy. Pelosi 
et al. were the first to study this approach and found that the addition of semiquantitative 
evaluation led to a significant improvement in both sensitivity and specificity. This study was 
performed only in patients with symptomatic total hip or knee arthroplasty and as reference 
tissue the left iliac crest was always used (also when the prosthesis was located on that side) 
(19). A major disadvantage of this interpretation method is that the iliac crest always has to 







In general, drawing the ROIs on the lesion and on reference tissues is observer-dependent. In 
addition, the selection of the location of the reference site may strongly influence the results. 
Therefore, in this study we also analysed four different reference tissues to calculate the L/R 
ratio in all patients: (1) contralateral tissue, (2) contralateral bone marrow, (3) ipsilateral bone 
marrow and (4) anterior superior iliac crest. To our knowledge, this is the first study that has 
focused on this methodology for semiquantitative measurements. For the whole group of 
patients, visual analysis performed better than any semiquantitative measurement. However, 
when visual analysis is doubtful, there could be added value in semiquantitative analysis. 
Semiquantitative analysis using the contralateral tissue as the reference site showed the best 
results, except in osteomyelitis and infected osteosynthesis material. In these two groups, 
the contralateral bone marrow as the reference site showed best results. The explanation for 
this is not completely understood. One could hypothesize that in these groups in the affected 
site high activation of bone marrow occurs, which could better be normalized by using other 
regions of bone marrow as the reference site instead of using the contralateral side. 
We defined any increase in uptake or size between delayed and late images as positive 
for an infection. However, this was arbitrarily decided since no studies have yet provided 
a definition of the threshold for the increase in uptake over time that should be applied 
to consider a patient positive for infection. This threshold may be significantly affected by 
several parameters, such as infection type (acute versus chronic), disease type (indication 
groups), and type of infective organism. Considering the results of our study, it is important 
that prospective studies evaluating this threshold for increased WBC uptake and the correct 
location for the reference site ROI are performed. 
In this study, the indications for which the referring clinician asked for WBC scintigraphy were 
mainly related to the musculoskeletal system. Therefore, the flow chart proposed below 
may in our opinion be used for the indications osteomyelitis, prosthetic infection, infected 
osteosynthesis and soft-tissue infections. For the other indications (infected neuropathic foot, 
vertebral infections, and infections in the head and neck region), patient numbers were too 
low to allow any conclusions to be drawn about the suitability of the flow chart. For vertebral 
infections (spondylodiscitis), other studies have already shown that 18F-FDG PET/CT is the best 
nuclear imaging method (1,4). The WBC scans for this indication were performed in 2009. 
Since 2010, we have routinely performed 18F-FDG PET/CT in patients with suspected vertebral 
infections. For the neuropathic foot, WBC scintigraphy still remains the gold standard nuclear 
imaging technique. We found comparable results to those previously reported in a large meta-
analysis (20). The debate as to which imaging technique is best for the diabetic foot is still 
continuing. One study has shown better results for WBC scintigraphy than for 18F-FDG PET/CT 
(21). Others, however, have found that 18F-FDG PET/CT is a highly specific imaging method 
for the diabetic foot (22). For suspected infections in the head and neck region, both WBC 
scintigraphy and 18F-FDG PET/CT may be used. Studies comparing the two methods are not 
available at this time. 
Finally, we searched the hospital database for the patients’ blood infection parameters and 
concomitant medication use at the date they underwent WBC scintigraphy. We found no 
correlation between the blood results and final diagnosis. Almost half of the patients (143) 
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were receiving antibiotics at the time of scintigraphy. Unfortunately, no data were available 
about the duration and dose of this antibiotic therapy. This was also the case for NSAID and 
(cortico)steroid treatment. No significant differences were found in sensitivity, specificity 
and diagnostic accuracy between patients receiving therapy and patients without therapy. 
Therefore, one preliminary conclusion can be made. Many doubts exist about the usefulness 
of WBC scintigraphy in patients receiving, for example, antibiotic therapy, since this may lead 
to false negative results. However, taking into consideration the results of this study and 
the many patients who were receiving concomitant antibiotic treatment, it is possible that 
antibiotic therapy does not influence the results of WBC scintigraphy. Prospective studies with 
full knowledge of the patients’ therapy are necessary to definitely resolve this issue. 
PROPOSED ACQUISITION AND INTERPRETATION FLOW CHART FOR WBC 
SCINTIGRAPHY
Taking the results of this study together, we conclude that dual time-point imaging with time 
decay-corrected acquisition should be performed in WBC scintigraphy. Visual analysis has a 
high diagnostic accuracy of 94.5% and is therefore sufficient in most patients. An increase in 
WBC uptake over time can be considered conclusive for infection, whereas a decrease in WBC 
uptake over time can be considered negative for infection. For visually doubtful or equivocal 
scans (stable uptake or minute changes in uptake over time), semiquantitative analysis using 
the contralateral tissue as the reference site should be added, except in osteomyelitis and 
osteosynthesis. For these two indications, the contralateral bone marrow should be used as 
the reference site. Based on these results, we propose an acquisition and interpretation flow 
chart for WBC scintigraphy (Figure 4). Following this flow chart in the 217 patients with time 
decay-corrected acquisition leads to a sensitivity of 97.9 %, a specificity of 91.8 % and a 








Proposed image acquisition and interpretation flow chart for WBC scintigraphy
CONCLUSION
For suspected infections of the bone (osteomyelitis, prosthetic infections, infected 
osteosynthesis) and of soft tissue, WBC scintigraphy should be performed with time decay-
corrected acquisition at 3–4 h and at 20–24 h after injection. This protocol is simple, accurate and 
reduces observer bias. Early imaging (30 min to 1 h after injection) may also be performed, but 
this is not strictly necessary and complicates the procedure and increases patient discomfort. 
In most cases, visual analysis of the time decay-corrected images is sufficient and leads to 
high diagnostic accuracy. Increased activity or increased area of uptake over time is considered 
positive for infection, and decreased or stable uptake over time is considered negative. When 
visual interpretation is doubtful, semiquantitative analysis and calculation of L/R ratio has 
added value. For semiquantitative analysis, any increase in L/R ratio over time is considered 
positive for infection. As reference site, the contralateral tissue should be used, except in 
osteomyelitis and infected osteosynthesis material. In these two indications, the contralateral 
bone marrow should be used as the reference site. 
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There is no consensus yet on the best protocol for planar image acquisition and interpretation of 
radiolabelled white blood cell (WBC) scintigraphy. This may account for differences in reported 
diagnostic accuracy amongst different centers. Here we report the results of a multicenter 
retrospectively study performed by analysing 235 WBC scans in patients with suspicion of a 
musculoskeletal infection divided in 2 groups with different performed acquisition protocols. 
Methods
The images of the first group (105 patients) were acquired with a fixed-time acquisition 
protocol and of the second group (130 patients) with a time-decay corrected acquisition 
protocol. The image interpretation was performed on planar images both qualitatively and 
semiquantitatively. Three different blind readers analysed the images.
Results
The most accurate imaging acquisition protocol is to acquire images at 3-4 h and at 20-24 h in 
time mode with acquisition times corrected for isotope decay. When using this protocol, visual 
analysis leads to high sensitivity and specificity for diagnosis of infection. Semiquantitative 
analysis might be used in doubtful cases, using no cut-off for the percentage of increase in 
radiolabelled WBC over time as a criteria to define a positive scan.
Conclusions
When having a suspicion of a musculoskeletal infection, WBC scintigraphy should be performed 
by acquiring images at least at two time points, one at 3-4 h (delayed images) and one at 
20-24 h (late images), and by using time-decay corrected acquisitions. Images should then be 









The use of 99mTc-HMPAO or 111In-oxine labelled white blood cells (WBC) is still considered the 
gold standard nuclear imaging technique to diagnose infections in the bone and soft tissue, 
except for spondylodiscitis (1,2). For acute osteomyelitis and for prosthetic joint infections, 
reported diagnostic accuracy is approximately 90% (3-5). However, there are also various 
reports that mention lower rates for sensitivity and specificity. These differences in diagnostic 
accuracy reported for WBC scintigraphy may be related to different image acquisition protocols 
and different interpretation criteria (6,7). To strengthen the clinical use of WBC scintigraphy, 
procedures and protocols are being standardized throughout the world. To this aim, the 
recent published guidelines by the Infection and Inflammation Committee of the European 
Association of Nuclear Medicine (EANM) provide indications, practical aspects, quality controls 
and safety procedures of this technique (8,9). Guidelines that describe the correct image 
acquisition and interpretation criteria for labelled WBC are also under preparation.
Accurate acquisition protocols and interpretation criteria require knowledge of the normal 
radiolabelled WBC biodistribution (ie. blood and bone marrow) and pathological variants 
of WBC localization in different tissues and organs (2). The general agreement for osteo-
muscular infections and soft tissue infections is that at least two imaging time points are 
necessary, delayed (3-4 h after re-injection) and late (20-24 h). Early imaging (30 min-1 h 
after re-injection), which may be a surrogate for bone marrow uptake, is optional. Image 
interpretation can be made qualitatively (visual) or semiquantitatively (calculation). In case 
of doubtful planar images with suspected bone marrow expansion, bone marrow imaging 
with 99mTc-colloids is currently performed to reduce the false positive rate (5,10). For exact 
localization of the infection SPECT/CT may have added value (11).
In this article, we retrospectively compared in a large series of 99mTc-HMPAO-WBC planar 
scintigraphies in different types of infections, two different acquisition protocols (time-decay 
corrected versus fixed-time acquisition) and two different interpretation criteria (visual versus 
semiquantitative evaluation), to determine which is the best combination to obtain the 
highest diagnostic accuracy for infection versus sterile inflammation. The hypothesis is that a 
sterile inflammation will not show an increased focal uptake with time, differently from an 
infection, and that this trend of increase/decrease in time is better detectable by acquiring 
time-decay corrected images than fixed-time acquired images. 










This is a retrospective study analysing patients that were referred for scintigraphy with 
99mTc-HMPAO labelled WBC from January 2009 to December 2011, in three University centers 
(University Medical Center Groningen, University of Pisa Medical School, and Sapienza 
University of Rome). Ethics Committee approved the study in all centers. We therefore 
analyzed 235 patients (n=115 from University Medical Center Groningen; n=80 from 
University of Pisa Medical School; n=40 from Sapienza University of Rome) with suspected 
osteomyelitis, suspected prosthesis infection or suspected soft tissue infection as shown in 
Table 1. Infection was suspected on the basis of clinical examination, blood tests (including 
WBC counts, C-reactive protein, erythrocyte sedimentation rate, acute phase proteins), urine-
analysis, three sets of blood cultures including at least one aerobic and one anaerobic from 
a peripheral vein (12), and/or conventional radiology, e.g. plain X-ray, ultrasound and/or 
contrast-enhanced computed tomography (CT). 
Final diagnosis of an infection or exclusion of an infection was defined on the basis of 
pathological, microbiological, or clinical diagnosis, with clinical follow-up of more than 6 
months for all patients. Overall, 109 patients were diagnosed with an infection and 126 were 
negative for infection (see Table 2).
Table 1 Patient characteristics (n = 235)
Age (years)
 Mean  61
 Median  63
 Range  16-93
 SD  17
Sex, n (%) 
 Female  131 (56)
 Male 104 (44)
Type of suspected infection, n (%)
 Osteomyelitis  80 (34)
 Hip prosthesis  63 (27)
 Knee prosthesis  66 (28)
 Shoulder prosthesis  3 (1)
 Soft tissue    23 (10) 
Blood tests, n (%) 
 WBC counts
  Increased (>10x109/L)  13 (5)
  Normal  134 (57)
 C-reactive protein
  Increased (>5 mg/L)  74 (31)
  Normal  69 (29)
  Erythrocyte sedimentation rate    
  Increased (>15 mm/h)  69 (29)








Final diagnosis in all patients and divided in the two groups studied with fixed-time acquisition (FT) and time-
decay corrected acquisition (TDC).
Diagnosis Total, n (%)  FT, n (% of total n)  TDC, n (% of total n) 
Infection
 Osteomyelitis  35 (32)  24 (69)  11 (31)
 Infected hip prosthesis  23 (21)  8 (35)  15 (65)
 Infected knee prosthesis  31 (28)  16 (52)  15 (48)
  Infected shoulder prosthesis  3 (3)  3 (100)  0 (0)
 Soft tissue infection  17 (16)  7 (41)  10 (59)
 Total 109 (46)  58 (53)  51 (47)
No infection 126 (54) 48 (38) 78 (62)
99mTc-HMPAO-WBC preparation and imaging protocol
Preparation and labelling of WBC were performed according to the guidelines for the labelling 
of leukocytes with 99mTc-HMPAO from the European Association of Nuclear Medicine (8). 
Radiolabelling efficiency was always between 70-85%.
In 105 patients, we used the fixed-time (FT) acquisition protocol by acquiring planar delayed 
and late images for 600 seconds each. In 130 patients, we used the time-decay corrected 
(TDC) acquisition protocol by acquiring planar (static) images at 30 min-1 h (optional “early 
images”, 100-200 sec), at 3-4 h (“delayed images”, 133-300 sec) and at 20-24 h (“late 
images”, 951-2396 sec) after reinjection of 370-555 MBq 99mTc-HMPAO labelled WBC (see 
Table 3). 
All images (128×128 matrix size or 256x256 matrix size depending on centers) were acquired 
on a SPECT gamma camera system (Siemens Symbia T, Siemens Medical Systems (Groningen), 
Hawkeye, GE Healthcare (Pisa) or SkyLight, Philips (Rome)) equipped with low-energy high 
resolution collimators with energy window centered at the 140 keV photo-peak of 99mTc using 
a width of 20%. 
All images were displayed and analysed using the same workstation (Osiris), to avoid 
differences in display of different camera systems. TDC images were displayed in number of 
counts, using the same intensity scale both for delayed and late images, thereby avoiding 
operator-bias in changing the intensity scale. Therefore, FT images were displayed in % of 
maximum counts as they usually appear in automatic mode on both Siemens, GE and Philips 
workstations. 
SPECT/CT was performed for precise location of the infectious focus. In these cases, the low-
dose CT transmission scan was acquired for 16 seconds over 220° for each transaxial slice. 
The full FOV consisting of 40 slices was completed in 10 minutes. The transmission data were 
reconstructed using filtered back-projection to produce cross-sectional images. Resolution 
of the CT scan was 2.2 mm and localization images were produced with a 4.5 mm pixel 
size, similar to the nuclear medicine emission images. The CT scans were reconstructed into 
a 256×256 matrix. The SPECT component of the same FOV was acquired using a 128×128 








matrix, 360° rotation, 6° angle step, and 40/60-sec-per-frame acquisition time at 4 and at 
24 hours, respectively. Both CT-attenuation corrected and non-corrected SPECT images were 
evaluated in the coronal, transaxial, and sagittal planes, as well as in three-dimensional 
maximum intensity projection (MIP) cine mode. Matching pairs of x-ray transmission and 
radionuclide emission images were fused using the Xeleris workstation (Pisa), and hybrid 
images of overlying transmission and emission data were generated.
Table 3
Examples of acquisition times for the time-decay corrected images with 99mTc-HMPAO-WBC.
 Hours after the  Corrected acquisition time Corrected acquisition time
 1st acquisition (seconds) if early images  (seconds) if early images
  were acquired for 100 seconds were acquired for 200 seconds
Delayed images 1.5 119 238
 2 126 252
 2.5 133 267
 3 141 283
 3.5 150 300 
Late images 19.5 951 1902
 20 1007 2015
 20.5 1067 2135
 21 1131 2262
 21.5 1198 2396 
Visual and semiquantitative image interpretation
The planar scintigraphic images were visually analysed separately by two experienced nuclear 
medicine physicians (PE, AG); in case of disagreement by the two observers a third reader 
(AS) reviewed the images and his decision was considered as for the final classification. The 
studies were classified (a) “negative for infection” if no uptake was seen in both delayed and 
late planar images or when the uptake was the same or decreasing in time, and (b) “positive 
for infection” when at least one focus of abnormal uptake characterized by time-dependent 
increase in radioactivity or increase in size from delayed to late planar images was observed. 
In some positive patients with peripheral osteomyelitis, when differential diagnosis between 
bone and soft tissue involvement was not ascertained at planar images, we did perform 
SPECT/CT for exact localization.
The visual analysis was performed using the same criteria for the non-decay corrected and 
the decay corrected images. For semiquantitative analysis, in all images a ROI was drawn 
over the area suspected for infection and copied to presumed normal reference tissue (e.g. 
anterior-superior iliac crest, unaffected contralateral bone, etc.) The mean counts per pixel 
in these ROIs were recorded to calculate Target/Background (T/B) ratios both in delayed 
and late images. When the T/B was similar or decreased with time the scan was considered 
negative for infection; when the T/B increased with time, the scan was considered positive. 
Images were classified using different thresholds of increase of T/B ratio over time: ≤ 5, ≤10, 







Data analysis and statistics
Results of 99mTc-HMPAO-WBC scintigraphy were correlated with those of conventional 
radiologic imaging and with the final microbiological, pathological or clinical diagnosis. For 
each patient results of visual and semi-quantitative interpretation were compared to the final 
diagnosis. Semi-quantitative analysis using < 5, < 10, < 20, and < 25% of increase in time, 
were calculated. 
All values are expressed as median and range, as customary for nonparametric data. Comparison 
of the two groups for clinical and demographic factors was performed by Pearson’s X2. The 
readers inter-observer agreement rates were also evaluated and expressed in weighted 
kappa which corrects for agreement by chance. The sensitivity, specificity, diagnostic accuracy, 
negative predictive value and positive predictive value were calculated and differences 
between groups compared by Chi-squared test. All statistical evaluations were performed 
using the STATA Statistical Software package, Release 10-2010 (STATA Corporation, College 
Station, Texas, USA).
RESULTS
No significant difference in age distribution or any other clinical parameters between the two 
groups was observed.
By adopting the interpretation criteria described above for scintigraphic detection of infection, 
it was possible to classify all the scans as either frankly positive or frankly negative, therefore 
without any equivocal result. 99mTc-HMPAO-WBC scans were totally negative in 121 cases 
(47/105 FT acquisition and 74/130 TDC acquisition; p=ns). At least one abnormal area with 
focal accumulation of the radiolabelled leukocytes with increase in radioactivity over time, 
or size, was detected in the remaining 114 patients (58/105 FT acquisition and 56/130 TDC 
acquisition; p=ns). Table 4 shows the results of 99mTc-HMPAO-WBC at visual analysis, in all 
patients and according to the specific clinical indication. Overall, TDC acquired images, as 
compared to the FT acquired images, showed comparable sensitivity (94.1% versus 94.8%; 
p=ns) and NPV (96.3% versus 93.3%; p=ns), but better specificity (100% versus 89.4%; 
p=0.006), accuracy (97.7% versus 92.4%; p=0.05) and PPV (100% versus 91.6%; p=0.05). 
Figure 1 shows examples of positive and negative radiolabelled WBC scan at the visual 
analysis. Even though numbers vary according to the specific clinical indication, the better 
performances for the TDC acquired images at the visual analysis are invariable with the 
exception of soft tissue infections (Table 4). 
For the semiquantitative analysis we found best accuracy, sensitivity and NPV when considering 
any percentage of increase of radioactivity in the suspected lesion over time, for both FT and 
TDC acquired images. By contrast, specificity and PPV increased by increasing the threshold of 
percentage increase (Table 5). 
Furthermore, accuracy, specificity and PPV are generally higher in the semiquantitative 
analysis when images are acquired with FT method, whereas sensitivity and NPV are higher 
when images are acquired with TDC method (Table 6). This is particularly true for osteomyelitis 








and hip prosthesis, but not for soft tissue infections and knee prosthesis. Figure 2 provides 
examples of visual and semiquantitative interpretation of images.
Inter-observer agreement rates for the interpretation of 99mTc-HMPAO-WBC images were higher 
for TDC acquired images as compared to the FT acquired images (lack of consensus in 11% and 
19% of cases, respectively, with the lower agreement for hip and knee prosthesis infections). 
The rate of concordance between the visual and the semiquantitative analysis was better 
considering any % of increase of radioactivity in time and for the TDC images (200/235) 
either considering all patients together or considering osteomyelitis and prosthetic infections 
alone. In case of soft tissue infection, the best agreement was obtained comparing the visual 
and the semiquantitative analysis considering 5% of increase of radioactivity in time (always 
better for the TDC images). 
Table 4
Results of qualitative (visual) analysis of 99mTc-HMPAO-WBC scintigraphy as compared to final diagnosis.
 Visual vs final diagnosis
 Osteomyelitis Prosthesis hip Prosthesis knee Soft tissue Total
 FT TDC FT TDC FT TDC FT TDC FT TDC
TP 23 11 7 14 15 14 7 9 55a 48
TN 23 20 10 29 9 25 1 5 42 79
FP 2 0 1 0 2 0 0 0 5 0
FN 1 0 1 1 1 1 0 1 3 3
          
Sens 96 100 87 93 94 93 100 90 95 94
Spec 92 100 91 100 80 100b 100 100 89 100b
Acc 94 100 89 98 88 98b 100 93 92 98b
PPV 92 100 87 100 88 100b 100 100 92 100b
NPV 96 100 90 93 89 93 100 83 93 96
TP = true positive, TN = true negative, FP = false positive, FN = false negative, Sens = sensitivity, 
Spec = specificity, Acc = accuracy, PPV = positive predictive value, NPV = negative predictive value, 
FT = fixed-time acquisition, TDC = time-decay corrected acquisition
TP, TN, FP, and FN in numbers; Sens, Spec, Acc, PPV, and NPV in percentages.
a including 3 cases of shoulder prosthesis








Results of semiquantitative analysis of 99mTc-HMPAO-WBC scintigraphy compared to final diagnosis, specified for 
both acquisitions protocols.
 Semiquantitative vs final diagnosis
 Any T/B increase T/B increase>5% T/B increase>10% T/B increase>20% T/B increase>25%
 FT TDC FT TDC FT TDC FT TDC FT TDC
TP 56 48 46 38 41 34 30 24 26 18
TN 34 59 40 65 45 69 45 69 45 69
FP 13 20 6 15 2 10 2 10 2 10
FN 2 3 13 12 17 17 28 27 32 33
          
Sens 97 94 78 76 71 67 52 47 45 35
Spec 72 75 87 81 96 87 96 87 93 87
Acc 86 82 82 79 82 79 71 72 68 67
PPV 81 70 87 72 95 77a 94 71a 96 64a
NPV 94 95 75 84 73 80 62 72 58 68
TP = true positive, TN = true negative, FP = false positive, FN = false negative, Sens = sensitivity, 
Spec = specificity, Acc = accuracy, PPV = positive predictive value, NPV = negative predictive value, 
FT = fixed-time acquisition, TDC = time-decay corrected acquisition
TP, TN, FP, and FN in numbers; Sens, Spec, Acc, PPV, and NPV in percentages.
a p < 0.05 (TDC compared to FT)
Table 6
Results of semiquantitative analysis of 99mTc-HMPAO-WBC scintigraphy, defined for each specific indication and 
compared to final diagnosis, specified for both acquisition protocols.
 Semiquantitative vs final diagnosis (any T/B increase)
 Osteomyelitis Prosthesis hip Prosthesis knee Soft tissue
 FT TDC FT TDC FT TDC FT TDC
TP 23 11 7 14 16 14 7 9
TN 23 17 9 20 6 17 1 5
FP 2 3 2 9 4 8 0 0
FN 1 0 1 1 0 1 0 1
        
Sens 96 100 88 93 100 93 100 90
Spec 92 85 82 69 60 68 100 100
Acc 94 90 84 77 85 78 100 93
PPV 92 79 78 61 80 64a 100 100
NPV 96 100 90 95 100 94 100 83
TP = true positive, TN = true negative, FP = false positive, FN = false negative, Sens = sensitivity, 
Spec = specificity, Acc = accuracy, PPV = positive predictive value, NPV = negative predictive value, 
FT = fixed-time acquisition, TDC = time-decay corrected acquisition
TP, TN, FP, and FN in numbers; Sens, Spec, Acc, PPV, and NPV in percentages.
a p < 0.05 (TDC compared to FT)









99mTc-HMPAO-WBC scintigraphy in patients with suspected bone and knee prosthesis infections acquired after 
4 h (delayed images) and 20 h (late images) with either fixed-time acquisition modality (left and middle 
panels) or time-decay corrected modality (right panels). In all cases the visual analysis correctly diagnosed 
osteomyelitis (left panel), aseptic bone marrow expansion (middle panel) and right knee infected prosthesis vs 
non-infected left knee prosthesis (right panel).
 
Figure 2
99mTc-HMPAO-WBC scintigraphy in two different patients with suspected low grade infection of the right 
hip prosthesis acquired after 4 h (upper panels) and 20 h (lower panels) with either fixed-time acquisition 
modality (left panels) or time-decay corrected modality (right panels). Images A and B at visual analysis were 
judged negative and semi-quantitative analysis showed a stable T/B over time (equivocal for infection). After 
prosthesis removal microbiology showed the presence of infection. Images C and D at visual analysis were 
judged negative and semi-quantitative analysis showed a stable T/B over time (equivocal for infection). After 
prosthesis removal microbiology confirmed the absence of infection. These two examples highlights how TDC 








It is commonly accepted that WBC images are visually classified as (i) negative if no uptake or 
a decrease in uptake from delayed to late images is present, (ii) positive when uptake is seen 
in both delayed and late images with increase in activity or size in time, and (iii) equivocal 
when uptake in delayed and late images is the same or slightly decreasing. However, a general 
criticism to the visual analysis is that it is strictly operator dependent and that the final results 
may differ significantly when images are acquired and displayed, using different ways with 
different contrast and background. Acquisition protocols are variable. Some author acquire, 
early, delayed and late images, with a fixed constant time for all images; others acquire all 
images with a fixed number of counts, but both methods are not corrected for isotope decay, 
are influenced by variations of background activity and are operator dependent. To reduce 
variability some authors suggest, after acquisition, to display images equalizing bone marrow 
activity, as reference. However, also bone marrow activity may change in time, therefore this 
modality of displaying images does not improve accuracy and is limited to expert readers and 
some regions of the body with a good bone-marrow activity. 
We suggest here to acquire images at different time points with different acquisition times, 
starting from a settled amount of time in the early images and deriving the corresponding 
acquisition time for delayed and late images by correction due to isotope decay (as shown in 
Table 3). As a result, delayed and late images have the same counting statistics of early images 
and comparison is possible reducing the operator bias (13-16). It is of course mandatory to 
display all images with same intensity scale in counts units and not in percentage of max 
counts per pixels that is another common display error. If images are correctly acquired and 
displayed, they are operator independent, reproducible, comparable and easy to interpret.
We used the same software system (Osirix) for all patients, in order to avoid differences in 
display of different software systems between the centers. However, we want to state that all 
data are reproducible on all three systems (GE, Philips and Siemens) by displaying images in 
count units with the same intensity scale.
Semiquantitative analysis may also be helpful when visual interpretation is doubtful. Regions 
of interest (ROIs) can be drawn over the part of the presumed infected focus, copied to 
presumed normal reference tissue (e.g. anterior-superior iliac crest, contralateral bone), and 
target-to-background (T/B) ratios can be calculated. However, location of ROIs in lesion and 
reference tissue is operator dependent. Additionally, the level of significance of the T/B ratios 
is arbitrarily decided and no studies have yet defined the threshold of increase of radiolabelled 
WBC over time to be considered positive. 
In this study, we retrospectively compared two different acquisition protocols for planar 
images (TDC vs. FT) and two different interpretation criteria (visually vs. semiquantitatively) 
to determine the criteria that allow highest diagnostic performances. 
Best results were obtained with TDC acquired images and visual analysis for bone associated 
infections but not for soft tissue infections. Despite statistical significance is reached only when 








considering the whole group of patients, for each bone indication a consistent improvement of 
the diagnostic performances was always achieved by acquiring TDC images. The added value 
of the TDC acquisition is more evident in patients with bone and prosthetic infections, hereby 
potentially limiting the need for bone marrow imaging with colloids. The FT acquired images 
possibly have an advantage in term of sensitivity, but lead to a significant drop in specificity 
and diagnostic accuracy. On the other hand, when soft tissue infections were considered, 
the advantage of TDC acquisition was not evident. This may have several explanations. First, 
there might be different kinetics of migration of radiolabelled WBC in bones and soft tissues. 
Additionally, soft tissue infections included muscular, brain, abdominal, heart, lung or dermal 
infections, thus being a very heterogeneous group with possible different behavior in terms of 
leukocyte recruitment and may need “ad hoc” interpretation criteria as already demonstrated 
for dermal filler infections and dermal infections in diabetic foot (13,14). In our study the 7 
cases of soft tissue infections acquired with FT modality were mainly muscular infections, 
whereas the 10 soft tissue infections acquired with TDC modality were all dermal infections 
and this difference may account for the different accuracy in our results.
Overall, the main advantage of TDC acquisition protocol is represented by the absence of 
operator interference and bias, that, by contrast, can strongly affect the results of FT acquired 
images. Indeed, TDC images were displayed in number of counts, using the same intensity 
scale both for delayed and late images, thereby avoiding operator-bias in changing the 
intensity scale. This is essential when interpreting time-decay corrected images but it is not 
possible when images are acquired with a fixed-time protocol. In this study there was little 
but significant difference in global diagnostic accuracy between FT and TDC acquired images 
(92.4% versus 97.7%; p<0.05) but we should consider that readers were experts also in FT 
acquired images. Indeed we can expect that a lower diagnostic accuracy of FT acquired images 
can be observed for less expert readers thus being TDC acquired images even more relevant. 
Our results indicate that any percentage of radioactivity increase over time leads to high 
sensitivity (Table 5). Increasing the threshold to i.e. 20% radioactivity increase over time 
improves specificity, but lowers sensitivity. 
The threshold of the percentage of T/B increase over time may be affected by several 
parameters such as the type of infection (acute versus chronic), the type of disease 
(osteomyelitis versus soft tissue infections), the sustaining microorganisms and the presence 
of concomitant antimicrobial treatment. Since all these factors can significantly modify the 
intensity and the pattern of radiolabelled WBC over time, further studies are warrant to give 
clinical validation to this approach. 
Another point of discussion is the placement of the ROIs, which can differ between operators 
(contralateral, bone marrow, etc.). Despite a recent study from our group showed that 
the contralateral region is the most accurate for positioning the ROI for the background 
semi-quantitative calculation (16), in this study it was not possible to apply this criterion 
and background ROIs were positioned either on ipsilateral bone marrow or muscle when 







To better localize the site and extent of infection, SPECT/CT images may be used. If sequential 
SPECT images are acquired, acquisition times for SPECT can also be normalized according 
to isotope decay using the same decay formula shown in Table 3. SPECT/CT is invaluable 
to better identify the site and delineate the extent of 99mTc-HMPAO-WBC uptake (i.e. bone 
or soft tissue) as compared to the planar and stand-alone SPECT images due to the easy 
identification of either bloodpool activity at the vascular bed or at bone marrow or e.g. non 
specific accumulation of 99mTc-HMPAO in the bowel. In this study, however, SPECT/CT was not 
used for diagnosing infection but for determining its extent in positive planar images.
The role of SPECT/CT has been established for soft tissue infections (14), endocarditis, cardiac 
devices, vascular prosthesis infections (11) and diabetic foot (17) when the need of anatomical 
landmarks is relevant. However, in some circumstances attention should be paid since intense 
uptake of the radiolabelled WBC localized close to the bone may lead to false positive results 
for osteomyelitis (see Figure 3).
Figure 3
Planar images of feet of a patient with a suspected osteomyelitis consequent to a fracture of the calcaneus 
bone with a cutaneous wound. At 30 min post-injection (early image) image was acquired for 100 sec/frame 
(61,269 counts) (A). At 3 h post-injection (delayed image, 2.5 hrs after first image) image was acquired for 
133 sec/frame (52,274 counts) (B). At 20 h post-injection (late image, 19.5 hrs after first image) image was 
acquired for 951 sec/frame (52,212 counts) (C) showing evident decrease of activity at visual analysis, sign of 
no osteomyelitis. At 3 h semiquantitative analysis showed T/B=2.2 and at 20 hrs T/B=1.8 confirming a decrease 
with time, sign of no infection but just wound inflammation.
The SPECT/CT at 20 hrs (D-G) however, does not allow to clearly identify the origin of uptake (cutaneous vs 
bone surface), thus being the visual analysis of planar imaging more accurate. Patient was operated to remove 
the bone fragment and no sign of osteomyelitis was confirmed at histology.








When evaluating bone/prosthesis infection and soft tissue infections, whole body imaging is 
mostly not necessary. However, such images allowed the check for the normal biodistribution 
of the radiolabelled autologous leukocytes and also the detection of distant sites of infection 
when suspected. In cases of sequential whole body imaging, acquisition times can also be 
normalized. 
A final comment is deserved to reassure from the general perception that TDC acquisition 
protocol is a very long time-consuming procedure, particularly for late images acquisition that 
might discourage the routine use of this protocol. In fact, at least in the majority of the cases, 
if the early images recorded for comparative purpose are acquired for a total of 300 seconds, 
the corresponding late images are completed in about 45 minutes that is a time recording 
very well tolerate by the majority of the patients. Indeed, in our experience we usually do not 
recorded any problem of patients’ compliance.
CONCLUSIONS
When having a suspicion of a prosthetic joint infection or osteomyelitis, WBC scintigraphy 
should be performed by acquiring images at least at two time points, one at 3-4 hours 
(delayed images) and one at 20-24 hours (late images). Early images (at 30min-1h post-
injection) may also be performed to have an early map of bone marrow distribution, but are 
not strictly necessary. 
The most reproducible and accurate acquisition protocol in musculoskeletal infections is using 
time-decay corrected acquisitions. 
Images must then be displayed using the same intensity scale in count units and not in 
percentage of max counts per pixel. 
When these methodological considerations are fulfilled, visual analysis of images is 
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White blood cell (WBC) scintigraphy is considered the nuclear medicine imaging gold standard 
for diagnosing osteomyelitis in the diabetic foot. Recent papers have suggested that the use 
of 18F-FDG PET/CT produces similar diagnostic accuracy, but clear interpretation criteria have 
not yet been established. Our aim was to evaluate the role of sequential 18F-FDG PET/CT in 
patients with a high suspicion of osteomyelitis to define objective interpretation criteria to be 
compared with WBC scintigraphy. 
Methods
Thirteen patients whom clinicians considered positive for osteomyelitis (7 with ulcers, 6 with 
exposed bone) were enrolled. The patients underwent 99mTc-exametazime WBC scintigraphy 
with acquisition times of 30 min, 3 h, and 20 h and sequential 18F-FDG PET/CT with acquisition 
times of 10 min, 1 h, and 2 h. A biopsy or tissue culture was performed for final diagnosis. 
Several interpretation criteria (qualitative and quantitative) were tested. 
Results
At final biopsy, 7 patients had osteomyelitis, 2 had soft-tissue infection without osteomyelitis, 
and 4 had no infection. 
The best interpretation criterion for osteomyelitis with WBC scintigraphy was a target-to-
background (T/B) ratio greater than 2.0 at 20 h and increasing with time. A T/B ratio greater 
than 2.0 at 20 h but stable or decreasing with time was suggestive of soft-tissue infection. 
A T/B ratio of no more than 2.0 at 20 h excluded an infection. Thus, sensitivity, specificity, 
positive predictive value, negative predictive value, and accuracy for osteomyelitis were 86%, 
100%, 100%, 86%, and 92%, respectively. 
For 18F-FDG PET/CT, the best interpretation criterion for osteomyelitis was a maximal 
standardized uptake value (SUVmax) greater than 2.0 at 1 and 2 h and increasing with time. A 
SUVmax greater than 2.0 after 1 and 2 h but stable or decreasing with time was suggestive of 
a soft tissue infection. An SUVmax less than 2.0 excluded an infection. 18F-FDG PET at 10 min 
was not useful. Using these criteria, sensitivity, specificity, positive predictive value, negative 
predictive value, and accuracy for osteomyelitis were 43%, 67%, 60%, 50%, and 54%, 
respectively. Combining visual assessment of PET at 1 h and CT was best for differentiating 
between osteomyelitis and soft-tissue infection, with a diagnostic accuracy of 62%. 
Conclusion
18F-FDG PET/CT, even with sequential imaging, has a low diagnostic accuracy for osteomyelitis 








According to data from the World Health Organization, about 180 million people in the 
world have diabetes mellitus, with foot infection being one of the most common and severe 
complications (1). Up to 15% of diabetic patients will develop foot ulcers, and about 15%–25% 
of these patients require amputation (2–4). About 2.5% of diabetic patients have a Charcot 
joint, a progressive degenerative disease of the musculoskeletal system usually involving 
the tarsal and tarsometatarsal joints (5). The disorder results in destruction of bone and 
soft tissue, causing significant damage to the bony architecture. Clinically, patients present 
with swelling, crepitus, palpable loose bodies, and osteophytes. The etiology may be caused 
by peripheral neuropathy complicated by motor, sensory, and autonomic disorders, and to 
vascular insufficiency, both secondary to diabetes. In addition, local trauma or pressure may 
result in diabetic foot. Antibiotic therapy, in conjunction with conservative surgery (debriding), 
may be curative and avoid amputation, but an early and prompt diagnosis is necessary. 
The detection of diabetic foot infection can be difficult. With clinical examination, it is difficult to 
differentiate between soft-tissue infection and osteomyelitis. The erythrocyte sedimentation 
rate is not specific (6). Bone biopsy is not always performed because it is an invasive procedure 
that loses its reliability when the biopsy fragment is contaminated by cutaneous bacteria (7). 
Therefore, imaging is crucial in the evaluation. Plain radiography and CT are used routinely but 
are not accurate enough. MRI is able to differentiate between osteomyelitis and soft-tissue 
infection (1,8), but the specificity is reduced if bony destruction, dislocation, marrow edema, 
synovial effusion, and loss of discernible bone and joint margins are present—conditions that 
characterize neuropathic joints as well as osteomyelitis. 
Nuclear medicine techniques play an important role in the diagnosis of infections. The 
sensitivity of 3-phase bone scintigraphy has been quite variable (≤ 75%) (9,10), but specificity 
for osteomyelitis in diabetic foot infection is low. White blood cell (WBC) scintigraphy with 
either 99mTc-exametazime– or 111In-oxine–labeled cells is currently the radionuclide gold 
standard for the diagnosis of osteomyelitis. The labeling method is well described in several 
guidelines, including those from the European Association of Nuclear Medicine, Society of 
Nuclear Medicine, and International Society of Radiolabeled Blood Elements (11–15). 
Another possibility is the use of 18F-FDG PET/CT, which has some theoretic advantages: no 
blood manipulation is necessary, acquisition time is shorter, and image resolution is higher. 
18F-FDG accumulates in inflammatory cells because these, like malignant cells, metabolize 
glucose as a source of energy (16). With the routine 18F-FDG PET protocols, it is not possible to 
reliably distinguish infection from inflammation. No acquisition protocols for 18F-FDG PET in the 
diabetic foot have yet been validated, and only a few comparison studies between 18F-FDG 
PET and WBC scintigraphy are available. 
One aim of this study was to define whether a new acquisition protocol with sequential 
18F-FDG PET/CT may help in differentiating between infection and inflammation and may 
contribute to the diagnosis of osteomyelitis in the diabetic foot. To meet this aim, we compared 







this protocol with WBC scintigraphy for diagnostic accuracy. Another aim was to investigate 
possible interpretation criteria—both qualitative and quantitative—for WBC scintigraphy and 
for 18F-FDG PET/CT to see which criteria are best able to differentiate between osteomyelitis, 
soft-tissue infection, and no infection at all. 
MATERIALS AND METHODS
Patients
Thirteen diabetic patients with a high clinical suspicion of foot osteomyelitis, as evaluated 
by the diabetologist and surgeon, were included in this study (12 men and 1 woman) and 
evaluated using WBC scintigraphy and sequential 18F-FDG PET/CT. Seven patients had ulcers 
of the forefoot or mid- to hindfoot with exposed bone, and 6 patients had a high clinical 
suspicion of osteomyelitis without exposed bone. The high clinical suspicion was based on 
the presence of signs and symptoms of infection. Wound infection was defined according to 
the criteria of the International Working Group on the Diabetic Foot as the presence of 2 or 
more signs and symptoms of local inflammation or systemic signs of infection with no other 
apparent cause, along with purulent exudates (17). In addition, other specific signs such as 
necrosis, delayed wound healing, and foul odor were used. 
Five patients had an increased level of hemoglobin A1c, but all had a blood glucose level below 
160 mg/dL at time of the 18F-FDG PET/CT scan. Four patients had an increased erythrocyte 
sedimentation rate and C-reactive protein, and 5 patients had leukocytosis. All patients were 
treated with antibiotic therapy, but this therapy was suspended 1 wk before the imaging 
studies, thereby not reducing the sensitivity of the imaging. The patients’ characteristics are 
listed in Tables 1 and 2. 
WBC scintigraphy was performed on day 1 and, for the delayed acquisition, at 20 h (day 
2), and 18F-FDG PET/CT was performed on day 2. One patient also underwent bone marrow 
scintigraphy with 99mTc-nanocolloids for differential diagnosis of Charcot foot. All patients 
underwent biopsy or surgery for definitive diagnosis within a week of the scans. 
Informed consent was obtained from all patients as requested by the local Medical Ethical 
Committee. 
99mTc-Exametazime WBC scintigraphy
WBC scintigraphy was performed according to previously published methods, with slight 
modifications (12,14), using Leukokit (Gipharma). Images of the foot (anteroposterior and 
mediolateral views) were acquired 30 min (100 s/image), 3 h (140 s/image), and 20 h 
(1,040 s/image) after intravenous injection of 555–740 MBq of 99mTc-exametazime. Because 
calculation of acquisition time was based on the decay of technetium, the resulting images 
were decay-corrected and their interpretation did not require an operator postacquisition 
modification. 
In 1 equivocal case, a bone marrow scan was performed using 185 MBq of 99mTc-Nanocoll (GE 
Healthcare) with images acquired 20 min after injection (600 s/image). This bone marrow 











   Men  12
   Women 1
Involved foot
   Left  7
   Right  6
Age (y)
   Mean ± SD  62.2 ± 10.9
   Range  50-89
Erythrocyte sedimentation rate (mm/h)
   Mean ± SD  56.8 ± 37.7
   Range  2.9-116
C-reactive protein (mg/L)
   Mean ± SD  6.2 ± 5.7
   Range  1.2-15.4
Leukocytes (109/L)
   Mean ± SD  7.3 ± 1.4
   Range  6-10
Days of antibiotic therapy
   Mean  45
   Range  30-60
18F-FDG PET/CT 
Patients had to fast for at least 6 h before receiving a 185 MBq intravenous injection of 
18F-FDG. They followed their regular drug schedule. The blood glucose level was measured 
before injection and was less than 160 mg/dL in all patients. 18F-FDG PET and unenhanced CT 
images of the lower limbs were acquired at 10 min (3 min per bed position), 1 h (4.5 min per 
bed position), and 2 h (6 min per bed position) after the injection, considering 18F decay time. 
A Gemini PET/CT system (Philips) was used, combining a third-generation multislice spiral 
CT scanner (low-dose, 16-slice, 100-mAs) with a dedicated full-ring PET scanner (bismuth 
germinate crystals). The PET and CT devices were mechanically aligned back to back and 
shared a table. Proper registration of images was ensured by shared positional information on 
the table and patient for both the CT and the PET acquisitions. Data obtained from the CT scan 
were used for attenuation correction of the PET data and for fusion with attenuation-corrected 
PET images to integrate physiologic and anatomic images. 








Characteristics of involved regions, type and size of the lesions, and results of bone biopsies and microbiology
 Patient Involved Charcot Type of Size of Bone biopsy Microbiology Final
 no. region foot lesion lesion (cm)   diagnosis
 1 Forefoot No Ulcer 2 x 2 x 2  Negative Sterile Negative
 2 Hindfoot Yes Ulcer 8 x 5  Negative Sterile Negative
 3 Hindfoot No Bone 5 x 1 x 2  Negative Sterile Negative
    exposed
 4 Forefoot No Ulcer 2 x 1 Negative Sterile Negative
 5 Hindfoot Yes Ulcer 6 x 7 Negative Proteus Soft-tissue
       mirabilis infection
 6 Forefoot No Ulcer 2 x 2  Negative Staphylococcus Soft-tissue
       epidermidis infection
 7 Forefoot No Ulcer 2 x 1 Osteomyelitis Staphylococcus Osteomyelitis
       aureus
 8 Forefoot No Bone 8 x 2 x 4  Osteomyelitis Staphylococcus Osteomyelitis
    exposed    aureus 
 9 Forefoot/midfoot No Bone 5 x 6 x 4  Osteomyelitis Staphylococcus Osteomyelitis
    exposed   aureus
 10 Forefoot/midfoot Yes Bone 6 x 3 x 7  Osteomyelitis Streptococcus Osteomyelitis
    exposed   agalactie
 11 Midfoot No Bone 5 x 1 x 2  Osteomyelitis Sterile Osteomyelitis
    exposed
 12 Forefoot No Bone 3 x 2 x 1  Osteomyelitis Staphylococcus Osteomyelitis
    exposed   epidermidis
 13 Forefoot No Ulcer 1 x 1 cm Osteomyelitis Staphylococcus Osteomyelitis
       aureus
Imaging analysis
For WBC scintigraphy, the determination of abnormal increased uptake was based qualitatively 
on visual assessment of asymmetry versus symmetry in comparisons with the other foot and 
with other parts of the same foot. The area of suspected infection was identified, and a 
region of interest was drawn around this lesion (target). The WBC scintigraphy findings were 
assessed quantitatively by drawing a second region of interest on the same area on the other 
foot (background) and calculating the target-to-background ratio (T/B) at each time point. 
For 18F-FDG PET/CT, the same procedure was followed. For quantification, the maximal 
standardized uptake value (SUVmax) in the target lesion was calculated at each time point. 
All images were analyzed by 3 independent nuclear medicine physicians, who reached 
agreement in every case. 
Bone biopsy, cultures, and surgery 
Bone biopsy was performed for a definitive diagnosis. The sample of bone (a small cylinder 
a few millimeters in length and 1.5–2 cm in diameter) was taken from the site of suspected 
osteomyelitis. The procedure was performed in outpatient settings and with local anesthesia. 
Biopsies were analyzed histologically for neutrophilic infiltration (considered a sign of 
osteomyelitis). When surgery was necessary, the bone biopsy was performed, or samples for 








To determine the highest diagnostic accuracy, several cutoff values of T/B and SUVmax were 
considered. Data were compared, and t tests were used when appropriate. 
RESULTS
Results of biopsy and microbiology
After biopsy or culture, osteomyelitis was proven in 7 patients and soft-tissue infection without 
bone involvement in 2. Four patients had no infection (Table 2). These final diagnoses were 
considered the gold standard. 
99mTc-Exametazime WBC scintigraphy
Table 3 lists the results of WBC scintigraphy and the T/B ratios after 30 min, 3 h, and 20 h. The 
visual (qualitative) assessment of the WBC scintigraphy showed a high diagnostic accuracy 
for the final diagnosis (92%). The best quantitative results occurred when the following 
interpretation criteria were used (Table 4): WBC scintigraphy was considered negative for an 
infection when the T/B ratio was no more than 2.0 after 20 h and the ratios were stable or 
decreasing over time; WBC scintigraphy was considered positive for osteomyelitis when the 
T/B ratio after 20 h was more than 2.0 and the ratios were increasing over time; and WBC 
scintigraphy was considered positive for a soft-tissue infection when the T/B ratio after 20 h 
was more than 2.0 but the ratios were stable or decreasing over time. 
Using these criteria, WBC scintigraphy was able to identify correctly all 4 patients who 
were without infection and 6 of the 7 patients with proven osteomyelitis. Only 1 patient 
was considered to have a soft-tissue infection on WBC scintigraphy but had a final diagnosis 
of osteomyelitis. This patient was also considered to have a soft-tissue infection on visual 
assessment. In the 2 patients who had a final diagnosis of soft-tissue infection, these 
quantitative criteria gave the correct diagnosis. Overall, the sensitivity, specificity, positive 
predictive value, negative predictive value, and diagnostic accuracy for osteomyelitis with 
these quantitative interpretation criteria were 86%, 100%, 100%, 86%, and 92%, respectively. 
18F-FDG PET/CT
The results of 18F-FDG PET/CT, including SUVmax calculated at 10 min, 1 h, and 2 h after 
injection, are also listed in Table 3. The best quantitative results were obtained using 
interpretation criteria that were comparable with the criteria of the WBC scintigraphy. 
However, the calculated T/B ratios 10 min after injection were not useful. The following 
interpretation criteria were used (Table 4): 18F-FDG PET was considered negative for infection 
when the SUVmax was less than 2.0 after 1 and 2 h; 18F-FDG PET was considered positive for 
osteomyelitis when the SUVmax was more than 2.0 after 1 and 2 h and was increasing over 
time; 18F-FDG PET was considered positive for a soft-tissue infection when the SUVmax was 
more than 2.0 after 1 and 2 h, but was stable or decreasing over time. 








Quantitative and qualitative results of WBC scintigraphy and 18F-FDG PET/CT compared with final diagnosis by 
biopsy
Pt  WBC scan  18F-FDG PET/CT scan
 no. 30 3 h 20 h Quantitative Qualitative 10 1 h 2 h Quantitative Qualitative Final
  min   result result min   results result + CT diagnosis
 1 2.1 1.9 1.5 Negative Negative 2.3 2.7 3.1 Osteo- Soft-tissue Negative
          myelitisa infection
 2 2.0 1.9 2.0 Negative Negative 2.0 1.9 1.9 Negative Negative Negative
 3 1.0 1.0 0.9 Negative Negative 1.4 1.4 1.6 Negative Negative Negative
 4 2.6 2.0 1.8 Negative Negative 0.6 1.5 1.0 Negative Negative Negative
 5 3.4 2.6 2.1 Soft-tissue Soft-tissue 2.0 2.4 2.6 Osteo- Osteo- Soft-tissue
     infection infection    myelitis myelitis infection
 6 1.5 2.1 2.1 Soft-tissue Soft-tissue - 3.6 2.8 Soft-tissue Soft-tissue Soft-tissue
     infection infection    infection infection infection
 7 2.1 3.0 3.0 Soft-tissue Soft-tissue - 3.6 3.2 Soft-tissue Soft-tissue Osteo-
     infection infection    infection infection myelitis
 8 2.3 2.5 2.7 Osteo- Osteo- 2.2 3.1 2.6 Soft-tissue Soft-tissue Osteo-
     myelitis myelitis    infection infection myelitis
 9 1.6 1.6 2.4 Osteo- Osteo- 1.8 2.2 2.9 Osteo- Osteo- Osteo-
     myelitis myelitis    myelitis myelitis myelitis
 10 3.0 3.9 5.1 Osteo- Osteo- 2.5 3.8 4.0 Osteo- Osteo- Osteo-
     myelitis myelitis    myelitis myelitis myelitis
 11 1.7 1.6 2.4 Osteo- Osteo- 2.4 2.8 2.8 Soft-tissueb Osteo- Osteo-
     myelitis myelitis    infection myelitis myelitis
 12 1.8 2.6 3.4 Osteo- Osteo- 2.0 1.8 1.6 Negative Negative Osteo-
     myelitis myelitis      myelitis
 13 3.6 8.1 13.9 Osteo- Osteo- 2.7 3.4 3.6 Osteo- Osteo- Osteo-
     myelitis myelitis    myelitis myelitis myelitis
aCT allowed exclusion of osteomyelitis but not soft-tissue infection
bCT allowed detection of osteomyelitis
Table 4
Interpretation criteria for WBC scintigraphy and 18F-FDG PET/CT
 Diagnosis WBC scintigraphy 18F-FDG PET/CT
 Negative for infection T/B ratio ≤ 2.0 after 20 h SUVmax < 2.0 after 1 and 2 h
  T/B ratios stable or decreasing over time 
 Osteomyelitis T/B ratio > 2.0 after 20 h SUVmax > 2.0 after 1 and 2 h
  T/B ratios increasing over time SUVmax increasing over time
 Soft-tissue infection T/B ratio > 2.0 after 20 h SUVmax > 2.0 after 1 and 2 h







Using these criteria, 18F-FDG PET was able to correctly identify 3 of the 4 patients who were 
without infection. One infection-free patient was considered to have osteomyelitis using 
these criteria. Only 3 of the 7 patients with proven osteomyelitis were correctly identified by 
18F-FDG PET. Of the remaining 4, 3 were considered to have a soft-tissue infection and 1 was 
considered to have no infection. Of the 2 patients with a soft-tissue infection, 1 was correctly 
identified by 18F-FDG PET and the other was considered to have osteomyelitis. The overall 
sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic 
accuracy of 18F-FDG PET for osteomyelitis with these quantitative interpretation criteria, was 
43%, 67%, 60%, 50%, and 54%, respectively. 
Combining the visual (qualitative) assessment of the 18F-FDG PET and CT images changed the 
results for 2 patients. In 1 patient, considered to have osteomyelitis when the interpretation 
criteria were used, CT allowed exclusion of osteomyelitis and showed a soft-tissue infection. 
This patient had a negative final diagnosis. In the other patient, with a soft-tissue infection 
when the interpretation criteria were used, CT was able to detect osteomyelitis. The overall 
diagnostic accuracy for the qualitative assessment was 62%. 
Examples of use of the interpretation criteria for WBC scintigraphy and 18F-FDG PET/CT are 
shown in Figures 1–3.
DISCUSSION
Infection of the diabetic foot is a common complication in diabetic patients and often requires 
hospitalization. Early diagnosis is invaluable but is difficult using noninvasive imaging 
techniques. Different radiologic and nuclear medicine imaging techniques are available, but 
most lack accuracy. WBC scintigraphy is considered the nuclear medicine gold standard and has 
high accuracy. To preserve cell viability, it is important that WBCs be labeled using a validated 
method performed by trained personnel. It is an ex vivo procedure for which there are several 
available guidelines. The image acquisition method and interpretation criteria may vary among 
centers and countries but are also important because they may affect the diagnostic accuracy 
of the technique (procedural guidelines are also available from most scientific societies). The 
use of 18F-FDG PET/CT should have the advantages of easier preparation, shorter acquisition 
times, and better image resolution, besides the fact that no blood manipulation is necessary. 
However, when one is following normal 18F-FDG PET protocols that call for imaging 60–90 min 
after injection, differentiation between infection and inflammation is usually not possible.








In patient 3, negative results concordant between WBC scintigraphy (T/B ratio < 2.0 and decreasing 
over time) and 18F-FDG PET/CT (SUVmax < 2.0): clinical image of diabetic foot (A); anterior and posterior 








Therefore, the aim of this study was to determine whether sequential 18F-FDG PET/CT could 
help with this differentiation. The results were discouraging. Several interpretation criteria 
were tried, but even the best criterion had only a low diagnostic accuracy. For example, 
when we used a criterion of SUVmax (after 2 h) > SUVmax (after 1 h) or SUVmax (after 1 h) > 
SUVmax (after 10 min), all patients were positive for osteomyelitis, including 3 of 4 patients 
that were finally found to be negative for infection. The highest accuracy for osteomyelitis was 
obtained using a positivity criterion of an SUVmax (after 2 h) of at least 2.0 and increasing 
over time. However, the diagnostic accuracy remained low: 54%. A typical pattern for 18F-FDG 
uptake over time in patients with a diabetic foot could not be defined. 
The acquisition 10 min after injection was found not to be useful. A dual-acquisition protocol 
could be helpful for differentiating between osteomyelitis and soft-tissue infection, but of 
primary relevance for this differentiation is the CT component. The contribution of CT is more 
important than the interpretation criteria, because the CT images contribute to the conclusion 
about whether the 18F-FDG uptake is primarily in the bone or in the surrounding soft tissue.
The literature includes only a few studies of the role of 18F-FDG PET (or PET/CT) in diabetic-
foot patients, and most of these studies had high accuracy results. Basu et al. evaluated a 
total of 63 patients and found a high SUVmax of 2.9–6.2 for osteomyelitis, compared with 
0.7–2.4 for Charcot joints and 0.2–0.7 for uncomplicated diabetic foot. The authors stated that 
18F-FDG PET can differentiate between Charcot neuroarthropathy, osteomyelitis, and soft-tissue 
infection (16). The same group also compared the utility of 18F-FDG PET with that of MRI and 
radiography in 101 subjects. 18F-FDG PET correctly diagnosed osteomyelitis in 21 of 26 patients 
and correctly excluded it in 74 of 80, with sensitivity, specificity, positive predictive value, 
negative predictive value, and accuracy of 81%, 93%, 78%, 94%, and 90%, respectively 
(18). Keidar et al. used PET/CT to evaluate 14 diabetic patients with 18 clinically suspected 
sites of infection for suspected osteomyelitis complicating diabetic foot disease. PET detected 
14 foci of increased 18F-FDG uptake suspected of being infection in 10 patients. PET/CT 
correctly localized 8 foci in 4 patients to bone, indicating osteomyelitis, and correctly excluded 
osteomyelitis in 5 foci in 5 patients, with the 18F-FDG uptake limited to infected soft tissues. 
Four patients showed no increased uptake and no further evidence of an infectious process 
on follow-up. The authors concluded that 18F-FDG PET can be used for diagnosis of diabetes-
related infection and that PET/CT enables accurate differentiation between osteomyelitis and 
soft-tissue infection (2). Only 1 study, published by Schwegler et al., found disappointing 
results for 18F-FDG PET, with MRI being superior to 18F-FDG PET and to 99mTc-labeled monoclonal 
antigranulocyte antibody scintigraphy (19). 
The low diagnostic accuracy we found for 18F-FDG PET, even with sequential scanning, is 
discordant with most results known from the literature. The reason for our low accuracy is not 
understood. A possible reason could be that the long duration of infection and lengthy use 
of antibiotics (mean, 45 d) led to a low uptake of 18F-FDG. However, our study also found a 
role for PET/CT in differentiation between osteomyelitis and soft-tissue infection, but the CT 
component was most important in that differentiation. 








In patient 13, positive osteomyelitis results concordant between WBC scintigraphy (T/B ratio > 2.0 and 
increasing over time) and 18F-FDG PET/CT (SUVmax > 2.0 and CT-confirmed localization in bone): clinical image 
of diabetic foot (A); anterior and posterior WBC scintigraphy images after 30 min, 3 h, and 20 h (B); transaxial 








In patient 12, discordant results between WBC scintigraphy, which was positive for osteomyelitis (T/B ratio 
> 2.0 and increasing over time), and 18F-FDG PET/CT, which was negative for osteomyelitis (SUVmax < 2.0): 
clinical image of diabetic foot (A); anterior and posterior WBC scintigraphy images after 30 min, 3 h, and 20 h 
(B); transaxial 18F-FDG PET/CT images after 1 h (C). Ant=anterior; Post=posterior. 







In agreement with the literature, our study found WBC scintigraphy to have high diagnostic 
accuracy for infectious disorders. The diagnostic accuracy we found—92%—was even higher 
than found in the literature but could be the result of the high prevalence of infection in our 
selected population. 
Agreement was excellent between the 3 independent nuclear medicine physicians who 
analyzed the WBC scintigraphy results; no discordance was found. Interpretation criteria 
showing high diagnostic accuracy were determined for WBC scintigraphy. Good differentiation 
between osteomyelitis, soft-tissue infection, and no infection at all is possible using the 
correct cell-labeling methods, acquisition protocols, and interpretation criteria. A T/B ratio 
greater than 2.0 after 20 h is suggestive of infection: osteomyelitis if the ratio is increasing 
over time; soft-tissue infection if the ratio is decreasing over time. A ratio of 2.0 or less can be 
considered negative for infection. 
Despite some limitation (such as a high pretest probability of disease in our population and 
a small sample size), this study leads to 2 important conclusions: osteomyelitis, when highly 
suspected clinically in the diabetic foot, is not necessarily present, and further examinations are 
required; sequential 18F-FDG PET is not useful for the diagnosis of diabetic foot osteomyelitis; 
WBC scintigraphy is more accurate. Trials on larger populations of patients may help elucidate 
the clinical role of 18F-FDG PET/CT in the diabetic foot. 
CONCLUSION
The results of this pilot study confirmed the high diagnostic accuracy of WBC scintigraphy 
in the diabetic foot. Interpretation criteria that are helpful in differentiating between 
osteomyelitis, soft-tissue infection, and no infection were determined. When the correct 
labeling procedures and acquisition protocols are followed, WBC scintigraphy remains the 
gold standard noninvasive imaging technique. 
18F-FDG PET/CT was found to have a low diagnostic accuracy in the diabetic foot. No useful 
SUVmax criteria for differentiating between soft-tissue infection and osteomyelitis could be 
found. Combining visual assessment of the PET and CT images was more useful. Sequential 
18F-FDG PET/CT was not found to be helpful for diagnosis of the diabetic foot. On the basis of 
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To investigate the diagnostic accuracy of fluoro-2-deoxy-D-glucose positron emission 
tomography (18F-FDG-PET) compared with computed tomography (CT) scanning and added 
value of fused 18F-FDG-PET/CT in diagnosing vascular prosthetic graft infection. 
Design
Prospective cohort study with retrospective analysis. 
Materials
Twenty five patients with clinically suspected vascular prosthetic infection underwent CT and 
18F-FDG-PET scanning.
Methods
Two nuclear medicine physicians assessed the 18F-FDG-PET scans; all CT scans were assessed 
by two radiologists. Fused 18F-FDG-PET/CT were judged by the radiologist and the nuclear 
medicine physician. The concordance between CT and 18F-FDG-PET and the inter-observer 
agreement between the different readers were investigated.  
Results
Fifteen patients had a proven infection by culture. Single 18F-FDG-PET had the best results 
(sensitivity 93%, specificity 70%, positive predictive value 82% and negative predictive value 
88%). For CT, these values were 56%, 57%, 60% and 58%, respectively. Fused CT and FDG-
PET imaging also showed high sensitivity and specificity rates and high positive and negative 
values. Inter-observer agreement for 18F-FDG-PET analysis was excellent (kappa = 1.00) and 
moderate for CT and fused 18F-FDG-PET/CT analysis (0.63 and 0.66, respectively).
Conclusion
18F-FDG-PET scanning showed a better diagnostic accuracy than CT for the detection of vascular 
prosthetic infection. This study suggests that 18F-FDG-PET provides a useful tool in the work-up 








Prosthetic graft placement to treat abdominal aortic aneurysms and aorto-iliac occlusive 
disease is common practice nowadays (1). The complication rate of this intervention is low. 
However, the most serious complications, prosthetic graft infection and aorto-enteric fistula, 
are life threatening. Previously, reports showed that prosthetic graft infection could lead to life 
or limb loss in >50% of the patients (1-4). The incidence of vascular prosthetic graft infection 
varies from 0.6% to 5% (5). 
The diagnosis of prosthetic infection is not easily obtained as clinical signs are variable, and 
include recurrent fevers and chills, back or groin pain, erythema, swelling or a pulsatile 
mass in the groin (1). In addition to clinical signs, the most common methods to evaluate 
and diagnose graft infection are evaluation of infection parameters in the peripheral blood 
(erythrocyte sedimentation rate, white blood cell count and C-reactive protein (CRP)), 
sinography, computed tomography (CT) scanning, magnetic resonance imaging (MRI), duplex 
ultrasound and, ultimately, surgical exploration. However, the predictive value for vascular 
prosthetic infection with either one of these diagnostic tools is relatively low (5). 
Recently, the use of [18F]fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-
PET) to visualize localization of infection in patients with suspected prosthetic graft infection 
has been proposed (6,7). 18F-FDG-PET can be used as a whole-body imaging technique giving 
functional characterization of hypermetabolic tissues and is becoming of utmost importance 
in diagnosis, staging and therapy monitoring in clinical oncology (8). Its value in the diagnosis 
of infectious diseases with elevated intracellular glucose metabolism has also been reported 
(9). Dumarey et al. found a high sensitivity for fused 18F-FDG-PET and CT images in diagnosing 
infections of different origin (10). This study also suggested a high negative predictive value. 
Other studies showed that 18F-FDG-PET imaging may also be useful in the field of patients 
with vascular diseases, including increased 18F-FDG uptake in vulnerable carotid plaques and 
expanding aortic abdominal aneurysm prone for rupture (7). Previously, some studies (3,11) 
reported on the value of 18F-FDG-PET/ CT in diagnosing vascular prosthetic infection. However, 
the reliability of 18F-FDG-PET, CT and fused 18F-FDG-PET/CT scans are unknown so far. Especially, 
the reliability determines the value of these diagnostic modalities in evaluating vascular 
prosthesis infections. 
In the present study, we aimed to investigate the diagnostic accuracy of single 18F-FDG-PET and 
fused 18F-FDG-PET/CT and agreement in reading between different observers in diagnosing 
vascular prosthetic infection in comparison with conventional CT scanning. 









Between March 2003 and March 2009, 25 patients with suspected vascular prosthetic graft 
infection underwent, besides routine CT scanning, an additional 18F-FDG-PET scan. Informed 
consent was obtained from all patients. Suspicion of vascular prosthetic graft infection was 
defined as undefined fever, elevated infectious variables in laboratory analysis (erythrocyte 
sedimentation rate, white blood cell count and CRP), and undefined malaises in patients with 
previously implanted prosthetic grafts. 
CT analysis
CT angiography was routinely applied in all patients with suspected prosthetic graft infection 
(Figures 1A and 1D). Whole-body CT scanning included CT scanning of the thorax, abdomen 
and aorto-iliofemoral tract. CT imaging was performed, after administration of intravenous 
contrast, by Multidetector CT Siemens Somatom Definition (Siemens AG, Medical Solutions, 
Forchheim, Germany). All scans were assessed by two radiologists (TP/HA) on a digital 
workstation, while blinded for clinical data. As previously reported in literature, the following 
items were regarded as being predictive for vascular prosthetic graft infection on CT scanning: 
the presence of aorto-enteric fistula, pseudo-aneurysm, intergraft thrombus, hydronephrosis, 
perigraftic fluid (based on Hounsfield units (HU)), perigraft air, perigraft soft tissue attenuation 
(HU), focal bowel wall thickening (mm), discontinuity of the aneurysmal wrap (mm), maximal 
diameter of the largest air bubble, maximal diameter of the fluid collection (mm) and visual 
judgement by a radiologist (12-14). The two radiologists scored each scan based on these 
features. The probability of prosthetic infection on CT angiography was classified as low or 
high, based on a visual scale judgement from 1 to 10 points. A low probability was defined 
from 1 to 5 points and a high probability from 6 to 10 points. For the purpose of this study, 
sensitivity, specificity, negative and positive predictive values were determined. 
18F-FDG-PET analysis
With each 18F-FDG-PET, whole-body mode (i.e., from halfway up the thigh to the crown of the 
head) studies were used on a 3D ECAT + scanner (Siemens Medical Systems, Knoxville, TN, 
USA) (Figures 1B and 1E). Patients received 18F-FDG intravenously based on their weight (5 
MBq per kg), while fasted but with ad libitum access to non-caloric beverages to create forced 
diuresis. The scans were performed after a waiting period of 60 min. Data were processed 
using standard software, applying an iterative reconstruction algorithm. Two experienced 
physicians in nuclear medicine (RS and AG) assessed the images visually while blinded for 
the CT scan information. The following features were used to further analyze and quantify 
the images: visual grading scale (I-IV), maximal standardized uptake value (SUVmax) and 
tissue-to-background (TB) ratio (15). The region of interests used in SUV analysis were three 
dimensional and based on the mean value within the 70% isocontour boundaries using a 
Siemens Leonardo workstation. The TB ratio was defined as the mean FDG uptake per volume 







Based on the visual grading scale, the probability of prosthetic infection on 18F-FDG-PET 
scanning was classified as low or high (visual grade I or II was defined as low, visual grade 
III or IV was defined as high). The intensity of FDG uptake was graded on a four-point scale 
as follows: grade 1, FDG uptake similar to that in the background; grade 2, low FDG uptake, 
comparable with that by inactive muscles and fat; grade 3 moderate FDG uptake, clearly 
visible and higher than the uptake by inactive muscles and fat, but distinctly less than the 
physiologic uptake by the bladder and grade 4, strong FDG uptake, comparable with the 
physiologic urinary uptake by the bladder.
Figure 1
Coronal (A-C) and lateral (D-E) views of CT, 18F-FDG-PET and fused 18F-FDG-PET/CT image of a by culture proven 
infected vascular prosthetic graft. In this particular case, an 85-year-old female patient underwent exclusion 
of an abdominal aortic aneurysm and replacement with an aorto-bi-iliac Dacron prosthetic graft. After 11 
months the patient was re-admitted with clinical signs of prosthetic infection. CT was judged negative, but 
PET scanning clearly showed increased 18F-FDG uptake at the level of the prosthesis (visual grade IV, SUV 
10.49, T/B ratio 9.1). Ultimately, Staphylococcus aureus was cultured from the graft.








Besides assessment of the conventional 18F-FDG-PET and CT images, data were merged 
by fusion software (Leonardo workstation (Siemens Medical Systems, Knoxville, TN, USA)) 
(Figures 1C and 1F) and subsequently assessed by one radiologist (TP) and one nuclear 
medicine physician (RS). Suspicion for graft infection was again categorized into two groups: 
high suspicion and low suspicion (based on a combination of the abovementioned features in 
CT scanning and 18F-FDG-PET scanning). 
End points
As per definition, all included patients had a high clinical suspicion for a prosthetic graft 
infection. A proven infection was defined as (1) positive staining of the prosthesis after re-
exploration (irrespective of antibiotic therapy) and (2) positive staining of perigraft fluid 
obtained by puncture. Positive staining was defined as positive Gram staining within 14 days 
after surgery. Not all patients included had a proven infection, most probably due to prolonged 
empiric and intensive administration of antibiotics. However, also for these patients, the data 
of CT- and 18F-FDG-PET scanning as well as for the fused images are presented. 
Statistical analysis
Continuous data were expressed as mean ± SD. The interobserver agreement between different 
readers was calculated by use of weighted kappa statistics. Kappa values of <0.4, between 0.4 
and 0.75, and >0.75 were considered to represent poor, fair to good and excellent agreement, 
respectively, based on the Fleiss classification (16). For the purpose of this study, sensitivity, 
specificity, negative and positive predictive values were determined. 
RESULTS
Patient characteristics
A total of 25 patients had a suspicion of a prosthetic graft infection and were included in the 
study. There were 22 males and three females with a median age of 67.2 years (58.1-74.1; 
25-75th percentile). Nearly all grafts were in the thoraco-abdominal-iliac tract (21 out of 25 
(83%)). Eleven (44%) patients clinically presented with fever, 16 (64%) patients with pain, 
three patients had fever and pain and only one patient (4%) was asymptomatic, but showed 
abnormalities in infection variables during standard follow-up (Table 1). 
CT characteristics
Based on CT judgement, prosthetic graft infection was likely (high suspicion) in 16 (64%) 
patients and not suspected (low suspicion) in nine (36%) patients. Perigraft fluid and perigraft 
air were observed in 48% versus 23% of cases, respectively. Other CT characteristics of these 















Diabetes mellitus 4 (16)
Malignancy 2 (18)
Type of treatment
 Open surgical  21  (84)
 Endovascular  4  (16)
Location graft prosthesis
 Aorto-iliacal  18  (72)
 Ilio-femoral  2  (18)
 Femoro-femoral  1  (4)
 Femoro-popliteal  1  (4)
 Thoraco-abdominal  3  (12)
Symptoms at presentation
 Asymptomaticb  1  (4)
 Fever  11  (44)
 Pain  16  (64)
Data in numbers (percentages) and median (25th-75th percentile)
a Defined as currently smoking or not currently smoking but having smoked in past 10 years




Aorto-enteric fistula 0 (0)
Pseudo-aneurysm 3 (12)
Intergraft thrombus 3 (12)
Hydronephrosis 1 (4)
Perigraft fluid 12 (48)
 Hounsfield units 35.5 (17.8-38.3)
Perigraft air 6 (23)
Perigraft soft tissue 7 (28)
 Hounsfield units 55.0 (50.8-73.8)
Focal bowel thickening 0 (0)
Discontinuity of aneurismal wrap 2 (8)
Maximal diameter fluid collection (mm) 6.3 (3.3-31.6)
Maximal diameter air bubble (mm) 37.4 (22.7-69.3)
Data in numbers (percentages) and median (25th-75th percentile)








The 18F-FDG-PET findings are shown in Table 3. Based on 18F-FDG-PET judgement, suspicion 
for prosthetic graft infection was high in 17 (68%) patients and low in eight (32%) patients. 
The median maximum standardized uptake value was 4.0 (2.7-6.0; 25-75th percentile). The 





 I 2 (8)
 II 6 (24)
 III 10 (40)
 IV 7 (26) 
SUVmaxa 4.0 (2.7-6.0)
T/B ratiob 3.4 (2.8-7.2)
Data in numbers (percentages) and median (25th-75th percentile)
a Maximum standardized uptake value
b Tissue-to-background ratio
18F-FDG-PET and CT comparison
CT-, 18F-FDG-PET as well as fused 18F-FDG-PET/CT findings were analyzed with respect to the 
level of concordance with cases of a proven infection. Fifteen (60%) patients had a proven 
infection. High likelihood of infection on 18F-FDG-PET was found in 14 of these 15 patients, 
sensitivity of 93%. The CT scan was judged positive in nine of these 15 patients, resulting 
in a mean sensitivity rate of 56% (mean; range 51-60%). Specificity of 18F-FDG-PET for the 
detection of prosthetic infection was 70%, and for CT 57% (mean; range 50-63%). Positive 
predictive values were 82% for FDG-PET and 60% (mean; range 55-64%) for CT. Negative 
predictive values for 18F-FDG-PET were 88%, and for CT 58% (mean; range 45-70%) (Table 4).
 
One patient had a proven prosthetic graft infection, but had a low suspicion for infection 
on CT and 18F-FDG-PET. In five patients with a proven infection, the CT and 18F-FDG-PET were 
discordant. These five patients had a high suspicion for infection on 18F-FDG-PET, but a low 
suspicion on CT. In 18 of 25 patients, CT scanning and 18F-FDG-PET scanning were concordant 
(72%). In the remaining seven patients, five patients were highly suspected for infection on 
18F-FDG-PET and had a proven infection; the other two were highly suspected on CT, however, 
without a proven infection. The inter-observer agreements were calculated between both 
the nuclear medicine physicians and radiologists, and were found to be good with a kappa 
value of 0.63 between the radiologists and excellent (kappa value 1.00) between the nuclear 
medicine physicians.  
Fused 18F-FDG-PET and CT imaging
After assessing the remaining seven patients, five patients were highly suspected for infection 
on 18F-FDG-PET and had a proven infection; the other two were highly suspected on CT. 







by software fusion and scored independently again (Table 4) by one radiologist (TP) and one 
nuclear medicine physician (RS). As a result, the concordance between the radiologist and 
nuclear medicine physician reached a high level; there was agreement in 21 of 25 cases 
(84%), with a kappa value of 0.66. Sensitivity and specificity rates for detection of infection 
by 18F-FDG-PET/CT, judged by a nuclear medicine physician, were 93% and 70%, respectively. 
Positive and negative predictive values were 82% and 88%, respectively. Sensitivity and 
specificity rates for detection of infection by 18F-FDG-PET/CT, judged by a radiologist, were 
73% and 60%, respectively. Positive and negative predictive values were 73% and 60%, 
respectively (Table 4). 
Table 5 shows the interval period between insertion of a vascular prosthesis and 18F-FDG-PET/
CT imaging. Statistical analysis showed no association between the interval period (mean 
35.4 months; range 1-105 months) and positive results on 18F-FDG-PET/CT scan. Furthermore, 
positive staining related to the interval period between vascular prosthesis insertion and 
18F-FDG-PET/CT scan was described. 
Table 4
Values of CT, 18F-FDG-PET, and fused 18F-FDG-PET/CT to detect vascular prosthetic graft infection. Results are 
depicted in sensitivity (SENS), specificity (SPEC), positive predictive value (PPV) and negative predictive value 
(NPV). Rad = radiologist; NMP = nuclear medicine physician.
Modality SENS (%) SPEC (%) PPV (%) NPV (%)
CT Rad 1 60 50 64 45
CT Rad 2 51 63 55 70
18F-FDG-PET NMP 1 93 70 82 88
18F-FDG-PET NMP 2 93 70 82 88
18F-FDG-PET/CT NMP  93 70 82 88
18F-FDG-PET/CT Rad  73 60 73 60
DISCUSSION
The primary aim of this study was to assess the value of 18F-FDG-PET scanning in the diagnostic 
work-up in patients suspected of vascular prosthetic graft infection. When compared with CT 
scanning, 18F-FDG-PET had a higher sensitivity, specificity, and positive and negative predictive 
values in our study. Compared with previous reports on the sensitivity and specificity rates of 
CT to detect vascular prosthetic infection, our CT values are relatively low (13,17). However, 
Fiorani et al. described that CT is accurate in diagnosing advanced graft infection (e.g., 
periprosthetic abscess and aorto-enteric fistula) but not in low-grade infection, with an overall 
specificity of 100% and an overall sensitivity of 55.5% (18). The fact that many patients in 
our study (17/25; 68%) used intensive antibiotic therapy at the time they were admitted to 
the hospital may reflect a study population primarily consisting of low-grade graft infections. 
These findings were also observed by Tegler et al. who described lower CT sensitivity and 
specificity in case of low-grade infections (19). 







The same limitation was seen in patients without a proven prosthetic graft infection (i.e., 
no positive culture). In these 10 ‘negative’ patients, the CT scan was judged positive in five 
patients and on 18F-FDG-PET there was a high suspicion in three patients. The difficulty in 
this group may be partly explained by the observation that, although these patients did not 
have a proven infection, they still could be affected. This phenomenon might be due to the 
intensive antibiotic therapy already administered to these patients before performing a CT or 
a 18F-FDG-PET scan. As a result, stainings for micro-organisms could already be negative at the 
time of determination. 
Table 5
Interval between insertion of vascular prosthesis and 18F-FDG-PET/CT scan combined with staining results.


























a Interval between initial operation and fused 18F-FDG-PET/CT scan
A second aim of this study was to investigate whether fusion of 18F-FDG-PET with CT would 
lead to better results in terms of sensitivity, specificity and positive and negative predictive 
values. Our data showed that both sensitivity and specificity rates and negative and positive 
predictive values of fused 18F-FDG-PET/CT data judged by the nuclear medicine physician were 
higher when compared with these values as judged by the radiologist. This could probably 
be explained by the fact that nuclear medicine physicians are also trained to judge CT scan 
as opposed to (interventional) radiologists, who are less trained in judging nuclear imaging. 







PET/CT, probably due to the better accuracy of 18F-FDG-PET for the detection of infected 
vascular prostheses. 
Interestingly, patient 6 showed a difficult but clinically relevant diagnostic dilemma. This 
patient was assessed ‘highly suspected’ with 18F-FDG-PET only, and ‘low suspected’ after CT 
scanning. After fusion, both the radiologist and the nuclear medicine physician considered this 
patient to have a ‘low suspicion’. In fact, this patient had a proven prosthetic graft infection. 
In this case, the 18F-FDG-PET scan would have been leading for the diagnosis. 
In recently published studies, 18F-FDG-PET/CT scanning was often false positive, both in 
symptomatic and asymptomatic patients (17,20). Basu et al. described that, although the role 
of FDG-PET/CT imaging in the assessment of infection and inflammation is controversial, this 
combined approach could be the study of choice for the precise localization of the infection 
(21). Our study seems to confirm this observation, as after fusion of 18F-FDG-PET and CT scan, 
the concordance in judgement was high. 
Recently, Spacek et al. reported that fused 18F-FDG-PET/CT imaging is an excellent tool to 
diagnose a vascular prosthetic infection; however, their study mostly evaluated patients with 
prosthesis in the lower extremities (20). Our study adds that both 18F-FDG-PET and 18F-FDG-
PET/CT imaging could also be applied to evaluate thoracic and abdominal vascular prosthetic 
infections. 
A third aim of this study was to analyze the interobserver agreement between the different 
readers of CT, 18F-FDG-PET and fused images. The inter-observer agreements between the 
two nuclear medicine physicians were excellent (kappa value = 1.00) and between the 
radiologists moderate (kappa value = 0.63). However, after fusion of the images, the inter-
observer agreement between the nuclear medicine physician and the radiologist was good 
(kappa value = 0.66). This implies that not only 18F-FDG-PET scans but also CT scans and fused 
18F-FDG-PET/CT scans are broadly applicable for evaluating prosthesis infection. 
A limitation of this study is that patients with vascular prosthetic graft infection always form 
a very heterogeneous population with different causal micro-organisms, different prosthetic 
materials used and different localizations of infection. Larger prospective studies are necessary 
for a better definition of the role of 18F-FDG-PET/CT in this specific group of patients. 
In conclusion, the present study shows that 18F-FDG-PET scanning has a higher accuracy for 
diagnosing vascular prosthetic graft infection compared with CT. There is a high concordance 
in CT and 18F-PET findings, especially after fusion of both modalities. Fused 18F-FDG-PET/
CT imaging merges anatomy and metabolism, thereby offering an interesting new tool to 
localize the infection. 
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Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the Western 
world and is responsible for approximately 50% of all deaths in the USA, Europe and Japan 
(1). CVD comprises three major areas, being coronary heart diseases (myocardial infarction, 
angina, heart failure and coronary death), cerebrovascular diseases (stroke, transient ischemic 
attacks) and peripheral vascular diseases (claudicatio intermittens, gangrene). 
Atherosclerosis is the major cause of cardiovascular disease (2). A variety of risk factors and 
pathobiological processes, often acting together, are associated with an increased risk for 
developing atherosclerosis in the coronary and peripheral vasculature. A major pathobiological 
process central to the pathogenesis of atherosclerosis is the deposition of cholesterol in 
the arterial wall (3). Other major, modifiable factors are diabetes mellitus, hypertension, 
cigarette smoking (active and passive), obesity and physical inactivity (4-6). Family history of 
premature coronary heart disease (genetic predisposition), age and gender are not modifiable 
independent risk factors for atherosclerosis (4). 
In addition to these major risk factors, clinical and epidemiological studies have indicated 
that once an atherosclerotic plaque reaches a certain stage of development, the plaque itself 
becomes a risk factor for future vascular events (7). This is because existing plaques can 
undergo rupture or erosion, thus favoring the formation of an occluding thrombus (8).
In the last couple of years our knowledge of the molecular mechanisms of atherosclerosis has 
greatly expanded. This led to the recognition that the rupture of vulnerable plaques is critical 
in converting asymptomatic atherosclerosis to a clinical event. The risk of plaque disruption 
was found to depend more on plaque composition and vulnerability (plaque type) than on the 
degree of stenosis (plaque size) (9). The most vulnerable plaques are relatively non-stenotic 
(<75% cross-sectional area stenosis, normal lumina on angiography), have a larger lipid core 
and an often inflamed thin fibrous cap (9-11). In contrast, low-risk plaques tend to be fibrotic 
and severely stenotic after a while.
Exploring the functional status in the plaque is therefore essential to predict the most probable 
clinical complication. This is where nuclear medicine is able to help. Based on our techniques, 
it might be possible to detect vulnerable plaques, plaques that will cause symptoms in the 
near future for the patient.
MOLECULAR EVENTS IN ATHEROSCLEROSIS
Atherosclerosis was always considered to be a lipid storage disease. However, recent advances 
in basic science have established a fundamental role for inflammation in all stages of this 
disease from initiation through progression and ultimately to the thrombotic complications 
(12). It is clearly an inflammatory disease (13). Hypercholesterolemia and other risk factors 
are important in approximately 90% of patients with cardiovascular disease (14), but 







lesion can represent different stages of an inflammatory process in the artery; if unabated and 
excessive, this process will eventually result in an advanced, complicated lesion with plaque 
rupture and thrombosis. This consideration has several practical clinical consequences in risk 
stratification, diagnosis and targeting of therapy.  
Figure 1 provides a brief overview of the complex cascade of events leading to plaque inception 
and plaque destabilization. Endothelial injury is initiated by a variety of injurious noxae, 
including hypertension, dyslipidemia, shear stress and infections (Figure 1A). Leaky damaged 
endothelium allows the passage of leukocytes and lipids into the subendothelial space. 
Activated endothelial cells increase the expression of adhesion molecules and inflammatory 
genes. Circulating monocytes migrate into the subendothelial space and differentiate into 
macrophages (Figure 1B). Macrophages take up lipids deposited in the intima by a number of 
receptors, including scavenger receptor A (SR-A) and CD36. Deregulated uptake of modified 
LDL through these receptors lead to cholesterol accumulation and “foam cell” (lipid loaded 
macrophages) formation. Multiple foam cells form the fatty streak (an irregular yellow-white 
discoloration on the luminal surface of an artery) and secrete proinflammatory cytokines and 
MMPs. Both factors amplify the local inflammatory response in the lesion and in the local 
matrix. Repeated cycles of inflammation (Figure 1C) lead to accumulation of macrophages, 
some of which can die in this location producing the so-called necrotic core. Living 
macrophages induces smooth muscle cell (SMC) proliferation and migration in the lesion 
to form the fibrous cap of the advanced complicated stable atherosclerotic lesion (“stable” 
plaque). T cells also play a major role in the path of inflammation. T cells may encounter auto-
antigens such as oxidized low-densitiy lipoproteins (LDL) and heat-shock proteins (HSP, both 
of endogenous and microbial origin). Both auto-antigens serve as the target for autoimmune 
responses in inflammatory diseases and produce cytokines that can influence the behavior 
of other cells present in the atheroma and so stimulate inflammation and plaque formation. 
Several different effector mechanism can be elicited by immune responses (Figure 1D). The 
combination of interferon-Υ (IFN-Υ) and tumor necrosis factor-β (TNF-β) upregulates the 
expression of chemokines (e.g. CXC3) promoting the development of the Th1 lymphocyte 
pathway which is strongly proinflammatory. The selective recruitment and activation of Th1 
T cells determines a potent inflammatory cascade leading to the transition from stable to 
“unstable/ruptured” plaque. During this transition we postulated the existence of a theoretical 
plaque structure known as “vulnerable” plaque, which is very similar to the unstable plaque 
except for plaque erosion/rupture. In this context, IFN-Υ strongly inhibits the proliferation 
of SMCs and the production of interstitial collagens by vascular SMCs, thereby affecting the 
stability of the fibrous cap (Figure 1E). Activated macrophages secrete procoagulant proteins 
and matrix metalloproteinases (MMPs) that can degrade collagen. In addition, ligation of 
CD40 expressed by macrophages increases the production of matrix-degrading proteases. All 
this leads to an unstable or ruptured plaque (Figure 1F).






Figure 1 The complex cascade of events leading to plaque development and destabilization
 
NUCLEAR MEDICINE IMAGING TECHNIQUES FOR DETECTING 
ATHEROSCLEROTIC PLAQUES
Many radiopharmaceuticals have been developed on the basis of molecules and cells involved 
in the development of atherosclerosis. These radiopharmaceuticals can be divided into four 
major groups, based on their target cells: (1) radiopharmaceuticals targeting atherosclerotic 
lesions components, (2) radiopharmaceuticals detecting atherosclerotic inflammation, (3) 
radiopharmaceuticals detecting thrombosis, and (4) radiopharmaceuticals detecting apoptosis. 
An overview of all the available tracers is provided in Table 1. I will now shortly discuss the 
two tracers that are most important regarding the scope of this thesis, 18F-fluorodeoxyglucose 
(18F-FDG) and radiolabelled Interleukin-2 (IL2).
18F-FDG is, as already discussed in Chapter 1 of this thesis, a glucose analogue that is trapped 
in cells in proportion to the cells’ metabolic activity. 18F-FDG is retained within plaque 
macrophages more avidly than within other plaque elements (15). In a group of patients 
that underwent carotid artery and aortic imaging, high inter- and intra-observer agreement 
and low variability of 18F-FDG uptake over 2 weeks was observed (16). Results in the iliac and 
femoral arteries were also highly reproducible; however, the FDG uptake in plaques in the 
carotid arteries was significantly higher than in both iliac and femoral vessels (17). In 30% of 
the patients with documented carotid atherosclerosis, inflammation was detected by 18F-FDG-
PET imaging. This raised the possibility for this non-invasive metabolic imaging modality to 







are necessary to determine if the detection of inflamed plaque by 18F-FDG-PET is useful for 
predicting future CVD (18). An example of 18F-FDG-PET imaging in atherosclerosis can be seen 
in Figure 2.
Table 1
Possible radiopharmaceuticals for imaging atherosclerosis
Radiopharmaceutical Target
 Atherosclerotic lesion components
99mTc-LDL/ox-LDL/ac-LDL  Foam cells
99mTc-LOX-1-mAb  Foam cells
99mTc-β-VLDL  Lipoproteins
125I/99mTc-MDA2, 125I-IK17  Lipids
99mTc-endothelin  Endothelin
 Inflammation 
99mTc/125I-MCP-1  Macrophages and monocytes
99mTc/123I-IL-8  Neutrophils
123I-IL-1 RA  Monocytes and lymphocytes
123I or 99mTc-IL2  Lymphocytes
18F-FDG  Metabolic glucose activity
 Thrombosis
111In-platelets  Platelets
99mTc-apcitide/P280  Activated platelets
99mTc-DMP444  Activated platelets
99mTc-Fibrin-Binding-Domain (FBD)  Fibrins
99mTc-labeled fibrin α-chain peptide  Fibrins
 Apoptosis
99mTc-annexin V  Apoptotic cells
As previously described in Chapter 1 of this thesis, IL2 has a high affinity for IL2 receptors 
(IL2R) expressed by activated lymphocytes during inflammation. IL2 is a growth-promoting 
factor of T lymphocytes and has effects on a wide variety of cells such as CD4+ T cells, CD8+ 
T cells, B cells and natural killer cells. Most prominently, it is important in T cell activation 
and inflammatory consequences thereof (19). Both 99mTc- and 123I-labelled IL2 have been 
successfully used in several diseases characterized by a chronic lymphocytic infiltration. Higher 
serum IL2 levels are associated with increased carotid artery intima-media thickness (IMT), 
a predictor of stroke and vascular disease (20). 99mTc-IL2 is therefore also used for imaging 
carotid atherosclerosis in humans. Fourteen patients (16 plaques) eligible for endarterectomy 
underwent 99mTc-IL2 scintigraphy before surgery. Another nine patients (13 plaques) received 
atorvastatin or a standard hypocholesterolemic diet and scintigraphy was performed before 
and after 3 months of treatment. 99mTc-IL2 accumulated in vulnerable carotid plaques and 
the accumulation correlated with the amount of IL2R+ cells within the plaque (measured ex 
vivo by histology). Also, the amount of 99mTc-IL2 within the plaque was influenced by lipid-
lowering treatment with statins (21). 99mTc-IL2 is a very promising tracer that could provide 
useful information for the selection of infiltrated vulnerable plaques at risk of rupture. In 
the next Chapter of this thesis, the specificity of this radiopharmaceutical for imaging the 
lymphocytic infiltration in carotid plaques is evaluated in vivo by planar and SPECT/CT imaging 






and ex vivo by microSPECT and autoradiography. Imaging examples of the uptake of 99mTc-IL2 
in atherosclerotic plaques of the carotid arteries are provided in the next Chapter of this thesis.
Figure 2
Upper left: CT image, transverse view, atherosclerotic plaque in widened abdominal aorta. Upper right: fused 
18F-FDG-PET and CT, transverse view, uptake in atherosclerotic lesion in abdominal aorta. Lower left: CT image 
coronal view (same patient), multiple atherosclerotic lesions in abdominal aorta. Lower right: fused 18F-FDG-
PET and CT, coronal view, FDG uptake in atherosclerotic lesions in abdominal aorta.
 
CONCLUSIONS
The identification of major, causal risk factors for the development of atherosclerosis provide 
clinicians reliable tools to identify individuals who are at high risk for atherosclerosis-related 
clinical events. However, the quantitative risk assessment would be significantly improved if 
atherosclerotic plaque burden could be assessed more directly. Non-nuclear imaging modalities 
have a lot of possibilities, but are not able to look at early events and plaque vulnerability. 
The emerging area of nuclear imaging techniques can provide measures of biological activity 
of atherosclerotic plaques, thereby improving the prediction of clinical events. Many tracers 
already have been studied and are based on atherosclerotic lesion components, inflammation 
and thrombosis. In recent years there has been a major improvement in tracer development 
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Recent advances in basic science have established that inflammation plays a pivotal role in 
the pathogenesis of atherosclerosis. Inflammatory cells are thought to be responsible for the 
transformation of a stable plaque into a vulnerable one. Lymphocytes constitute at least 20% 
of infiltrating cells in these vulnerable plaques. Therefore, the interleukin-2 (IL2) receptor, 
being over expressed on activated T-lymphocytes, may present an attractive biomarker for 
plaque vulnerability.
The aim of this study was to evaluate the specificity of radiolabelled interleukin-2 (99mTc-hynic-
IL2) for imaging the lymphocytic infiltration in carotid plaques in vivo by planar and SPECT-CT 
imaging and ex vivo by microSPECT and autoradiography.
Methods
For the in vivo study, 10 symptomatic patients that were scheduled for carotid endarterectomy 
underwent 99mTc-hynic-IL2 scintigraphy. The images were analyzed visually on planar and 
SPECT images and semi-quantitatively on SPECT images by calculating target-to-background 
ratios. After endarterectomy, immunomorphology and immunophenotype was performed on 
plaque slices.
For the ex vivo studies, 4 additional patients were included and, after in vitro incubation 
of removed plaques with 99mTc-hynic-IL2, autoradiography and microSPECT images were 
performed.
Results
Visual analysis defined clear 99mTc-hynic-IL2 uptake in 7 out of the 10 symptomatic plaques. 
SPECT/CT allowed visualization in 8 out of 10. A significant correlation was found between the 
number of CD25+ lymphocytes and the total number of CD25+ cells in the plaque and the T/B 
ratio with adjacent carotid artery as background (Pearson r = 0.89, p = 0.003, and r = 0.87, p 
= 0.005 respectively).
MicroSPECT imaging showed clear 99mTc-hynic-IL2 uptake within the plaque wall and not in the 
lipidic core. With autoradiography, only CD3+ lymphocytes were found to be labelled.
Conclusion
These in vivo and ex vivo studies confirm the specificity of 99mTc-hynic-IL2 for imaging activated 
T-lymphocytes in carotid plaques. 99mTc-hynic-IL2 is a true marker for the inflamed plaque and 








Recent advances in basic science have not only established that atherosclerosis is a lipid 
storage disease, but also that inflammation, haemorrhage and cell death have a fundamental 
role in all stages of the disease from initiation through progression and ultimately to the 
thrombotic complications of atherosclerosis (1-3). Atherosclerotic plaques that cause clinical 
events are often called vulnerable or unstable plaques. Several studies highlighted the role of 
inflammatory cells in the transformation of a stable plaque into a vulnerable one (4-7). 
Many radiological invasive (intravascular ultrasound, intravascular MRI, angioscopy and 
intravascular optical coherence tomography) and non-invasive (ultrasound with Doppler 
flow, electron-beam computed tomography, computed tomography angiography, magnetic 
resonance angiography) imaging techniques are used in plaque imaging (1,8). They allow 
early detection of plaque formation, but do not provide any biomolecular information on the 
actual risk of plaque rupture. Vulnerable plaques are often mildly stenotic and histologically 
characterized by a large lipidic/necrotic core, a thin fibrous cap, and infiltration of lymphocytes 
and macrophages (1,3,9,10). Lymphocytes are a significant cell population and constitute at 
least 20% of infiltrating cells in these vulnerable plaques. Most of these lymphocytes are 
activated and stimulate macrophages to produce matrix metalloproteinases, that can destroy 
the fibrous cap causing plaque rupture (11). Against this background, non-invasive in vivo 
identification of vulnerable plaques prone to rupture would be useful to allow prevention of 
complications.
The Interleukin-2 receptor (IL2R) may present an attractive biomarker for detection of 
vulnerable plaques, as it is over expressed on activated T-lymphocytes during inflammation. 
IL2, radiolabelled with either 99mTc or 123I, binds with high affinity to IL2R and was already 
successfully used to detect activated T-lymphocytes in several diseases characterized by a 
chronic lymphocytic infiltration (12-15) including atherosclerosis (16,17). High levels of IL2 
in serum are also associated with increased carotid artery intima-media thickness, which is a 
predictor of stroke and vascular disease (18). Therefore, imaging with radiolabelled IL2 may 
provide useful information for the selection of infiltrated vulnerable plaques at risk of rupture 
and hence of patients at risk for clinical events.
The aim of this study was to confirm the specificity of 99mTc-hynic-IL2 for imaging lymphocytic 
infiltration in carotid plaques in vivo by planar and SPECT-CT imaging and ex vivo by microSPECT 
and autoradiography. 
In vivo and in vitro evidence that 99mTc-hynic-interleukin-2 is able to detect T-lymphocytes in 









Ten symptomatic (amaurosis fugax, recent TIA, minor or moderate stroke) patients with uni- 
or bilateral carotid stenosis between 70 and 99% at ultrasonography and a gray scale median 
of <50% (indicative of hypo-echoic plaques with calcifications) were scheduled for carotid 
artery endarterectomy and were included in this study. The medical history of the patients 
was screened for risk factors for atherosclerosis (diabetes mellitus, smoking, hypertension, 
hyperlipidemia, and body mass index (BMI)) as well as for the use of statins (Table 1). 
The present study was approved by the local medical ethical committee (trial number 
2008/132). All subjects gave their written informed consent before entering the study.
Radiolabelling of IL-2
99mTc-hynic-IL2 was produced as previously described (19) and checked for appearance, 
radiochemical purity, specific activity, sterility and pyrogens.
99mTc-hynic-IL2 scintigraphy
99mTc-hynic-IL2 scintigraphy was performed in all patients before surgery. Planar antero-
posterior images (600 seconds, 256x256 matrix) from head to kidneys were acquired 60 
minutes after intravenous injection of 78-194 MBq 99mTc-hynic-IL2. This was followed by 
tomographic (SPECT) imaging combined with CT imaging of the neck region. All images were 
acquired on a SPECT/CT gamma camera system (Siemens Symbia T, Siemens Medical Systems, 
Knoxville, TN, USA).
For planar imaging, the location of the plaque was determined by drawing a marker on 
the skin of the patient at the plaque region on the basis of ultrasound scanning. For SPECT 
imaging, the location of the plaque was based on CT. All studies were visually reviewed 
by two experienced observers, familiar with the normal biodistribution of 99mTc-hynic-IL2 in 
patients. 99mTc-hynic-IL2 uptake at the location of the plaque was calculated by drawing a 
region of interest (ROI) at the location of the skin marker in the planar imaging. In addition, 
a ROI was drawn over the carotid artery just below the bifurcation as background region. A 
planar carotid plaque to background ratio (T/B
planar
) was calculated by using the mean counts 
per ROI. 
Semi-quantitative analysis on SPECT images was performed by drawing volumes of interest 
(VOIs) at the plaque (regions defined on CT) and by drawing circular VOIs at an adjacent area 
in the carotid artery, at bone marrow in the cervical region (C1 or C2) and at the temporal 
muscle. The maximum number of counts in a pixel within the plaque VOI was divided by 
the maximum counts in the background areas to calculate the SPECT T/B ratio for the carotid 
artery (T/B
carotid
), SPECT T/B ratio for bone marrow (T/B
bm











After endarterectomy, formalin fixed carotid plaques were cut into cross sections of 3 
mm thickness and paraffin embedded. Three micron sections were cut and stained with 
hematoxylin/eosin for histological examination. Cell populations have been characterized 
studying the following antigens: CD3 for T lymphocytes (CD3 polyclonal: Ventana Medical 
Systems, Roche), CD68 for monocytes/macrophages (CD68 confirm; Ventana Medical Systems, 
Roche), α-smooth muscle actin-1 (SMA) for smooth muscle cells (actin smooth muscle; 
Ventana Medical Systems, Roche), and CD25 for IL2R-positive cells (CD25 4C9; Ventana Medical 
Systems, Roche). For each antibody, the absolute number of positive cells was determined in 
the entire plaque section by digital pathology analysis performed with BioImagene software 
(Ventana Medical Systems, Tissue diagnostics, Roche) assisted by an expert histopathologist. 
Furthermore, the total plaque area and the areas with CD3/CD25 positive T-lymphocytes were 
measured and the percentage of infiltrated plaque area was calculated using a grid with an 
area of 0.22 mm2.
Ex-vivo studies: plaque incubation, microSPECT and autoradiography
For the ex-vivo studies 4 additional patients were included with a carotid stenosis between 
70 and 99% at ultrasonography. These patients were not operated before in the contralateral 
carotid and used no statins for at least 3 weeks before surgery.
Carotid endarterectomy was performed under general anaesthesia using standard techniques; 
affected plaques were removed gently and transported immediately after excision in 
phosphate-buffered saline (PBS) under sterile conditions and subsequently incubated with 
185 MBq 99mTc-IL2 (same labelling procedure as in the in-vivo study), diluted in 10 ml PBS, for 
one hour at room temperature. 
In case of autoradiography, after incubation, the plaque was washed twice in RPMI medium 
(10 min each with 10 ml medium), dried and embedded in paraffin. Slices (10 µm thickness) 
were first processed for immunohistochemistry for CD3 staining by peroxidase and then 
covered by liquid emulsion (Ilford K5) and incubated in the dark at -20 °C for 2 weeks before 
development (16). Slides were finally stained with haematoxylin and eosin (H&E). 
In case of microSPECT, the plaques were flushed two times for 10 minutes with 10 ml PBS 
after incubation, fixed on the microSPEC bed, stored in a humid environment to prevent 
dehydration and scanned (U-SPECT-II, Milabs, Utrecht, the Netherlands) for one hour. After 
imaging, the plaque was immersed in paraformaldehyde for 48 hours, and subsequently 
embedded in paraffin and processed for histology. 
In vivo and in vitro evidence that 99mTc-hynic-interleukin-2 is able to detect T-lymphocytes in 








Continuous data are expressed as average +/- standard deviation. Categorical variables 
are expressed as absolute numbers and percentages. Differences between T/B ratios were 
calculated using student’s t-tests. Correlation analyses were performed by linear regression 
and calculation of Pearson correlation coefficient (r). p<0.05 was considered statistically 
significant. All tests were performed using GraphPad Prism version 5.0 for Windows (GraphPad 
Software, San Diego, California, USA).
RESULTS
Patients
The clinical data of patients are summarized in Table 1. In 8 out of the 10 patients, a plaque 
was also found on CT on the contralateral side (asymptomatic plaque). In 8 out of the 10 
patients, time interval between 99mTc-hynic-IL2 scintigraphy and carotid endarterectomy was 
within 2 weeks (median 6 days, range 1-14 days). In one patient surgery was cancelled, 
since on repeated preoperative echocardiography one day before the intended operation a 
near-occlusion of the carotid artery was found. In one patient immunomorphology could not 
be performed due to problems with the storage of the plaque leading to non-representative 
material for histological examination. So eventually, out of the 10 enrolled patients we were 
able to perform histology in 8 of them.
Table 1
Individual patient data
 Patient Sex Age Symptoms Degree Contra- Dyslipi- Diabetes Hyper- Smoking Statines Duration Surgery Interval Histology
 No.  (yr)  of lateral demia  tension   statines  scan-   
     stenosis plaque       (weeks)  surgery
              (days)
 1 M 71 CVA 70-99 Y Y N Y Y Y 3 Y 9 Y
 2 M 57 Amaurosis 80-99 Y N N Y Y Y 1 Y 10 N
    fugax
 3 F 74 TIA 70-99 Y N N Y Y Y 1 N - N
 4 F 68 Amaurosis 80-99 N N Y N N N - Y 1 Y
    fugax
 5 M 67 TIA 50-70 N Y N Y N Y 404 Y 3 Y
 6 M 65 TIA 80-99 Y N N Y Y Y 202 Y 14 Y
 7 F 77 TIA 80-99 Y N N Y N Y 3 Y 31 Y
 8 M 55 CVA 70-99 Y N N N Y Y 3 Y 14 Y
 9 M 55 TIA 80-99 Y N N N Y N - Y 3 Y
 10 M 65 Amaurosis 80-99 Y N N N N Y 2 y 3 Y













Individual scintigraphic and histological results
 Patient Activity Ratio SPECT SPECT ratio SPECT Total Total Total Total plaque Lymphocyte Lymphocyte/
 No. (MBq) T/Bplanar Ratio T/Bbone ratio CD25+  CD25+  CD25+  area (µm
2) area (µm2) total area (%)  
    T/Bcarotid  marrow  T/Bmuscle
  lympho  macro  cells
 1 78 2.50 2.20 2.50 2.13 549 1399 2532 311,237,519 5,254,930 1.69
 2 129 0.71 2.07 0.67 1.58 - - - - - -
 3 194 0.97 1.22 1.09 1.63 - - - - - -
 4 89 2.15 1.13 0.88 1.36 37 170 226 56,228,692 2,034,453 3.62
 5 114 0.25 2.24 0.60 1.35 615 1472 2808 47,509,203 452,405 0.95
 6 185 0.55 0.59 0.78 1.24 82 163 297 25,439,295 2,543 0.01
 7 176 0.64 2.21 1.43 1.21 581 1003 1888 38,058,182 3,020,163 7.94
 8 185 0.88 1.88 0.98 1.79 622 1227 2668 47,793,601 713,710 1.49
 9 176 1.62 1.69 1.26 1.89 346 1614 2199 42,465,606 1,346,589 3.17
 10 179 1.32 1.91 0.85 1.47 319 937 2334 34,215,170 1,552,810 4.54
Figure 1
Examples of 99mTc-hynic-IL2 uptake in symptomatic plaques (red arrows): upper panels: (A) CT and (B) SPECT/
CT of patient 1 in the study with high uptake in the symptomatic plaque (T/B
carotid
 > 2.0); middle panels: (C) CT 
and (D) SPECT/CT showing moderate uptake in symptomatic plaque (patient 9, T/B
carotid
 between 1.0 and 2.0); 
lower panels (E) CT) and F (SPECT/CT) showing no uptake in a symptomatic plaque (patient 6, T/B
carotid 
< 1.0). 
Green arrows in upper and lower panel show asymptomatic plaques showing no significant uptake. Notice 
also the variable uptake in salivary glands and tonsils due to co-present inflammation.
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99mTc-hynic-IL2 scintigraphy and correlation with histology
On visual inspection of planar images, we clearly defined 99mTc-hynic-IL2 uptake in 7 out of 
the 10 symptomatic plaques. Analysis of SPECT/CT images allowed plaque visualisation in 
8 out of the 10 symptomatic plaques. Examples of 99mTc-hynic-IL2 uptake in the plaques are 
shown in Figure 1. Interestingly, the highest plaque uptake was found in patient n° 1, the only 
dyslipidemic, hypertense and smoking patient. The calculated ratios (planar and SPECT) of the 
symptomatic plaques are shown in Table 2.
CD25+ cells were found in all samples of studied plaques, although the percentage of CD25+ 
lymphocytes varied between plaques (5-99% of all CD3+ lymphocytes). Moreover, CD25 was 
expressed not only on the surface of T-lymphocytes, but also on macrophages and on smooth 
muscle cells. The number of CD25+ T-lymphocytes, CD25+ macrophages, and the total number 
of CD25+ cells (including lymphocytes, macrophages and smooth muscle cells) are shown in 
Table 2. An example of H&E, CD3, and CD25 staining of an atheromatous plaque is shown in 
Figure 2.
A significant correlation was found between the number of CD25+ T-lymphocytes in the 
plaques and the T/B
carotid
 ratio on SPECT (Pearson r = 0.89, p = 0.003) and the total number 
of CD25+ cells and the T/B
carotid
 ratio (Pearson r = 0.87, p = 0.005) as shown in Figure 3. No 
significant correlation was found between the number of macrophages or smooth muscle 
cells with the T/B SPECT ratios (although macrophages and smooth muscle cells were more 
abundant than activated T-lymphocytes), between the planar T/B ratio and the counted cells 
on histology, and between the ratios (both planar and SPECT) and the area of the plaque in 
which CD3+/CD25+ lymphocytes were found.
We also looked at the 8 asymptomatic plaques that were found at the contralateral carotid 
artery in the 10 patients. Uptake was found in 2 out of the 8 plaques at planar imaging 
(overall we imaged 9 out of 18 plaques, including symptomatic and asymptomatic), and in 3 
out of the 8 plaques on SPECT/CT imaging (overall 11 out of 18 total plaques). Nevertheless, 
the T/B
planar
 was significantly higher (p = 0.039) in the symptomatic plaques (mean 1.20 +/- 
0.22) as compared to the asymptomatic ones (0.83 +/- 0.11).The T/B
carotid
 was also found 
significantly higher in the symptomatic plaques as compared to the asymptomatic plaques 
(1.61 +/- 0.58 vs 1.13 +/- 0.26, p = 0.02). Significant differences were also found between 
symptomatic and asymptomatic plaques using the T/B
muscle
 (1.57 +/- 0.30 vs 1.31 /- 0.22, p = 
0.03) but not when considering the T/B
bm
 (1.10 +/- 0.55 vs 0.93 /- 0.29, p = ns).
Ex-vivo studies
After microSPECT, clear 99mTc-IL2 uptake was seen within the plaque wall. 99mTc-hynic-IL2 
uptake was heterogeneously distributed with most uptake on the internal wall of plaque but 
not in the central lipidic and necrotic areas (Figure 4). 
With autoradiography combined to immunohistochemistry we clearly proved that only CD3+ 
lymphocytes were able to sufficiently bind the 99mTc-hynic-IL2 (Figure 5). CD3- cells (usually 








Histological example of an atheromatous plaque from a carotid endarterectomy. Row I: Haematoxylin/
eosin stain, row II: CD3 stain, row III: CD25 stain; column 1: 2x magnification, colums 2 and 3: 10x 
magnification. Circled area magnified in column 2, squared area magnified in column 3. Panels A, B, C show 
an atheromatous plaque with heavy inflammatory infiltrate with a high percentage of CD3+ (panels D, E and 
F) and CD25+ lymphocytes (panels G, H and I). Notice that the CD25 stain is more abundant than CD3 due to 
staining of both lymphocytes, macrophages and smooth muscle cells. Furthermore, not all CD3+ cells are also 




 ratio with the total number of CD25+ T-lymphocytes at histology (upper graph) and 
with the total number of CD25+ cells (including lymphocytes, macrophages and smooth muscle cells) at 
histology (lower graph).
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MicroSPECT of a carotid endarterectomy specimen after in vitro incubation with 99mTc-hynic-IL2. (A) coronal, (B) 
sagittal, and (C) transversal slice showing high but heterogeneous uptake of the radiopharmaceutical around 
the central lipidic core.
Figure 5 
Autoradiography of carotid endarterectomy specimen (400x magnification) after incubation with 99mTc-hynic-
IL2. Thick arrows: groups of CD3+ lymphocytes (brown stained cells) showing high binding of labelled IL2 
(black dots). Dotted arrows: CD3- cells (pink stained nuclei of mainly macrophages or CD3- lymphocytes) 








For many years, most people considered atherosclerosis to be a cholesterol storage disease 
characterized by the collection of cholesterol and thrombotic debris in the artery wall. Over the 
last decade, the concept that inflammation played a primary role in atherogenesis has gained 
interest (2). Infiltrating lymphocytes are thought to play a central role in this inflammatory 
process by cross-talking with macrophages and secreting several cytokines that contribute 
to the evolution of the plaque and eventually to its vulnerability. As it is over expressed on 
activated T-lymphocytes during inflammation, the IL2R presents an attractive biomarker for 
detection of inflammation in plaques.
In this study we aimed at confirming the potentiality of radiolabelled IL2 for imaging vulnerable 
carotid plaques, as previously demonstrated (16,17) and, most importantly, we demonstrated 
the specificity of 99mTc-IL2 binding to activated T-lymphocytes at microscopic level. The small 
patient series presented showed uptake of 99mTc-hynic-IL2 in 8 out of 10 symptomatic plaques 
and in 3 out of 8 asymptomatic plaques on SPECT-CT imaging. The uptake in all symptomatic 
plaques was semi-quantitatively significantly correlated to the number of CD25+ lymphocytes 
and to the total number of CD25+ cells (including macrophages and smooth muscle cells) 
after histological examinations of the plaques. Furthermore, T/B ratios, both on planar and on 
SPECT images (taking the adjacent carotid artery or nearby muscles) were significantly higher 
in the symptomatic plaques compared to asymptomatic plaques in the same individuals. 
Many previous publications indicate that structural changes following inflammatory damage 
within the plaque are critical in promoting plaque rupture (11), and the results of this in vivo 
study confirm that this imaging modality allows non-invasive in vivo quantification of plaque 
inflammation.
As well as in our previous study (16), the histological examination of the plaques revealed 
that IL2R are not only expressed on inflammatory cells (lymphocytes and macrophages) but 
also on smooth muscle cells. However, correlation with the T/B ratios was only found with 
the number of CD25+ lymphocytes and the total number of CD25+ cells, not with the number 
of macrophages or smooth muscle cells. Indeed, a positivity for CD25 does not necessarily 
mean the presence of fully functional IL2R and does not reflect the density of IL2R expression 
on cells. Therefore we wanted to evaluate at microscopic level whether radiolabelled IL2 
was able to significantly bind only to T-lymphocytes or also to macrophages and smooth 
muscle cells. In the presented ex-vivo studies 99mTc-IL2 was only found to significantly bind 
to CD3+ lymphocytes (i.e. T-lymphocytes), but not to a significantly detectable level to 
macrophages or smooth muscle cells or CD3- lymphocytes. Our explanation is that, probably, 
macrophages and smooth muscle cells express barely or with low density the α-chain of the 
IL2R and therefore do not bind IL2 efficiently. For autoradiography, we used an anti-CD3 and 
not an anti-CD25 (less abundant on lymphocytes than CD3) because in previous preliminary 
unpublished experiments we did not obtain an appropriate staining of section with anti-CD25 
in emulsion covered sections. Furthermore, staining with anti-CD25 would have not allowed 
us to differentiate T-lymphocytes from the other cell types. MicroSPECT of carotid plaques was 
also important to evaluate whether 99mTc-IL2 could penetrate within the plaque but without 
non-specific binding to the lipid or necrotic core.
In vivo and in vitro evidence that 99mTc-hynic-interleukin-2 is able to detect T-lymphocytes in 







Taking together the information obtained by autoradiography, microSPECT and in vivo studies, 
our results confirm our hypothesis that only the binding of radiolabelled IL2 to activated 
T-lymphocytes contributes to in vivo plaque imaging.
Various other nuclear medicine techniques have also been applied to study cells involved 
in the pathogenesis of the atherosclerotic plaque by (i) targeting the atherosclerotic lesion 
components, including 99mTc-labelled low-density lipoproteins (LDL) (20-22) and 99mTc-
endothelin (23), (ii) targeting apoptotic cells with 99mTc-annexin V (24,25), (iii) targeting 
cells involved in thrombosis, e.g. 111In-labelled platelets (26), (iv) targeting the involved 
inflammatory cells, including tracers to image macrophages, monocytes, neutrophils and 
lymphocytes (11,27-29), (v) imaging the metabolic glucose activity of macrophages with 
18F-fluorodeoxyglucose (18F-FDG) (30-33), and (vi) imaging the vascular endothelial growth 
factor (VEGF), which is also linked to plaque vulnerability (34). All these tracers have their 
limitations in the detection of plaque vulnerability. For example, labelled LDL does not provide 
information on the presence of infiltrating lymphocytes that are the trigger of macrophage 
infiltration (35) and the labelling of autologous LDL can be performed only in specialized 
centers. Labelled annexin V correlated with macrophage content (25). However, the question 
remains if apoptotic macrophage content is representative of vulnerability. Imaging the 
VEGF receptor in human carotid endarterectomy specimens with 89Zr-bevacizumab showed 
promising results; however, due to the long half-life of 89Zr, imaging in humans is possible only 
4 days after injection and the radiation burden is relatively high compared to other tracers. 
Most studies reported the use of 18F-FDG to detect macrophage content and vulnerability in 
atherosclerotic plaques (36). However, it must be considered that FDG is a non-specific agent 
and reflects only the metabolic status of the plaque, and is for instance not usable in coronary 
artery disease, due to high background activity in the heart muscle. The accumulation in all 
highly metabolizing cells results in suboptimal specificity in depicting vessel wall inflammation 
(34). 99mTc-hynic-IL2 shows the presence of activated T-lymphocytes in the plaques and this is 
a true marker of an inflammation and of plaque instability.
Although our study shows very encouraging results, it also has some limitations. First of all, 
the low number of patients restricts the statistical power of this study. However, still we 
reached highly significant results. Some patients in this study used statins, some only for a 
couple of weeks, others already for years (Table 1). In an earlier published longitudinal study 
in 9 patients, changes of 99mTc-IL2 uptake in plaques, before and after atorvastatin treatment 
or a cholesterol-lowering diet was investigated (16) and results showed that the uptake 
significantly decreased after treatment with statins. These data were confirmed by another 
study demonstrating a favourable effect of statins on plaque stabilization and it particular has 
been supposed that statins may directly modulate inflammation within the plaque (37). So, 
statin treatment in our patients may have influenced the uptake of 99mTc-IL2 in symptomatic 
and asymptomatic plaques. Larger patient studies are necessary to evaluate the predictive 
value of IL2 scintigraphy. The administered activity of 99mTc-IL2 in our patients varied (range 
78-194 MBq) due to different production yield. The complex and time consuming labelling 
procedure and purification of 99mTc-IL2 has to be performed by experienced and highly 







higher production yield and higher administered activity as compared to the first patients. This 
demonstrates that a learning curve is needed for the production of 99mTc-IL2.
Despite these limitations, the results of this study are important and confirm that it is possible 
to image inflamed plaques with 99mTc-hynic-IL2. What is most important, in our opinion, still 
to be defined, is a cut-off value for positivity regarding the uptake. This is needed for better 
sensitivity and specificity of the technique and for conducting large longitudinal studies. The 
low spatial resolution of the gamma camera, especially in such small objects as plaques in the 
carotid artery, decreases the diagnostic value of this technique (that was avoided in this study 
by using also the micro SPECT technique as proof of principle). Certainly the use of a PET tracer 
for imaging activated lymphocytes and the use of PET/CT could allow better plaque detection, 
localization, and quantification. [18F]-FB-IL2 has already proved stable, biologically active, and 
allowing the in vivo detection of activated lymphocytes in animal studies (38) thus being a 
promising PET radiopharmaceutical for human atherosclerotic plaque imaging.
CONCLUSION
The results of these in vivo and in vitro studies confirm the specificity of 99mTc-hynic-IL2 for 
imaging T-lymphocytic infiltration in carotid plaques and strengthen the hypothesis that 
this radiopharmaceutical is a true marker for the inflamed plaque and therefore of plaque 
instability. 
In vivo and in vitro evidence that 99mTc-hynic-interleukin-2 is able to detect T-lymphocytes in 
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Amyloidosis is the name of a group of diseases characterized by extracellular tissue deposition 
of fibrils composed of low molecular weight subunits of a variety of serum proteins (amyloid). 
This structure of the fibrils is responsible for its insolubility and resistance to proteolysis. 
Amyloid fibrils are derived from a variety of protein precursors. The extracellular deposition 
of amyloid fibrils in organs and tissues often causes prominent swelling of the affected organ 
and tissue and results in loss of function. Deposition of amyloid can be localized (produced in 
and limited to one organ or site of the body) or systemic (deposition in various organs and 
tissues throughout the body). Clinical manifestations are based on the site of the amyloid 
deposits and are related to the type of precursor protein involved. 
Systemic amyloidosis is usually fatal and is the cause of about 1 per 1,000 deaths in developed 
countries. About 3,000 new cases are diagnosed annually in the United States, but amyloidosis 
is probably underdiagnosed in the elderly population. 
SYSTEMIC AMYLOIDOSIS
Systemic deposition of amyloid is directly related to the grim prospects of systemic amyloidosis. 
There are several subtypes of amyloidosis based on the type of protein involved and/or the 
etiology for the formation of protein fibrils. Three major systemic types of amyloidosis can be 
distinguished (1-3): 
AA type amyloidosis is caused by long-lasting inflammation. Serum amyloid A protein (SAA), 
an acute phase reactant, is the precursor protein. Most frequently observed (about 90%) 
are renal manifestations, such as proteinuria (progressing to nephrotic syndrome) and loss 
of renal function (progressing to renal failure). Less frequent manifestations are autonomic 
neuropathy, splenomegaly, hepatomegaly, goiter, and cardiomyopathy. 
Amyloid light-chain (AL) type amyloidosis is caused by an, often low-grade, plasma cell 
dyscrasia. Lambda or kappa immunoglobulin light chain fragments are the precursors of this 
amyloid type. Clinical manifestations are diverse and depend on the severity of deposition 
in the various organs and tissues. Amongst them are cardiomyopathy, hepatomegaly, 
splenomegaly, nephrotic syndrome, renal failure, orthostatic hypotension, diarrhea, peripheral 
and autonomic neuropathy, arthropathy, carpal tunnel syndrome, and glossomegaly.
ATTR type amyloidosis may be hereditary or age-related (senile). The hereditary form is caused 
by an autosomal dominantly inherited point mutation of the precursor protein transthyretin 
(TTR). More than 100 mutations have been described. Transthyretin is the acronym of transport 
protein of thyroid hormone and retinol binding protein. Prominent clinical manifestations are 
familial peripheral and autonomic neuropathy, but cardiomyopathy, renal failure, and eye 
involvement (vitreous opacities) have also been observed in the course of the disease. Severe 






patients, normal TTR can also behave as precursor protein (‘wild-type’) by a still unknown 
mechanism. This occurs in 25% of the patients over the age of 80 years and is characterized 
by a slowly progressive cardiomyopathy. 
These three types are often difficult to discriminate, show variable involvement of many 
organs and tissues, and are challenging in finding the most appropriate treatment.
LOCALIZED AMYLOIDOSIS
Localized deposition of amyloid plays a still unresolved role in a wide variety of diseases such 
as Alzheimer’s disease (β-protein in the plaques) and diabetes mellitus type II (amylin in the 
islands of Langerhans). Furthermore, tumorous localized amyloidosis can occur independently 
and can be often found in specific sites of the body, such as eyelid, larynx, ureter, skin, etc. 
If in these particular organs amyloid is detected, but not elsewhere in the body, one may 
conclude to localized amyloidosis. In most other sites (bone marrow, heart, bowel, lung, 
joint, etc.), amyloid deposition is nearly always involved in systemic amyloidosis, but can be 
localized occasionally. In this situation it is necessary to demonstrate histological proof at one 
site (such as bone marrow, skin, or rectum) and typical clinical involvement (such as nephrotic 
syndrome, hepatomegaly, macroglossia, or cardiomyopathy) at another site to conclude that 
amyloidosis is systemic (4).  
HISTOLOGY
The diagnosis of amyloidosis is based on showing the presence of amyloid deposits in tissue. 
Method of choice is staining of a tissue specimen with Congo red, which shows a characteristic 
apple-green birefringence in polarized light (Figure 1). Aspiration of a subcutaneous fat 
sample of the abdominal wall is the most elegant and least inconvenient method for this 
purpose, with a sensitivity ranging between 54% (5) and – in experienced hands – 93% (6) 
with a corresponding specificity of 100% (6). These data are comparable with those of the 
well-known rectum biopsy (6,7). In case one of the primary biopsy sites (fat or rectum) is 
negative for amyloid and suspicion of amyloidosis remains strong, a biopsy of the clinically 
involved site is useful to increase the chance of detecting amyloid. A bone marrow biopsy can 
also be used, but has a rather low sensitivity of 50-60% (6,7). If all screening biopsies are 
negative but suspicion of amyloidosis remains strong, a biopsy of the affected organ or tissue 
is indicated (6,8).







Example of an abdominal subcutanoues fat aspirate, stained with Congo red: (A) viewed in normal light; 




For clinical evaluation of the patient, it is useful to obtain a clinical overview of the “amyloid 
load”, i.e. affected organs and tissues and severity of amyloid deposition in vital organs 
(such as heart, liver, and kidneys). One has to ask the patient for family history, impotence, 
orthostatic complaints, loss of sensibility, fatigue, weight loss, and bowel problems. Physical 
examination should focus on signs such as orthostatic blood pressure, friability of the skin, 
glossomegaly, arthropathy, hepatomegaly, splenomegaly, edema, cardiac failure, and loss of 
sensibility and muscle strength of extremities.
A systemic clinical approach is indicated. The heart can be examined with electrocardiography 
(signs of low voltage and pseudo-anteroseptal infarction), chest X-ray (normally sized heart 
despite signs of cardiac failure), echocardiography (thickness of septum and ventricular 
walls), MRI (wall thickness, delayed contrast-enhanced imaging), 24 hour Holter registration 
(conduction, rhythm, and heart rate variability) and a MUGA scan (left ventricle ejection 
fraction). Plasma levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) 
and cardiac troponin T (TnT) are useful as cardiac biomarker. The kidneys can be examined 
with serum albumin, creatinine clearance, urine sediment and proteinuria. The liver can 
be examined with serum albumin, liver enzymes such as alkaline phosphatase, bilirubin, 
coagulation tests, and cholinesterase. Thyroid stimulating hormone can be used as marker for 
the thyroid and fasting cortisol for the adrenal glands. Autonomic function test and heart rate 
variability can be used for the evaluation of autonomic neuropathy. Electromyography can be 
used to assess peripheral neuropathy and quantitative sensory testing (QSR) to assess small 
fibre neuropathy. Abdominal ultrasound is useful to evaluate size and echogenicity of liver, 
spleen and kidneys.
The amyloid community agreed upon guidelines for organ involvement (9). These consensus 







Consensus criteria for organ involvement of amyloid depositions. Derived from Gertz et al (9).
Organ Criterion
Kidney 24-hr urine protein > 0.5 g/day, predominantly albumin
Heart Echo: mean wall thickness > 12 mm, no other cardiac cause
Liver Total liver span > 15 cm in the absence of heart failure or alkaline phosphatase > 1.5  
 times institutional upper limit of normal
Nerve Peripheral: clinical; symmetric lower extremity sensorimotor peripheral neuropathy
 Autonomic: gastric-emptying disorder, pseudo-obstruction, voiding dysfunction not  
 related to direct organ infiltration
Gastrointestinal tract Direct biopsy verification with symptoms
Lung Direct biopsy verification with symptoms; Interstitial radiographic pattern
Soft tissue Tongue enlargement with submandibular swelling, clinical
 Arthropathy
 Claudication, presumed vascular amyloid 
 Skin (recurrent periorbital purpura)
 Myopathy by biopsy or pseudohypertrophy 
 Lymphadenopathy (may be localized) 
 Carpal tunnel syndrome
NUCLEAR MEDICINE TECHNIQUES IN CLINICAL EVALUATION
123I-Serum Amyloid P component (123I-SAP) 
Currently, the best whole body imaging method uses the Serum Amyloid P component (SAP) 
labelled with 123iodine (123I-SAP). This nuclear imaging technique is used to image the extent 
and distribution of amyloid deposits in patients with all types of amyloidosis (10-12) and 
has nowadays an important role in the diagnosis and follow-up of patients with (suspected) 
amyloidosis.
In the human body, SAP is produced only by hepatocytes, and the plasma concentration 
seems to be regulated at a rather constant level, even during aggregation of SAP into amyloid 
deposits. This suggests that the synthesis of SAP can be increased dramatically (13). The 
normal function of SAP is not known. All types of amyloid bind in a calcium-dependent 
manner to SAP, and therefore it is a suitable tool to be used for the imaging of all types of 
amyloidosis (14). 
For 123I-SAP scintigraphy, patients are intravenously injected with 200 MBq 123I-SAP. Uptake of 
free 123I in the thyroid is prevented by oral administration of potassium iodide. Scintigraphy is 
performed 24 hours after injection of the tracer. Anterior and posterior total body images and 
SPECT/CT of the abdomen are acquired.
The images are assessed in a semi-quantitative way by comparing each organ directly to the 
normal blood pool distribution. Organ involvement is graded 3 (overwhelming uptake), 2 
(intense uptake), 1 (positive uptake without any doubt) and 0 (normal) (12). Examples are 
shown in Figure 2. In AA amyloidosis, abnormal uptake in the spleen is common. The most 
frequently uptake patterns in this amyloid type are: (1) abnormal uptake in the spleen only, 






(2) abnormal uptake in spleen and kidneys, and (3) abnormal uptake in spleen, kidneys 
and adrenal glands. In AL amyloidosis, abnormal uptake in the spleen is also common. 
Uptake in other organs, such as liver, kidneys, bone marrow and joints, is very diverse. In 
ATTR amyloidosis, only abnormal uptake in the spleen and/or kidneys is seen. In healthy 
individuals, there is no organ deposition of 123I-SAP, and the tracer is then confined to the 
circulating blood pool and organs with high blood content. Measurements of 123I-SAP retention 
in blood and urine are performed after 24 and 48 hours to provide a rough quantitative 
estimate of the amyloid load in the patient (15).
Sensitivity of 123I-SAP scintigraphy for AL and AA amyloidosis is about 90%, but it is only 48% 
for hereditary ATTR amyloidosis (15). The overall specificity is 93% (12). 123I-SAP scintigraphy 
can serve as a clinical tool for evaluation of amyloidosis patients.
This nuclear medicine technique has two major limitations. First of all, the heart cannot be 
visualized with this technique, most likely due to lack of fenestrated endothelium in the 
myocardium (12). Secondly, SAP is isolated and purified from serum of healthy donors and 
the potential infection risk is probably the major reason why this useful technique is currently 
being used only in the United Kingdom (London) and The Netherlands (Groningen).
18F-fluorodeoxyglucose (18F-FDG)
It is important to establish whether the amyloid deposits are localized or systemic, since 
therapy differs completely between these two types of amyloidosis. If screening biopsies 
of rectum and abdominal fat tissue do not show amyloid deposition, localized amyloidosis 
seems to be the most probable conclusion. However, it would strengthen the diagnosis if 
positive arguments for localized amyloid deposition can also be obtained. In localized AL 
amyloidosis giant cells are thought to be present because of their role in the production of 
amyloid (16). In systemic AL, AA and ATTR amyloidosis, however, giant cells are thought to 
be unnecessary for the formation and deposition of amyloid. The accumulation of SAP in 
amyloid deposits probably acts as a kind of camouflage, thereby protecting these deposits 
from recognition and clearance by giant cells (17).
18F-FDG offers the possibility to visualize the inflammatory reactions of multinuclear giant cells 
and may therefore useful to distinguish between localized and systemic amyloidosis. This 







Clinical examples of semi-quantitative assessment of 123I-SAP scintigraphy. Grading of organ involvement: 
overwhelming (3), intense (2), positive without any doubt (1) and normal (0).
 
CARDIAC AMYLOIDOSIS
Cardiac morbidity is based on several pathophysiological mechanisms which occur as a 
consequence of myocardial deposits of amyloid. Large amounts of deposits may lead to 
myocyte dysfunction, which is a result of a mechanical obstruction. This may lead to systolic 
or diastolic dysfunction and symptoms of heart failure. Deposits in the conduction system can 
lead to dysrhythmias as a result of neuronal dysfunction and to syncope due to arrhythmia 
or even heart block. Infiltration of amyloid in the atria as well as the ventricles may cause 
atrial dysfunction and electromechanical dysfunction of the atrial electrical activity (e.g. atrial 
fibrillation). This may lead to thromboembolism. Accumulation of amyloid in the coronary 
arteries may explain the manifestation of angina or infarction. 
Cardiac involvement is predominantly present in AL type amyloidosis. Up to 50% of patients 
suffer from cardiac manifestations and 25% show congestive heart failure (18). Atrial fibrillation 
and conduction abnormalities are also common. Cardiac involvement is less common in AA 
type amyloidosis. Less than 5% of patients with this type have cardiac involvement (19). 
In ATTR type amyloidosis cardiac involvement is as frequent as in AL type but leads more 






rarely to LV systolic dysfunction and clinical congestive heart failure. Problems that occur are 
cardiac denervation, diastolic dysfunction and atrioventricular block. The problems associated 
with ATTR types vary with the specific mutation variant (20). Some mutations are invariably 
associated with cardiac disease, others usually only with neurological disease, and many 
with a combination of both. The senile form often has cardiac involvement and is related 
with congestive heart failure and conduction abnormalities. Cardiac involvement in AL type 
amyloidosis often leads to significant rapidly progressive cardiac dysfunction, while the ATTR 
types are typically associated with milder clinical manifestations and slower progression (21). 
NUCLEAR MEDICINE POSSIBILITIES TO IMAGE CARDIAC AMYLOIDOSIS
Echocardiography, 12-lead ECG, and MRI are currently considered the standard for non-
invasive diagnosis of cardiac amyloidosis. However, these techniques are not suitable for 
differentiation between amyloid cardiomyopathy and other forms of cardiomyopathy, are not 
able to determine the type of amyloidosis and have only limited diagnostic utility in the early 
phase of the disease (22,23).
To visualize cardiac amyloid involvement, different nuclear imaging methods are available. All 
use SPECT tracers and each technique is based on a different physiological mechanism (Table 
2). The best results found in literature are related to the imaging of myocardial innervation 
by 123I-metaiodobenzylguanidine (123I-MIBG). MIBG is retained in sympathetic nerve endings, 
and the localization of MIBG relates to the presence of sympathetic nerves. Myocardial defects 
in MIBG activity seem to correlate with impaired cardiac sympathetic nerve endings due to 
amyloid deposits. This can be identified very early in cardiac amyloidosis and shows better 
results than with other tracers. The clinical severity of disease correlates with a decrease 
in MIBG uptake. Overall, 123I-MIBG is a good option for objective evaluation of cardiac 
















 99mTc labelled (pyro)phosphates
 67Gallium
 111In-antimyosin antibody
Ventricular function 99mTc-pertechnetate (ventriculography)
a MIBG = Metaiodobenzylguanidine
b BMIPP = β-methyl=iodophenyl pentadecanoic acid
c V-DMSA = pentavalent dimercaptosuccinic acid
Many publications evaluated the use of phosphate derivates for detecting cardiac involvement 
of amyloidosis. Recently, it was found to be a new diagnostic tool to define the type of 
amyloid cardiomyopathy, since high uptake was found in ATTR amyloid cardiomyopathy, 
whereas absent or weak uptake was found in AL amyloidosis (24). Furthermore, in ATTR 
amyloidosis, bone scintigraphy was able to reflect the extent of cardiac amyloid deposition 
(25), and to identify myocardial infiltration by amyloid already in an early stage of disease 
(26). To further elaborate on these findings, we evaluated the role of cardiac uptake on 
bone scintigraphy in patients with ATTR amyloidosis in different phases of their disease, in 
different gene mutation types, and in patients with and without liver transplantation, and also 
correlated the cardiac uptake with echocardiographic findings, ECG characteristics and plasma 
levels of cardiac biomarkers. This research study is described in Chapter 8 of this thesis.
CONCLUSIONS
Amyloidosis is a rare, but serious and potentially life-threatening disease. A systemic 
evaluation of patients with systemic amyloidosis helps to get a grip on this intangible 
disease. Histological proof of amyloid deposits, verification of systemic involvement, and 
determination of the particular type of amyloid and its precursor form the backbone of 
clinical evaluation. Nuclear medicine techniques, such as 123I-SAP scintigraphy may help to 
evaluate the amyloid burden within a patient, but has two major limitations: evaluation of 
the cardiac burden is not possible and 123I-SAP is only available in two centers worldwide. 
Other nuclear techniques may be useful in the diagnostic strategy to characterize the patient 
with amyloidosis. 18F-FDG-PET might offer the possibility to differentiate between localized 
and systemic amyloidosis (Chapter 7 of this thesis) and bone scintigraphy might be able to 
diagnose cardiac involvement in patients with ATTR amyloidosis already in an early stage of 
disease (Chapter 8 of this thesis).
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Amyloidosis is a group of diseases characterized by deposition of fibrils and this deposition 
may be localized or systemic. The presence of giant cells is typical of localized AL amyloidosis 
in contrast to systemic amyloidosis. Because of this presence of giant cells we hypothesize that 
18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) 
may show uptake in localized amyloidosis but not in systemic amyloidosis. The aim of the 
study was to evaluate the utility of 18F-FDG PET/CT in distinguishing systemic amyloidosis from 
localized amyloidosis. 
Methods
A retrospective search in the hospital computer system showed 21 patients with histologically 
proven systemic or localized amyloidosis who recently had undergone 18F-FDG PET/CT. Twenty 
patients also had undergone 123I-serum amyloid P component (SAP) scintigraphy.
Results
Of 11 patients with localized amyloidosis, 10 showed markedly increased FDG uptake at the 
amyloid site, whereas one showed slightly increased FDG uptake. 123I-SAP scintigraphy (in ten 
patients) was positive in three patients at the amyloid site and negative for any other specific 
organ involvement in nine patients, with a weakly positive spleen in one other patient. In ten 
patients with systemic amyloidosis, increased FDG uptake was not found in any affected organ 
containing amyloid, whereas 123I-SAP scintigraphy was positive for specific organ involvement 
in nine patients. 
Conclusion
18F-FDG PET/CT may be supportive of the usual diagnostic tests in differentiating between 
systemic amyloidosis (no increased FDG uptake at the amyloid site) and localized amyloidosis 
(increased FDG uptake at the amyloid site). Apart from diagnosis, this finding has potential 








Amyloidosis is the name of a group of diseases characterized by deposition of proteinaceous 
fibrils composed of low molecular weight subunits of a variety of serum proteins (amyloid). 
The extracellular deposition of amyloid fibrils in organs and tissues results in loss of function 
and often causes prominent swelling of the affected organ or tissue. Deposition of amyloid 
may be localized (restricted to one particular organ or tissue) or systemic (in various organs 
and tissues throughout the body). The precursor protein is used for typing amyloid in the 
current classification of amyloidosis (1). 
The most common form of localized amyloidosis is caused by foci of otherwise benign 
monoclonal B cells or plasma cells producing monoclonal immunoglobulin light chains that 
are deposited as AL amyloid (2). Localized AL amyloidosis differs from systemic AL amyloidosis 
by the local presence of clonal plasma cells and of giant cells (3,4). It is hypothesized that in 
localized amyloidosis giant cells are involved in the production of amyloid (4). 
In systemic amyloidosis, three major types can be distinguished: (1) AA amyloidosis, caused by 
long-standing inflammation, and the precursor being serum amyloid A protein (SAA), an acute 
phase reactant, (2) AL amyloidosis, caused by an often low-grade plasma cell dyscrasia with 
lambda or kappa immunoglobulin light chain as precursor, and (3) ATTR amyloidosis, caused 
by autosomal dominantly inherited point mutations of the precursor protein transthyretin. 
Signs and symptoms differ among the various types (1,5,6). 
It is important to establish whether the amyloid deposits are localized or systemic. Some sites 
of the body are almost exclusively involved in systemic amyloidosis, such as kidneys, liver, 
nerves, abdominal fat and spleen. If such a site is positive for amyloid, it can be designated as 
systemic amyloidosis. Localized amyloid can often be found in some other specific sites of the 
body, such as eyelid, cardiac atria, larynx, ureter, skin and several other sites. If in these cases 
amyloid is not detected elsewhere in the body, it can be designated as localized amyloidosis. 
Most other sites (for example, bone marrow, heart, bowel, lung and joint) are nearly always 
involved in systemic amyloidosis, but are occasionally only localized. In this situation it is 
necessary to demonstrate histological and/or clinical presence of amyloid in two different 
organs or tissues. Histological proof at one site and typical clinical involvement at a different 
site are sufficient to establish a diagnosis of systemic amyloidosis (7). 
Nuclear medicine is also able to play a role in the diagnostic pathway of patients with 
amyloidosis. The currently available whole-body imaging method is the use of serum amyloid 
P component (SAP), labelled with radioactive 123I. SAP becomes specifically and highly 
concentrated in amyloid deposits of all types as a result of its calcium-dependent binding 
to amyloid fibrils (2). 123I-SAP scintigraphy is used to image the extent and distribution of 
amyloid deposition in patients with all types of amyloidosis and nowadays has an important 
role in the diagnosis and follow-up of patients with (suspected) amyloidosis (8,9). 







The well-known tracer 18F-fluorodeoxyglucose (FDG), used in positron emission tomography 
(PET), offers the advantages, in comparison with 123I-SAP scintigraphy, of a better spatial 
resolution and quantification possibilities. Furthermore, the combination of PET and computed 
tomography (CT) in one imaging modality brings physiology and anatomy together. Our 
hypothesis is that 18F-FDG-PET(/CT) might offer the possibility to visualize the inflammatory 
reactions of multinuclear giant cells around localized amyloid, whereas 18F-FDG-PET(/CT) might 
be negative in systemic amyloid because of the absence of giant cells and other inflammatory 
cells. 
The aim of this study was to evaluate the utility of 18F-FDG-PET(/CT) in distinguishing patients 
with systemic amyloidosis from patients with localized amyloidosis.  
MATERIALS AND METHODS
Patients
We reviewed all records from January 2007 through June 2012 in the local hospital information 
system to search for patients with histologically proven systemic or localized amyloidosis, 
who had undergone an 18F-FDG-PET(/CT) scan. We collected all reports with regard to the 
investigations in these patients that were performed for a final diagnosis, including nuclear 
imaging methods such as 123I-SAP scintigraphy. 
Amyloid was diagnosed in all patients by the presence of typical apple-green birefringence 
in polarized light in a tissue specimen stained with Congo red dye. Localized amyloidosis was 
defined by its typical clinical presentation of only one tissue affected with amyloid, despite 
a rigorous search for amyloid in other sites, such as rectum, bone marrow and subcutaneous 
fat. Systemic amyloidosis was defined either by the detection of amyloid in a biopsy of kidney, 
liver, nerve, spleen or subcutaneous fat or by positive biopsies derived from at least two 
different organs or tissue types. We looked in all biopsy reports for the description of the 
presence of multinuclear giant cells. 
18F-FDG-PET(/CT)
Before 2010, 5 MBq/kg 18F-FDG was injected intravenously after a fasting time of 6 h. Blood 
glucose was determined prior to injection and was normal. PET images were acquired 1 h 
after the administration from the base of the skull through the pelvic region on an ECAT HR+ 
PET camera (Siemens Medical Systems, Knoxville, TN, USA). Transmission scan for attenuation 
correction was done for 5 min using an external ring source filled with 68Ge/68Ga. 
After 2010, 3 MBq/kg 18F-FDG was injected intravenously, due to the higher sensitivity properties 
of the new generation PET/CT system. Fasting time, blood glucose level determination and 
scanning time after the administration were the same. PET/CT images were acquired from 
the top of the skull through the pelvic region on a Biograph mCT camera (Siemens Medical 
Systems, Knoxville, TN, USA) with the transmission CT images used for attenuation correction. 








SAP was purified and prepared from Dutch blood donors according to Dutch pharmaceutical 
standards in our centre. Radiolabelling with radioactive iodine (obtained from Amersham 
Cygne, Eindhoven, The Netherlands) and quality control were performed as described 
elsewhere (10). After prevention of thyroid uptake of free iodide by oral administration of 
potassium iodide, 200 MBq 123I-SAP containing 100 µg protein was injected intravenously. 
Scintigraphy was performed 24 h after injection. Before 2010, total body anterior and 
posterior views as well as abdominal anterior, left anterolateral and posterior detail views 
were acquired on a gamma camera (Siemens DIACAM or MULTISPECT 2, Hoffman Estates, IL, 
USA). 
After 2010, total body anterior and posterior views, anterior and posterior detail views of 
the abdomen, including single photon emission computed tomography (SPECT)/CT of the 
abdomen, were acquired on a SPECT/CT gamma camera system (Siemens Symbia T, Siemens 
Medical Systems, Knoxville, TN, USA). 
All scans were reviewed by an experienced nuclear medicine physician. The interpretation 
and rules of the visual assessment of the SAP scans are explained elsewhere (9). In brief, the 
images are assessed in a semi-quantitative way by comparing each organ directly or indirectly 
to the normal blood pool distribution. Organ involvement is graded as 3+ (overwhelming 
uptake), 2+ (intense uptake), 1+ (positive uptake without any doubt) and 0 (normal). 








A total of 21 patients (11 men and 10 women) were found, 11 of whom had been diagnosed 
with localized amyloidosis and 10 with systemic amyloidosis. All diagnoses were biopsy proven. 
All patients had undergone 18F-FDG-PET(/CT); 20 of the 21 patients also had undergone one or 
more 123I-SAP scans. An overview of the patients’ characteristics, including histopathological 
and imaging findings, can be found in Table 1. 
Localized amyloidosis
Eleven patients had been diagnosed with localized amyloidosis, after an extensive evaluation 
of other amyloid locations. All localized amyloid depositions were biopsy proven. Five of them 
had been localized in the lung, two in the extremities (one upper leg, one ankle), one in the 
colon, one in the bone marrow, one in the right groin region and one patient had a lesion in 
the brachial plexus. In eight patients, giant cells were present in the biopsy. 
All 11 patients had undergone an 18F-FDG-PET(/CT) scan. Initially, four patients were scanned 
for other medical reasons. However, as we noticed positive uptake on 18F-FDG-PET(/CT) at 
the location of amyloid deposition, we routinely performed 18F-FDG PET(/CT) in the next 
seven patients diagnosed with localized amyloidosis. Of the 11 patients scanned, 10 showed 
markedly increased uptake of FDG at the known location of the amyloid deposits. One patient 
showed only weakly increased FDG uptake at the amyloid location in the bone marrow. 
123I-SAP scintigraphy was performed in 10 of 11 patients. Three were positive at the known 
location (one lung, one ankle, one right groin), one was weakly positive in the spleen and 
six were negative. Examples of both scans in patients with localized amyloidosis are shown 









 Pat. Age Sex Biopsy Giant Localized Type Clinically 123I-SAP 18F-FDG (amyloid- 
 no.   proof cells or  involved  scintigraphy  related findings) 
     systemic body site
 1 55 M Yes - Localized AL Left upper Negative Positive (cutaneous 
       kappa  leg  and muscular)
 2 63 M Yes + Localized AL Left ankle Positive Positive 
       kappa   (left ankle)  (left ankle)
 3 74 M Yes - Localized AL Colon Negative Positive 
       lambda    (descending
          colon, sigmoid)
 4 56 F Yes + Localized AL Lungs Positive (lungs) Positive (lungs)
       lambda
 5 59 M Yes + Localized AL Right groin Positive Positive
       lambda  (right groin) (right groin)
 6 56 F Yes + Localized AL Right main Negative Positive (right
       lambda bronchus  bronchus and
          right lung)
 7 81 F Yes + Localized AL Right lung Positive  Positive
       kappa  (spleen 1+) (right lung)
 8 64 M Yes - Localized ALa Bone Negative Positive 
        marrowb  (bone marrow)
 9 62 M Yes + Localized ALa Left lung Negative Positive 
          (left lung)
 10 63 F Yes + Localized ALa Right Negative Positive 
        brachial  (right brachial 
        plexus  plexus and 
          lower neck)
 11 72 F Yes + Localized ALa Lungs ND Positive (lungs)
 12 50 M Yes - Systemic AL Bone marrow, Positive  Negative
       kappa nerves  (bone marrow) 
 13 62 F Yes - Systemic AL Heart, liver,  Positive    Negative
       kappa kidneys (spleen 2+, liver 1+,
         kidneys 1+)
 14 60 F Yes - Systemic AL Bone Positive   Negative
       lambda marrow (spleen 1+,
         bone marrow)
 15 81 M Yes - Systemic AA Kidneys Negative Negative
 16 58 M Yes - Systemic Al Liver, heart,  Positive   Negative
       lamda kidneys (spleen 3+, liver 3+)
 17 47 F Yes - Systemic Al Kidneys,  Positive  Negative
       lambda soft tissue (spleen 1+)
 18 38 M Yes - Systemic AA Kidneys,  Positive Negative
        bowel (spleen 2+,
         right kidney 1+) 
 19 48 F Yes - Systemic AA Liver, spleen,  Positive Negative
        kidneys (spleen 2+, liver 3+)
 20 65 F Yes - Systemic ATTR Nerves,  Positive (spleen 1+) Negative
        bowel 
 21 76 M Yes - Systemic AL Heart, nerves,  Positive  Negative
       lambda kidneys (spleen 1+)







SAP = serum amyloid P component, FDG = fluorodeoxyglucose, M = male, F = female, AL = light chain, AA = 
amyloid A, ATTR = transthyretin-derived, ND = not done
a Most probably AL type; immunohistochemistry negative for AA and ATTR, but equivocal for kappa, lambda or 
both
b The biopsy showed normal bone marrow with < 5% polyclonal plasma cells and amyloid deposition. 
Since all other investigations and biopsies were negative for amyloid, the patient was diagnosed with 
localized amyloidosis of the bone marrow
Systemic amyloidosis
Ten patients had been diagnosed with systemic amyloidosis (six AL, three AA and one 
ATTR), all biopsy proven. In none of the biopsies were giant cells present. All ten patients 
underwent an 18F-FDG-PET(/CT) scan, for different reasons, such as to evaluate locations of 
multiple myeloma (in AL amyloidosis), suspicion of an infection (one patient), and for staging 
carcinomas. Increased FDG uptake was found in multiple myeloma lesions, in the tumors and, 
in some cases, the metastases and in a location suspicious for an infection. However, in none 
of the ten patients was increased FDG uptake found in the organs that were known to have 
high amounts of amyloid deposits. 
In all ten patients 123I-SAP scintigraphy was also performed and nine patients were judged 
positive for specific organ involvement. The spleen was involved eight times, the liver 
three times, the kidney(s) two times and the bone marrow two times. One patient with AA 
amyloidosis showed no specific organ involvement on the SAP scan, and this was reported to 
be a false-negative result. An example of both scans in a patient with systemic amyloidosis 
is shown in Figure 3. 
Figure 1
Patient 1 in Table 1 had been diagnosed with localized amyloidosis in the muscles and cutis. A 18F-FDG-PET 
showing physiological uptake in the brain, oropharynx, left ventricle, stomach, kidneys and bladder and 
multiple cutaneous and muscular lesions with high FDG uptake. B 123I-SAP scintigraphy of the same patient, 
anterior (left) and posterior (right) views, showing asymmetrical physiological uptake in the thyroid and 








Patient 2 in Table 1 had been diagnosed with localized amyloidosis in the left ankle. Both 18F-FDG-PET (A) 
and 123I-SAP scintigraphy (B, anterior (left) and posterior (right) views of the torso, and C, anterior (left) and 
posterior (right) views of the lower legs and ankles) show uptake in the region of the left ankle. Note: on 
18F-FDG-PET uptake can also be seen in the mediastinal and hilar lymph nodes (sarcoidosis) and uptake in the 
finger joints due to exercises in the waiting time (computer game).
Figure 3
Patient 16 in Table 1 had been diagnosed with systemic amyloidosis (AL type). A 18F-FDG-PET showing 
elevated uptake in the muscles due to diabetes mellitus, but without increased FDG uptake in the organs. 
B 123I-SAP scintigraphy, anterior (left) and posterior (right) views, showing highly increased uptake in liver and 
spleen.








The aim of this study was to evaluate the utility of 18F-FDG-PET/CT in distinguishing patients 
with systemic amyloidosis from patients with localized amyloidosis. As hypothesized, 18F-FDG-
PET/CT scans were clearly positive in all but one of the patients with localized amyloidosis and 
negative in all patients with systemic amyloidosis. Sometimes it remains difficult to distinguish 
systemic from localized amyloidosis, and currently available investigation techniques are not 
always able to differentiate between the two. If screening biopsies of rectum and abdominal 
fat tissue do not show amyloid deposition elsewhere, localized amyloid seems to be the 
most probable conclusion. However, it would strengthen the diagnosis if positive arguments 
for localized amyloid deposition can also be obtained. In this situation, 18F-FDG-PET/CT can 
contribute to better differentiation. The results of our study indicate that 18F-FDG-PET/CT is 
positive in localized amyloidosis and negative in systemic amyloidosis. 
Until recently, no studies have been published that evaluated the role of 18F-FDG-PET/CT in 
both systemic and localized amyloidosis. Several case reports mention increased FDG uptake 
in patients with localized amyloidosis, most of them localized in the lungs (11-17), but other 
locations have been mentioned as well, including the nasopharynx (18) and lymph nodes 
(19). 
In systemic AL amyloidosis, two case reports mention increased FDG uptake in organs affected 
by amyloid, namely liver and adrenal glands (20) and joints (21). Two other case reports 
showed non-specific uptake in bone and muscles in one patient (22) and did not show any 
increased FDG uptake in affected intestines in the other patient (23). A recently published 
study by Mekinian et al. is the only study that used 18F-FDG-PET/CT in a group of patients. They 
analyzed ten patients with AL amyloidosis, systemic type in six patients and localized type in 
four patients. FDG uptake was positive in three of the four patients with localized amyloidosis, 
namely in the nasopharynx, duodenum and skin. FDG uptake was positive in four of the six 
patients with systemic amyloidosis, namely nasopharynx (n=2), lung (n=2) and bone, joint 
and muscular areas (n=1 each) (24). These results differ from our results in patients with 
systemic amyloidosis and cannot be explained easily. One possible explanation is that in our 
study uptake in the nasopharynx and muscles was usually considered to be non-specific (as 
can be seen in Figures 1, 2 and 3).
It is good to notice that both our study and the study of Mekinian et al. have clear limitations: 
because of their retrospective design and the small number of patients there is an obvious 
need for prospective and blinded studies with sufficient numbers of well-defined patients 
representing all major types of amyloidosis. However, it will be difficult to obtain funding 
for a study in patients with systemic amyloidosis when the expected results are that the 
FDG uptake will not be positive. Another limitation of our study is the group of patients with 
systemic amyloidosis and subset of four patients with localized amyloidosis that underwent 
18F-FDG-PET. In these patients the scans were performed for other reasons and the results may 
not automatically be representative for all amyloidosis patients. A next limitation of our study 







with increased FDG uptake suspicious for myeloma in the patients with multiple myeloma. In 
most of these cases the clinical picture, the presence of osteolytic bone lesions, a favorable 
response to radiotherapy and a negative SAP scan at that site confirmed the clinical diagnosis 
of multiple myeloma at that site. 
In our study, the findings on 123I-SAP scintigraphy are comparable to those mentioned in 
earlier studies. Scan results were positive in the majority (nine of ten) of the patients with 
systemic amyloidosis. In only one patient was no specific uptake in the organs visible. This 
results in a sensitivity of 90 %, comparable with the results mentioned in a large study in 189 
patients with amyloidosis (9). The availability of 123I-SAP scintigraphy in our centre provided 
us with a unique opportunity to compare the results of FDG uptake with the results of well-
established SAP uptake in virtually all patients. 
18F-FDG is known to be taken up not only by cells involved in inflammation and infection 
(leucocytes), but also in cells involved in the clean-up response, such as macrophages, 
monocytes and giant cells. Westermark recently hypothesized that giant cells in localized 
amyloidosis directly participate in the transformation of the soluble full-length light chains into 
insoluble fibrils formed from N-terminal light chain fragments (4). In localized amyloidosis, 
we suppose that this results in high uptake of FDG in the surrounding giant cells and in other 
immunoreactive cells (macrophages, monocytes and leucocytes) around it. In our patients, 
8 of 11 patients with localized amyloidosis showed giant cells in the biopsy material, in 
agreement with the observations of Olsen et al. and the hypothesis of Westermark. In three 
patients giant cell involvement was not specifically reported: one with localization in the 
upper leg, one in the colon and one in the bone marrow. However, in all three patients 
inflammatory cells were seen, which may also explain the uptake of FDG. 
In localized AL amyloidosis giant cells are thought to be present because of their role in 
the production of amyloid (4). In systemic AL, AA and ATTR amyloidosis, however, giant 
cells are thought to be unnecessary for the formation and deposition of amyloid. This is in 
agreement with the biopsy results: giant cells were not present in any of the patients. The 
absence of giant cells and inflammation probably explains why none of the patients with 
systemic amyloidosis showed FDG uptake at the sites with proven amyloid deposits. This 
absence of giant cells and inflammation is a stable feature of systemic amyloidosis because 
of the accumulation of SAP in amyloid deposits, probably acting as a kind of camouflage and 
thereby protecting these deposits from recognition and clearance by giant cells (25). SAP is 
selectively concentrated in amyloid deposits by its avid binding to all amyloid fibril types. SAP 
binding stabilizes amyloid fibrils, protects them from proteolysis in vitro and contributes to the 
pathogenesis of systemic amyloidosis in vivo (26,27). Therefore, it seems that SAP makes the 
amyloid deposits inaccessible for phagocytic clearance mechanisms (25). This camouflaging 
role of SAP in the clearance of amyloid may be operative in both systemic and localized 
amyloidosis. 








In this study, we investigated the utility of 18F-FDG-PET(/CT) in distinguishing patients with 
localized amyloidosis from patients with systemic amyloidosis. Uptake of FDG was seen in 
all patients with localized amyloidosis, thereby confirming the hypothesis of Westermark 
about the essential role of multinuclear giant cells around the localized amyloid deposits. On 
the contrary, no FDG uptake at all was seen in patients with systemic amyloidosis, probably 
because high amounts of SAP make the amyloid deposits unavailable for inflammatory and 
phagocytic cells. 
Compared to 123I-SAP scintigraphy, 18F-FDG-PET(/CT) seems to be better able to distinguish 
between patients having localized or systemic amyloidosis. 18F-FDG-PET(/CT) is not able to 
define localized or systemic amyloidosis. However, once systemic disease has been ruled out 
by the usual tests, this technique may have additional value by providing supportive evidence. 
Furthermore, it may have a role in therapy evaluation and monitoring during follow-up. This 
finding has potential clinical application and warrants further prospective clinical trials to 
strengthen the evidence of our hypothesis. In future, this may help to reduce the number of 
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To assess the usefulness of bone scintigraphy with 99mTechnetium-hydroxymethylene 
diphosphonate (99mTc-HDP) for the detection of cardiac involvement in a group of patients with 
ATTR amyloidosis in different phases of disease, to relate the findings to echocardiography, 
ECG, and cardiac biomarkers, and to evaluate different bone scintigraphic techniques and 
calculation methods for quantification of the cardiac uptake and for correlation with 
echocardiographic features and cardiac biomarkers.
Methods
Forty-one patients underwent clinical examinations, echocardiography, ECG, measurement of 
cardiac biomarkers, and bone scintigraphy (planar imaging and SPECT-CT) and were subsequently 
subdivided into three groups: (1) carriers of an amyloidogenic TTR mutation, n=11, (2) proven 
ATTR amyloidosis without echocardiographically-defined (mean wall thickness >12 mm) 
cardiac amyloidosis (AC), n=19, and (3) ATTR amyloidosis with echocardiographically-defined 
cardiac amyloidosis, n=11. Planar and SPECT-CT images were analyzed visually according to a 
routine scoring system (grade 0-3) and semi-quantitatively by heart-to-whole body (H/WB) 
and heart-to-skull (H/S) ratio on planar images and by a left ventricle-blood pool ratio on 
SPECT-CT images.
Results
All patients with ATTR and echocardiographically-defined AC and none of the carriers showed 
high cardiac uptake on bone scintigraphy. Furthermore, 8 out of 19 patients with ATTR without 
echocardiographically-defined AC showed high cardiac uptake. Highest correlations were 
found between H/S ratio on planar bone scintigraphy with troponin T (r=0.76, p<0.0001) and 
H/WB ratio with left ventricular mass index (r=0.73, p<0.0001).
Conclusion
Bone scintigraphy with 99mTc-HDP may detect cardiac involvement in patients with ATTR 
amyloidosis prior to echocardiographic evidence of cardiac involvement. Cardiac uptake on 
bone scintigraphy correlates with severity of cardiac involvement using echocardiography, 
ECG, and cardiac biomarkers. Visual grading and calculation of H/S ratio on planar imaging are 








Systemic amyloidoses are diseases characterized by deposition throughout the body of 
insoluble fibrils (amyloid) derived from soluble serum proteins. One of the major systemic 
types is ATTR amyloidosis that may be hereditary or age-related (senile) (1). The hereditary 
type is caused by autosomal dominantly inherited point mutations (about 100 mutations have 
been described) of the precursor protein transthyretin (TTR). In the age-related type it is the 
normal (‘wild-type’) TTR that behaves as precursor protein. In both ATTR-types myocardial 
involvement is frequently seen, characterized by a restrictive cardiomyopathy due to amyloid 
deposition in both myocardial tissue and atrioventricular conduction system, leading to 
intractable heart failure, conduction disturbances or fatal arrhythmias.
 
Diagnosing ATTR amyloidosis and typing with confidence is challenging since patients often 
present with a wide variety of symptoms. In the hereditary type, as TTR is primarily produced 
by the liver, liver transplantation is the only effective way to get rid of the mutated protein 
precursor as treatment for the disease. However, this only applies for patients in which the 
disease is minimally interfering with organ function, particularly cardiac function. Treatment of 
the age-related form is restricted to symptom relief with conventional heart failure therapy (2).
 
Echocardiography, 12-lead electrocardiography (ECG), and magnetic resonance imaging (MRI) 
are currently considered the standard for non-invasive diagnosis of cardiac amyloidosis (3-6). 
But these techniques are neither suitable for differentiating between amyloid cardiomyopathy 
and other forms of cardiomyopathy, nor for determining the type of amyloidosis. Furthermore, 
these techniques have only limited diagnostic utility in the early phases of the disease 
(1,2,5,7-9).
 
Bone scintigraphy with radiolabelled diphosphonate was found to be a new diagnostic tool for 
defining the type of amyloid cardiomyopathy, since high uptake was found in ATTR amyloid 
cardiomyopathy whereas absent or weak uptake was found in AL (immunoglobulin light 
chain-derived) amyloid cardiomyopathy (10). In ATTR amyloidosis, bone scintigraphy was able 
to reflect the extent of cardiac amyloid deposition (11) and to identify myocardial infiltration 
by amyloid across a wide spectrum of morphological and functional cardiac involvement, 
allowing early diagnosis of the disease (12). Furthermore, myocardial uptake was found to be 
a prognostic determinant of cardiac outcome in ATTR, either alone or in combination with left 
ventricular (LV) wall thickness (12).
The aims of this study were (1) to further assess the usefulness of bone scintigraphy with 
99mTechnetium labelled hydroxymethylene diphosphonate (99mTc-HDP) for cardiac involvement 
in a group of patients with ATTR amyloidosis in three different phases of their disease (carriers 
of the mutation without the disease, ATTR amyloidosis patients without echocardiographic 
signs of cardiomyopathy, and ATTR amyloidosis patients with echocardiographically-
defined cardiomyopathy) and (2) to correlate the cardiac uptake on bone scintigraphy 
with echocardiographic findings, ECG characteristics, and cardiac biomarkers (N-terminal 
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Furthermore, we performed not only planar bone scintigraphy but also single photon emission 
computed tomography/computed tomography (SPECT/CT) in a large subset of patients, 
enabling other methods to quantify the uptake of the diphosphonate tracer in the heart. 
As third aim of this study, different bone scintigraphic imaging techniques and calculation 
methods were evaluated for quantification of the cardiac uptake and for correlation with 
echocardiographic features and cardiac biomarkers.
METHODS
Patients
In our referral center for the diagnosis and treatment of amyloidosis, all patients with 
suspected or known ATTR amyloidosis, either TTR mutation carriers without amyloid or ATTR 
patients with histologically proven disease activity (hereditary and age-related form, after 
or without liver transplantation), underwent clinical examination, echocardiography, ECG, 
and quantification of cardiac biomarkers (NT-proBNP and TnT) as part of the usual diagnostic 
workup to exclude or confirm cardiac amyloidosis. Furthermore, neurological tests (peripheral 
neuropathy), autonomic function tests (autonomic neuropathy), eye examinations (vitreous 
involvement), examination of the kidney function (estimated glomerular filtration rate (eGFR) 
and evaluation of serum proteins in the urine (proteinuria)) were performed. Between March 
2012 and March 2013, these patients were also asked to provide standard informed consent 
for acquiring bone scintigraphy with 99mTc-HDP. This research study was approved by the local 
medical ethics committee of our hospital.
Histology
Systemic amyloidosis was diagnosed by the presence of typical apple-green birefringence in 
polarized light in a tissue specimen stained with Congo red dye in a biopsy of subcutaneous 
fat or in at least one involved organ. Typing of ATTR amyloidosis was performed by 
immunohistology of a biopsy or by a transthyretin ELISA of abdominal fat tissue (13). Hereditary 
ATTR was defined by a documented TTR gene mutation at DNA analysis. When there was no 
TTR mutation found with this analysis, wild-type (age-related form) ATTR was diagnosed.
Echocardiography
The following echocardiographic variables were measured according to standard 
recommendations and using standard techniques: left ventricle (LV) ejection fraction, septum 
thickness, LV posterior wall thickness, LV mass index and right ventricle free wall thickness. 
Using Doppler recording of transmitral flow velocity, the ratio of peak flow velocity of LV rapid 
diastolic filling (peak E) to peak flow velocity during atrial contraction (peak A) was measured 
(E/A ratio). Furthermore, the early diastolic velocity of the lateral (e’lat) and septal (e’sep) 
mitral annulus was measured and the ratio between mitral inflow velocity (E) and average of 
the lateral and septal e’ values (E/e’ ratio) was calculated.
Cardiac amyloidosis was defined as a mean left ventricular wall thickness (septum and 
posterior wall) greater than 12 mm in the absence of hypertension or other potential 







amyloidosis were: right ventricular free wall thickening in the presence of left ventricular 
thickening and in the absence of pulmonary or systemic hypertension, granular sparkling 
appearance of ventricular myocardium, and pericardial effusion (2,9). Left ventricular mass 
index was classified as increased when > 130 g/m2 in men and > 110 g/m2 in women (15), 
E/A ratio > 2 indicated restrictive filling, and E/e’ ratio was judged normal when <8, judged 
as possible increased LV filling pressure between 8 and 15, and judged as increased filling 
pressure when > 15 (16,17).
Other diagnostic definitions
The presence of low voltage on 12-lead electrocardiography, intraventricular conduction 
delay and anteroseptal pseudo-infarction were considered suggestive for cardiac amyloidosis. 
Elevation of NT-pro BNP (< 75 years: > 125 ng/l; > 75 years: > 450 ng/l) and TnT (>14) may 
be seen in cardiac amyloidosis. Although elevation of these biomarkers are seen in a wide 
variety of cardiac disorders, normal values of NT-pro BNP and TnT exclude significant cardiac 
amyloidosis.
Peripheral neuropathy was defined clinically by a typical symmetric ascending sensorimotor 
peripheral neuropathy. The presence of carpal tunnel syndrome alone did not constitute 
peripheral nerve involvement. Autonomic neuropathy was defined by presence of orthostatic 
hypotension, gastric-emptying disorder, intestinal pseudo-obstruction or bladder dysfunction 
not related to direct organ infiltration (14). Eye involvement was defined by infiltration of 
amyloid deposits in the vitreous, producing characteristic glass-wool-like sheets and globular 
opacities (18). Impaired kidney function was defined as an eGFR < 60 ml/min/1.73 m2 
(generic sign of impaired renal function) and/or a 24-hr urine protein excretion ≥ 0.5 g/day 
( a marker of amyloidotic kidney involvement), with other causes of proteinuria excluded.
Bone scintigraphy protocol, image analysis and uptake quantifications
All patients received 700 MBq 99mTc-HDP intravenously. Planar anterior and posterior whole 
body scans were obtained 3 hours after injection. In a large subset of patients (n=36), a SPECT-
CT of the thorax including the heart was also performed. The SPECT images were acquired 
using a 128x128 matrix, 180° degrees of rotation, 64 views, 15 sec per view. All scans were 
acquired on a SPECT/CT dual head gamma camera system (Siemens Symbia T, Siemens 
Medical Systems, Knoxville, TN, USA). 
Visual image analysis was performed in consensus by 2 experienced nuclear medicine 
physicians (RS and AG) blinded to all other patient data. Visual scoring of cardiac uptake was 
scored on planar images using a routine scoring system (12,19,20), see Figure 1: (0) absent 
cardiac uptake and normal bone uptake, (1) mild cardiac uptake, inferior to bone uptake, 
(2) moderate cardiac uptake associated with attenuated bone uptake, and (3) high cardiac 
uptake with decreased or absent bone uptake. Visual scoring of cardiac uptake on SPECT was 
scored as follows: (0) absent cardiac uptake, (1) mild cardiac uptake, lower than mediastinal 
background, (2) moderate cardiac uptake higher than mediastinal background but lower than 
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Semi-quantitative analysis on planar images was performed by calculating the heart-to-
whole-body (H/WB) and heart-to-skull (H/S) ratio. For this purpose a geometric mean image 
was calculated on a pixel by pixel basis using the anterior and posterior image data. Regions 
of interest (ROIs) were placed over the heart, kidneys, bladder and within the skull on this 
geometric mean image. If residual activity was detected at the injection site, a ROI was 
defined on that location as well. This way, the geometric means for each ROI were calculated. 
The H/WB method was described earlier (12,19,20) with the total image counts corrected for 
kidney and bladder uptake and residual activity at the injection site considered as whole-body 
uptake. The H/S ratio was also calculated for each patient as the ratio between heart uptake 
and uptake in the skull.
 
Semi-quantitative analysis on SPECT-CT images was performed by drawing volumes of interest 
(VOIs) over the left ventricle and on the ascending aorta (valve area till aortic arch, defined as 
blood pool background). The total counts in the VOIs were divided by the volume of the VOIs, 
leading to a VOI concentration. By dividing the VOI concentration in the left ventricle by the 
VOI concentration in the bloodpool, the LV/blood pool ratio was calculated.
Figure 1









Continuous data are expressed as median (range). Categorical variables are expressed as 
absolute numbers and percentages. For wide ranging right-skewed quantities (NT-proBNP) 
values were normalized using logarithmic scales. This log transformation of NT-proBNP 
was already described to improve the prognostic value in patients with pulmonary arterial 
hypertension (21). Analyses between bone scintigraphic results and echocardiography, ECG and 
cardiac biomarkers were performed with unpaired t-test (two subgroups). Analyses between 
different subgroups of patients were performed with one-way ANOVA (three subgroups) and 
Bonferroni post test to compare all pairs of subgroups. Analyses of categorical variables were 
performed with Fisher’s exact tests. Correlation analyses were performed by linear regression 
and calculation of Pearson correlation coefficient (r). P<0.05 was considered statistically 
significant. All tests were performed using GraphPad Prism version 5.0 for Windows, GraphPad 
Software, San Diego, California, USA.
RESULTS
Patient population
Forty-one patients fulfilled the study criteria and entered the analysis. Eleven of them (27%) 
were carriers of a TTR gene mutation, 19 patients (46%) were diagnosed histologically 
with ATTR amyloidosis but had no echocardiographic signs of cardiac involvement, and 11 
patients (27%) were diagnosed echocardiographically as ATTR amyloidosis with amyloid 
cardiomyopathy (mean LV wall thickness > 12 mm), 6 of them proven by endomyocardial 
biopsies. Table 1 summarizes the main clinical findings in the patient population, divided into 
these three subgroups. 
In the whole patient group, half of the patients (n= 20, 49%) were diagnosed with a 
Val30Met mutation. Other TTR mutations (non-Val30Met) found were Val71Ala (10 patients), 
Tyr114Cys (2), Gly47Glu (1), Glu89Lys (1), Val122Ile (1), whereas no mutation was found in 
6 patients (wild-type ATTR). In total, 17 patients underwent liver transplantation, 13 because 
of diagnosed ATTR amyloidosis, and four for other reasons. Of interest, these last four patients 
received a donor liver of a patient with ATTR amyloidosis; three patients are considered carriers 
without clinical signs of amyloidosis, but one patient with clinical signs has been histologically 
diagnosed to have systemic ATTR amyloidosis.
Laboratory findings, echocardiography and ECG
Characteristics of cardiac biomarkers, eGFR, echocardiography and ECG are shown in Table 1 
for the three groups. In summary, TnT, log NT-proBNP, many echocardiographic features (LV 
ejection fraction, mean LV wall thickness, septum thickness, LV posterior wall thickness, LV 
mass index, E/A ratio, E’-lat, E’-sep and E/e’ ratio) and ECG features (PR duration, QRS duration, 
and QTc duration) differed significantly between the ATTR group with echocardiographically-
defined amyloidotic cardiomyopathy (AC) and each of the two other groups, respectively. 
Furthermore, NT-proBNP differed also significantly between carriers and ATTR group without 
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Table 1 Patient characteristics, laboratory, echocardiographic, ECG and bone scintigraphic findings.
 
  Carriers ATTR without AC ATTR with AC P-value
  N = 11 N = 19 N = 11 
 Clinical characteristics    
Age (yrs) 55 (25-76) 53 (32-72) 68 (55-83) 0.006 * 
Male 5 (45) 11 (58) 9 (82) 0.23
NYHA functional class ≥ 2 1 (9) 5 (26) 10 (91) 0.0001 *
Peripheral neuropathy 0 18 (95) 4 (36) <0.0001 **
Autonomic neuropathy 0 6 (32) 2 (18) 0.12
Eye involvement 0 7 (37) 3 (27) 0.06
Disease duration after histological 
proof (mo) n.a. 40 (19-208) 19 (1-119) 0.38
TTR mutations    0.0003 *
 met30 8 (73) 10 (53) 2 (18)
 non-met30 3 (27) 9 (47) 3 (27)
 wild type 0 0 6 (55) 
Liver transplantation 3 (27) 12 (63) 2 (18) 0.06 **
 Laboratory markers    
NT-proBNP plasma level (ng/l) 75 (10-557) 247 (86-797) 2660 (368-9227) <0.0001  
     ***#
Troponin T plasma level (ng/l) 5 (4-11) 10.5 (4-117) 56 (25-178) <0.0001 *
eGFR (ml/min*1,732) 72 (33-111) 76 (46-134) 60 (27-92) 0.08
 Echocardiographic findings    
LV ejection fraction (%) 60 (55-60) 60 (52-60) 44 (28-60) <0.0001 *
LV mean wall thickness (mm) 8.8 (7.0-10.5) 9.5 (8.0-12.0) 18.9 (13.9-22.5) <0.0001*
Septum thickness (mm) 9.0 (8.0-12.0) 10.0 (7.0-14.0) 18.0 (16.0-24.0) <0.0001*
LV posterior wall thickness (mm) 8.3 (6.0-9.0) 9.6 (7.8-13.0) 16.3 (9.8-26.0) <0.0001*
Right ventricular wall thickness (mm) 4.0 (3-4.5) 4.0 (3.0-7.0) 9.0 (5.0-12.0) <0.0001*
LV mass index (g/m2) 63.5 (62-69) 76.0 (51.0-103.0) 210.5 (167.0-270.0) <0.0001*
E/A ratio  1.04 (0.70-2.20) 1.06 (0.70-2.50) 3.25 (0.80-14.00) 0.002*
e’-lat (cm/s) 9.6 (5.7-15.5) 10.7 (5.0-17.1) 5.9 (2.5-7.5) 0.0004*
e’-sept (cm/s) 8.6 (5.1-15.5) 9.3 (3.8-12.1) 3.3 (1.9-5.4) <0.0001*
E/e’ 7.2 (4.3-10.7) 7.3 (4.3-15.7) 15.3 (7.5-38.7) 0.0005*
 ECG findings    
PR duration (ms) 150 (132-202) 169 (132-215) 202 (138-192) 0.004*
QRS duration (ms) 84 (70-102) 89 (78-152) 118 (78-156) <0.0001*
QT duration (ms) 392 (348-502) 396 (330-465) 433 (336-514) 0.10
QTc duration (ms) 402 (381-446) 432 (375-509) 467 (437-558) <0.0001*
 Bone scintigraphic findings    
Visual grading score, planar    <0.0001***
0  11 (100) 6 (32) 0 (0)
1  0 (0) 5 (26) 0 (0)
2  0 (0) 6 (32) 5 (45)
3  0 (0) 2 (10) 6 (55)
Visual grading score, SPECT    < 0.0001***
0  10 (91) 7 (41) 0 (0)
1  1 (9) 4 (23) 0 (0)
2  0 (0) 3 (18) 4 (50)
3  0 (0) 3 (18) 4 (50) 
Heart-to-whole-body-ratio, planar 1.48 (1.30-2.07) 1.88 (1.28-2.93) 2.88 (2.04-3.91) <0.0001*
Heart-to-skull-ratio, planar 1.20 (0.40-2.70) 2.16 (1.17-9.06) 5.43 (2.74-8.18) 0.0002***







Values are in median (range) or in absolute numbers (percentage)
*Statistically significant between ATTR with AC and the other two groups (ATTR without AC and carriers)
** Statistically significant between ATTR without AC and the other two groups (ATTR with AC and carriers)
***Statistically significant between each group and the other groups
# Log transformed NT-proBNP
AC = amyloid cardiomyopathy, NYHA = New York Heart Association, TTR = transthyretin, yrs = years, mo = 
months, n.a. = not applicable
Bone scintigraphy
Visual and semi-quantitative scintigraphic findings, both on planar imaging and with SPECT-
CT, are summarized in Table 1. None of the 11 carriers tested positive at visual score analysis 
on planar images, and only one of 11 carriers showed slightly elevated (grade 1) uptake 
on SPECT-CT. Among the 19 patients with ATTR without echocardiographically-defined AC, 
8 patients on planar imaging showed uptake grade 2 or 3. In these 8 patients with cardiac 
uptake, NT-proBNP, TnT, echocardiographic and ECG findings did not significantly differ from 
the other patients (n=11) in this group without cardiac uptake on the bone scan. All 11 
patients with ATTR and echocardiographically-defined AC showed high uptake (grade 2 or 3), 
both on planar images and on SPECT-CT. 
At semi-quantitative analysis, H/WB ratio, H/S ratio, and SPECT LV/bloodpool ratio were 
significantly higher in patients with ATTR and echocardiographically-defined AC, compared 
to both carriers and ATTR patients without echocardiographically-defined AC. Concerning the 
H/S ratio, there was also a significant difference between carriers and ATTR patients without 
echocardiographically-defined AC. However, there is overlap between the H/S ratio of patients 
with and without echocardiographically-defined AC, so for the individual patient it remains 
difficult to provide conclusions based on the H/S ratio alone. The semi-quantitative scintigraphic 
findings (H/S ratio) of the carriers, ATTR patients with echocardiographically-defined AC, and 
ATTR patients without echocardiographically-defined AC are shown in Figure 2.
Figure 2
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Scintigraphic correlations with cardiac biomarkers and echocardiographic findings
In the overall population, the highest correlation was found between H/S ratio and TnT 
(r = 0.76, p < 0.0001), followed by the correlation between H/WB ratio and LV mass index 
(r = 0.73, p < 0.0001, SPECT ratio with LV mass index (r = 0.72, p = 0.0005), and SPECT ratio 
with TnT (r = 0.71, p < 0.0001) (Figure 3). Interestingly, the correlation between all semi-
quantitative scintigraphic findings and LV mass index was better than with LV mean wall 
thickness, till now the standard echocardiographic measurement for AC. Taken all scintigraphic 
quantifications together, H/S ratio was on average found to correlate best with cardiac 
biomarkers and echocardiographic findings, with significant correlations between H/S ratio 
and TnT (r = 0.76, p < 0.0001), log NT-proBNP (r = 0.63, p = 0.0005), mean wall thickness 
(r = 0.68, p < 0.0001), and LV mass index (r = 0.71, p = 0.001), see Table 2.
If restricted to only the patients with ATTR, the same correlations were found, with the best 
correlation between H/S ratio and TnT (r = 0.71, p < 0.0001). In the subgroup of ATTR patients 
without echocardiographically-defined AC, a correlation was found between NT-proBNP and 
cardiac uptake on bone scintigraphy (visual grade on planar imaging, r = 0.49, p = 0.04).
Figure 3 
Highest correlations found between semi-quantitative scintigraphic results and laboratory and 
echocardiographic findings. In all patients planar images were acquired and H/S ratio calculated. SPECT/CT 








Correlations between different bone scintigraphic calculations techniques and most important 
echocardiographic features and cardiac biomarkers 
 Mean wall LV mass index NT-proBNP Troponin T
 thickness (mm  (g/m2) (ng/l) # (ng/l) 
 Pearson r p-value Pearson r p-value Pearson r p-value Pearson r p-value
Planar ratios
Heart-to-skull 0.68 <0.0001 0.71 <0.0001 0.63 0.0005 0.76 <0.0001
Heart-to-whole-body 0.57 0.003 0.73 <0.0001 0.60 0.01 0.56 0.0002
SPECT ratio
LV-blood pool 0.59 0.0006 0.72 <0.0005 0.57 0.0006 0.71 <0.0001
# Log transformed NT-proBNP
Correlation analyses expressed as Pearson correlation coefficient (r). 
P<0.05 was considered statistically significant.
Subgroups of ATTR patients 
We divided the patients with proven ATTR amyloidosis into three subgroups to search for 
differences between ATTR patients with Val30Met gene mutation (n = 12), ATTR patients with 
all other gene mutations (non-Val30Met, n = 12) and wild-type TTR (n = 6). As expected, 
significantly higher TnT values, thicker LV mean wall thickness, and higher LV/bloodpool SPECT 
were found in patients with wild type TTR. With visual grading score, both on planar images 
and on SPECT images, most patients with Val30Met mutation had lower scores, whereas 
most patients with non-Val30Met mutation had scores grade 2 or 3. The H/S ratio seemed 
to be most appropriate for differentiating Val30Met from non-Val30Met mutation patients. 
In a scatter plot (Figure 4) is shown that half of the patients with non-Val30Met mutation 
(black bullets) had a high H/S ratio (>3) but a normal LV mean wall thickness (< 12 mm, no 
echocardiographically-defined AC), whereas only one patient with Val30Met (open bullet) had 
a high H/S ratio but a normal LV mean wall thickness. This may be an important observation 
since these patients, defined as having no AC based on echocardiographic findings, do show 
high uptake on bone scintigraphy and therefore may already have cardiac involvement. 
Thirteen patients underwent liver transplantation because of ATTR amyloidosis, the median 
time between liver transplantation and bone scan was 36 months (range 6-181). Before liver 
transplantation, the median LV mean wall thickness was 9 mm (range 8-10). At the time of 
bone scintigraphy, 11 patients were still in the ATTR group without echocardiographically-
defined AC with a median LV mean wall thickness of 9,3 mm (range 8-11.5), not different from 
before. However, five out of these 11 patients showed cardiac uptake on bone scintigraphy 
(two patients planar grade 1, two patients grade 2 and one patient grade 3) and four of the 
five had a TTR-non-Met30 mutation. No differences were found in NT-proBNP and TnT in the 
patients with and the patients without cardiac uptake. Two patients, both with ATTR-non-
Met30, developed echocardiographically-defined cardiac involvement in the period between 
liver transplantation and bone scintigraphy (group ATTR with AC): one patient already one 
year after transplantation, and the other patient three years after transplantation. At the 
moment of bone scintigraphy, the LV mean wall thickness of these patients was 20,2 and 18,9 
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Figure 4 
Scatterplot of H/S ratio vs. LV mean wall thickness in patients with ATTR amyloidosis subdivided into Val30Met 
(open bullets), non-Val30Met (black bullets) and wild type TTR (grey bullets) groups
DISCUSSION
Diagnosing cardiac amyloidosis is a challenge in clinical practice. Histological confirmation 
obtained by endomyocardial biopsy is the gold standard, however, this is limited to centers 
with cardiopathology facilities, is an invasive procedure, and harbours a non-negligible risk of 
perforation and bleeding. Furthermore, typing of amyloid using immunohistochemistry is fraught 
with errors and more definitive techniques such as mass spectroscopy are not widely available. 
In patients with known systemic amyloidosis, typical findings on echocardiography and/or ECG 
might help for this diagnosis. However, these techniques are not able to differentiate between 
cardiac amyloidosis and other causes of restrictive cardiomyopathy, nor to differentiate between 
the etiologic types of amyloidosis.
Cardiac uptake on bone scintigraphy has been found useful to distinguish ATTR type (high 
uptake) from AL type (no or weak cardiac uptake) and to allow early diagnosis of the disease, 
even before abnormalities can be found with echocardiography (10-12). Cardiac uptake on bone 
scintigraphy (planar visual grade > 0) reflects the extent of amyloid infiltration histologically 
confirmed by endomyocardial biopsy (12).
 
Our results strengthen earlier findings (11,12). Correlations were found between cardiac uptake 
on bone scintigraphy and findings on echocardiography and laboratory parameters. Highest 
correlations were found between cardiac uptake and TnT and between cardiac uptake and LV 
mass index. LV mass index correlated better with cardiac uptake than LV mean wall thickness. 
This is good to notice, since LV mean wall thickness > 12 mm is the current criterion to define 
cardiac involvement in amyloidosis (14). If confirmed in other studies, this finding indicates that 









As expected this study showed various parameters to differentiate ATTR patients 
with echocardiographically-defined AC from carriers and from ATTR patients without 
echocardiographically-defined AC (see Table 1). An interesting finding, however, is that NT-
proBNP also differentiated carriers from ATTR patients without echocardiographically-defined AC. 
This is really worthwhile to be explored by additional analyses. For example, one could follow 
the patients longitudinally in time from being carrier to full blown AC and evaluate which of the 
three (i.e. cardiac biomarkers, echocardiography or bone scintigraphy) will be the most sensitive 
to reflect the onset of cardiac involvement.
 
In the already mentioned studies, only planar bone scintigraphy was performed but with dual 
time point imaging (5 minutes and 3 hours after injection). Heart tracer retention, heart/whole 
body retention and visual cardiac score were found to correlate with echocardiographically-
defined AC. In these studies, also H/WB ratio was determined and found higher in patients with 
cardiomyopathy. In our opinion, H/WB ratio is not the best calculation method on planar images, 
since whole body counts, although corrected for renal and bladder uptake, may potentially be 
confounded by high uptake of the isotope in bones due to other osteoblastic bone diseases 
(arthritis, osteoarthritis, recent fractures, etc). Calculating the H/S ratio may be a better method, 
since uptake within the skull is rather stable among patients. Since SPECT/CT was also performed 
in most of our patients, SPECT was visually graded and the uptake on SPECT was calculated by 
determining the ratio between LV uptake and uptake in the ascending aorta (LV-blood pool 
ratio). Both planar and SPECT visual grade and H/S ratio on planar imaging were found to differ 
between carriers and ATTR patients without echocardiographically-defined AC, between carriers 
and ATTR patients with echocardiographically-defined AC and between ATTR patients without 
and with echocardiographically-defined AC. H/S ratio was found to correlate better than H/WB 
ratio and LV/blood pool ratio on SPECT imaging. 
As a consequence of these results and the correlation of cardiac uptake on the bone scan with 
echocardiographic features and cardiac biomarkers, visual analysis of and calculation of H/S ratio 
at planar images is in our opinion preferred in these patient groups. SPECT/CT is not necessary 
to perform since it showed no advantages in visual and semiquantitative analysis over planar 
imaging, whereas it has some disadvantages compared to planar imaging (extension of the image 
acquisition time and radiation dose of the CT). Furthermore, there is nearly always homogenous 
increased uptake in the whole left ventricle, as can already be seen on planar imaging. It is not 
necessary to perform SPECT/CT to define the extent of amyloid infiltration in various segments of 
the myocardium, since AC is nearly always a diffuse disease of the myocardium.
 
In the patient group with ATTR without echocardiographically-defined AC (as defined by LV mean 
wall thickness), 13 of the 19 patients (68%) showed cardiac uptake on bone scintigraphy (five 
patients with planar visual grade scale 1, six patients with grade 2, and two patients with grade 
3). In this group, a linear correlation was found between cardiac uptake and NT-proBNP. Bone 
scintigraphy could therefore be an early marker of cardiac involvement in this patient group. 
This is supported by the finding that all patients with echocardiographically-defined AC showed 
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Patients with ATTR and echocardiographically-defined AC caused by non-Val30Met mutations 
tend to have a worse prognosis compared to patients with a Val30Met mutation [22,23]. An 
important finding was that half of the patients with non-Val30Met mutations had high cardiac 
uptake on the bone scan (H/S ratio >3), whereas other findings were not clearly indicating 
AC. A similar finding was found in ATTR patients after liver transplantation, with five out of 11 
patients showing cardiac uptake without other signs of AC. We agree with other authors that it 
is reasonable to hypothesize that the severity of cardiac uptake on bone scintigraphy could be 
a prognostic determinant of cardiac events (12). Patients with non-Val30Met mutation have a 
worse prognosis, and significant organ involvement precludes approval of liver transplantation 
(for the heart based on echocardiography). One may argue that if patients with non-Val30Met 
mutation show cardiac uptake on bone scintigraphy, liver transplantation should be seriously 
reconsidered or even combined liver and heart transplantation should be considered since 
cardiac infiltration is already present and may progress in spite of liver transplantation. 
This study has some limitations. Although the number of patients in this study is high compared 
to the low incidence of this rare disease, it is still a relatively small population, restricting the 
statistical power of the analyses. Analysis was performed transversally. To strengthen the results, 
prospective and longitudinal studies are necessary. We performed many statistical tests on the 
data which may increase the risk of some false positive correlations due to the small number of 
patients and the high number of statistical tests. The data presented in Table 1 could be influenced 
by the 6 patients with wild-type ATTR. These patients have by definition cardiomyopathy with 
enlarged hearts and impaired heart function and this may have impact on the comparison with 
the other patient subgroups. Endomyocardial biopsies were not performed in order to prove AC 
in patients with high uptake on bone scintigraphy. This had already been proven in another study 
(12); furthermore, endomyocardial biopsy may lead to complications as stated above.
Other studies in this field were performed with 99mTc-3,3-diphosphone-1,2-propanodicarboxylic 
acid (99mTc-DPD). Earlier studies did not show any significant differences in diagnostic accuracy 
among the different bone seeking agents used in bone scintigraphy (24,25). However, the 
imaging agent that was used in this study (99mTc-hydroxymethylene diphosphonate) was not 
described earlier in this patient population. Since the results of this study may be confounded by 
subgrouping of patients that may bias results in favor of the technique, further studies in larger 
populations are necessary to confirm its utility in these patient groups. 
Several other nuclear tracers have been investigated for imaging of AC, however with little results. 
99mTc-pyrophospate uptake was found higher in subjects with ATTR cardiac amyloid compared to 
a cohort of patients with AL amyloidosis (26). Some clinical evidence was found for the use of 
123I-metaiodobenzylguanidine (123I-MIBG) in which myocardial defects in MIBG activity correlates 
with impaired cardiac sympathetic nerve endings due to amyloid deposits (1). MIBG heart-to-
mediastinum ratio was found lower and wash-out higher in patients with echocardiographic 
signs of amyloidosis and may even detect cardiac denervation in ATTR patients before signs of 
AC were evident on echocardiography (1,27). A recently published study in two patients with 
ATTR amyloidosis showed that both bone scintigraphy and MIBG scintigraphy seem to be able to 







The exact mechanism of diphosphonate binding to amyloid is still not completely elucidated. 
It may be explained by the high calcium concentration in amyloid tissue (29,30). The presence 
of calcium in amyloid may be due to the non-fibrillar glycoprotein amyloid P component (29). 
The finding that uptake is almost exclusively seen in ATTR patients might be explained by a 
different composition of amyloid fibrils, different affinities of diphosphonate for amyloid proteins 
and differences in tissue involvement (11). In vitro analysis provided evidence that TTR binds to 
calcium (31).  
CONCLUSIONS
The results of this study confirm that bone scintigraphy identifies cardiac involvement 
in patients with ATTR amyloidosis. Bone scintigraphy with 99mTc-HDP may detect cardiac 
involvement in patients with ATTR amyloidosis prior to echocardiographic evidence of cardiac 
involvement. Cardiac uptake on bone scintigraphy correlates better with LV mass index than 
with LV mean wall thickness. 
Visual analysis of and calculation of H/S ratio at planar images is the preferred method for 
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This thesis describes several imaging techniques and interpretation criteria for the diagnosis 
of various infectious and inflammatory diseases. However, what is discussed in the previous 
chapters, is just a minor part of all possibilities that nuclear medicine offers in this field. 
New imaging methods, new radiopharmaceuticals and new imaging techniques are under 
continuous development. In the world of medicine, interest in inflammation is growing and 
growing. For example, inflammation is also thought to be a key player for the development 
of malignancies. Maybe, inflammation is the cradle of all diseases… 
We are still looking for new radiopharmaceuticals and we will keep on trying and trying to 
obtain as many information we can to prevent, diagnose and cure these diseases …. and we 
have to remember: Rome wasn’t built in one day.
In the meanwhile we may change techniques, methods and/or radiopharmaceuticals, but 
nevertheless we remain steadfast in our determination to achieve diagnostically accurate 
imaging of infection and inflammation. As Horace said in Epistles 1.11.27: “Caelum, non 
animum, mutant qui trans mare currunt” (the sky may change but not the soul of who run 
across the sea).
In the last chapter of this thesis, I will focus on four important concepts that deserve to be 
investigated in the forthcoming years. 
1. EXTENDING THE ROLE OF 18F-FDG-PET/CT IN THERAPY EVALUATION
For therapy evaluation in infection and inflammation with 18F-FDG, hardly any indication exist. 
The European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use 
(CHMP) only mentions the use of 18F-FDG for the therapeutic follow-up of unresectable alveolar 
echinococcosis, in which it may be used in the search for localizations of active parasites 
during medical treatment and after treatment discontinuation. Despite this lack of attention, 
to my opinion, 18F-FDG-PET/CT is not only valuable for therapy monitoring in many infectious 
and inflammatory diseases, but could even play a pivotal role in their management, leading 
to better drug dosage, proof of the usefulness of the treatment, and early modification of the 
therapeutic strategy.
In vasculitis, many case reports and several larger patient studies mention a role of 18F-FDG-
PET/CT in guiding treatment strategy and evaluating therapy response. 18F-FDG-PET was found 
suitable for detecting giant cell arteritis. The use of 18F-FDG-PET for therapy evaluation after 
the use of steroids was possible for 3 months. Therapy evaluation on later time points did not 
have added value (1). Another study found 18F-FDG-PET/CT to be a useful, accurate tool for 
monitoring therapy with steroids as it correlated well with clinical and biochemical findings 
(2). In patients that did not respond on therapy with steroids, cyclophospamide was found to 
be an effective therapy. 18F-FDG-PET/CT was a useful tool to determine whether to continue 







In sarcoidosis, there is convincing evidence in literature: 18F-FDG-PET/CT is a valuable 
imaging tool in assessing treatment efficacy and deciding whether to switch to an alternate 
therapeutic regimen (4-7, see also Figure 1). Almost all patients in these studies were treated 
with steroids, which resulted in a decrease in uptake on 18F-FDG-PET but also in clinical and 
biochemical improvement. One study concluded that 18F-FDG-PET/CT is not only useful to 
assess the efficacy of steroid treatment, but may also be useful for monitoring other therapies, 
such as infliximab, an anti-TNFα antibody (8).
Figure 1
An example of the value of 18F-FDG-PET/CT in a patient with sarcoidosis. (A) baseline scan, (B) scan after 
3 months of steroid therapy with progression of lung infiltrations, and (C) scan after 3 months of therapy 
with steroids and methotrexate together, resulting in a complete remission (the linear uptake is located in a 
muscle in the back and considered physiological muscle uptake).
 
For therapy evaluation in patients with osteomyelitis, results are also hopeful although not 
conclusive yet. 18F-FDG-PET/CT had a strong impact on the clinical management (initiation or 
prolongation of antibiotic therapy or recourse to surgical intervention) in 52% of patients (9). 
In children, 18F-FDG-PET/CT was found superior to MRI in distinguishing between infection and 
reparative activity within the musculoskeletal system after treatment for acute osteomyelitis. 
Termination of antibiotic treatment for children after acute osteomyelitis seems justified 
when laboratory and clinical parameters are normal, and 18F-FDG-PET/CT is unsuspicious (10).
In autoimmune diseases, literature studies that evaluated the use of 18F-FDG-PET for therapy 
monitoring, are scarce. In rheumatoid arthritis, the reduction of 18F-FDG joint uptake in the 
follow-up scans correlated significantly with clinical evaluation of disease activity (11). 
Changes in the mean SUV between baseline scans and the scan after two weeks of treatment 
with infliximab correlated significantly with disease activity scores (12). In inflammatory 
bowel diseases, only one study in only five patients was published. Findings of decrease or 
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What should be kept in mind, is (in some cases) the ability of 18F-FDG-PET/CT to differentiate 
between malignancy and infection. Of course, not with one (baseline) scan. However, by 
changes (decrease) in uptake after a short time of treatment (steroids or antibiotics) it may 
be sometimes possible to differentiate on the short term. For example, the differentiation 
between autoimmune pancreatitis and pancreatic cancer may be possible. By looking 
carefully at the pattern of 18F-FDG accumulation, accompanying other autoimmune diseases, 
and the change in 18F-FDG uptake after treatment, it may be possible to differentiate between 
these two entities. At baseline, 18F-FDG-PET shows more diffuse uptake in the pancreas in 
autoimmune pancreatitis compared to the more focally located lesions in pancreatic cancer. 
The detection of other autoimmune diseases, such as uptake in the salivary glands (sclerosing 
sialadenitis), in the thyroid (autoimmune thyroiditis) and in the bile ducts (cholangitis), also 
points towards the diagnosis autoimmune pancreatitis. Furthermore, a decrease in pancreatic 
uptake after a short period of steroid therapy (2 weeks) may be useful for discrimination 
(14,15). This approach is interesting, and should be better evaluated in larger patient groups 
and in different indications.
To my opinion, 18F-FDG-PET/CT offers a unique possibility for monitoring of therapy efficacy in 
patients with fungal infections. Antifungal therapy is expensive and must be given for a long 
time, sometimes even for months. Till now, only case reports describe the use of 18F-FDG-
PET in monitoring treatment in invasive aspergillosus, chronic disseminated candidiasis, and 
pneumocystis carinii pneumonia, all with good results (16-18). In daily practice in our hospital, 
however, we evaluated already several patients with 18F-FDG-PET/CT with good results. 
This technique is really worthwhile to help deciding whether therapy should be continued, 
stopped, or switched. The added value of the use of 18F-FDG-PET/CT in patients with fungal 
infections before, during and after therapy should be evaluated in the near future.
Another field that has to be explored in the next years, are the inflammatory diseases in 
children. At this moment, we are building up expertise in the diagnosis and therapy evaluation 
of children with polymyositis, dermatomyositis, sclerodermia, juvenile rheumatoid arthritis 
and chronic recurrent multifocal osteomyelitis. 18F-FDG-PET/CT offers a unique noninvasive 
imaging technique in this special group of patients.
An overview of the current applications of 18F-FDG-PET for the diagnosis and therapy evaluation 








Current application of 18F-FDG-PET for diagnosis and therapy evaluation in various inflammatory and infectious 
diseases
 Disease Evidence  Developing Need for Class of Comments
  for clinical  evidence for multicentre recommendation
  usefulness clinical studies  - level of
   usefulness  evidence
Vasculitis
 Diagnosis +   I-A Differentiation possible
      between GCA, TA, and PANa
 Therapy evaluation +   I-C Best time point at 3 months
Sarcoidosis
 Diagnosis +   I-A High sensitivity, low specificity
 Therapy evaluation +   I-C For evaluating steroid therapy,
      maybe also for others
Rheumatoid arthritis
 Diagnosis  + + IIa-C
 Therapy evaluation  + + IIa-C  
Inflammatory bowel      Especially in children
diseases
 Diagnosis +   IIa-C
 Therapy evaluation  + + IIa-C 
Autoimmune thyroiditis
 Diagnosis -   III-B
 Therapy evaluation -   III-B
Autoimmune pancreatitis
 Diagnosis  + + IIa-C Maybe for differentiation
      between AIPa and cancer
 Therapy evaluation  + + IIb-C  
Osteomyelitis
 Diagnosis +   I-A Only in chronic osteomyelitis
 Therapy evaluation  + + IIa-C  
Spondylodiscitis
 Diagnosis +   I-A
 Therapy evaluation  + + IIa-C  
Prosthetic joint infections     White blood cell scintigraphy
 Diagnosis -  + IIb-C still first choice
 Therapy evaluation -  + IIb-C 
Diabetic foot     White blood cell scintigraphy
 Diagnosis -  + IIb-C still first choice
 Therapy evaluation -  + IIb-C
Echinococcosis
 Diagnosis +   I-C
 Therapy evaluation +   I-C 
Fungal infections
 Diagnosis  +  IIa-C
 Therapy evaluation  + + IIa-C Maybe helpful to reduce high
      costs of antifungal therapy
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2. SPECIFIC TARGETING AND PERSONALIZED MEDICINE
Advances in disease understanding, molecular techniques and translational medicine have 
taken us to the threshold of a new way to practice medicine. Personalized medicine has 
come within grasp and has the potential to provide optimized treatment based on individual 
characteristics of the patient. Potential tools are now available to speed up drug development 
and drug targeting. Because of high costs of drug development, a close collaboration between 
academics, pharmaceutical industry, and government is essential, providing the framework 
for developing drugs more efficiently. Oncology is leading this new thinking process with 
multiple examples of clinical translation of molecular disease characteristics into personalized 
medicine strategies that are becoming the standard of care. 
Nuclear medicine techniques, including PET, may play a crucial role by providing objective 
biomarkers for this personalized medicine, not only in oncology, but also in infectious and 
inflammatory diseases. These techniques offer the unique opportunity to target cells and 
molecules that are involved for:
 - Histological characterization of infectious and inflammatory lesions (specific receptor 
expression)
 - Selection of patients for receptor-targeted therapy (overexpression of a specific 
receptor) 
 - Therapy response prediction (intensity of receptor expression)
 - Therapy response follow-up (modulation of receptor expression)
Not many examples are available yet to support this new thinking strategy in the field of 
inflammation and infection. Radiolabelled anti-TNFα monoclonal antibodies (infliximab and 
adalimumab) have demonstrated their usefulness and prognostic value. They can aid to 
selection of patients that can benefit from anti-TNFα therapy in patients with Crohn’s disease 
and rheumatoid arthritis. Studies with labelled infliximab demonstrated specific drug targeting 
to inflamed joints and showed that the selection of candidates for unlabelled anti-TNFα therapy 
and prediction of therapy response could be facilitated (19). Patients with rheumatoid arthritis 
without adalimumab uptake at pre-therapy scintigraphy do not benefit from unlabelled anti-
TNFα therapy, whereas patients with uptake showed most clinical benefit from therapy (20).
Nuclear medicine imaging in the field of infection and inflammation goes beyond diagnosis of 
infection and inflammation. It makes evaluation of therapeutic effects possible by assessing 
the activity state before and after the treatment. It provides the opportunity to histologically 
characterize pathological processes, highlight the cell type and subtype that are involved in 
the process, detect the presence of a therapeutic target, quantify the presence of bacteria 
and biologically active molecules, such as cytokines and chemokines, and detect the presence 
of apoptotic and autoreactive cells. It may allow evidence-based biological therapy by 
assessing which molecule will localize in an inflamed area, before using the same unlabelled 
molecule therapeutically. All this information is more and more useful to clinicians to define 








3. NEW HYBRID IMAGING TECHNIQUES: PET-MRI
While PET enables the acquisition of functional data at the molecular level, MRI provides 
superior soft-tissue resolution and information about anatomy. Hybrid PET/MRI systems 
can combine these imaging characteristics. PET/MRI systems can be either simultaneous or 
sequential. Although imaging data from separate PET and MRI systems may be combined, 
simultaneous imaging systems have major theoretical advantages that could be of interest to 
the whole medical community. The general advantages of a simultaneous PET/MRI system as 
compared to conventional PET/CT systems are: 
 - Recording of dynamic and moving phenomena, which could enable to use 
radiopharmaceuticals with short half-lives
 - Identical position of the patient during image acquisition with both modalities leading 
to a substantial reduction in motion artefacts due to heart beating, intestinal motion 
and breathing.
 - Absolute match between the tissue information of both modalities under the same 
physiological conditions. 
 - Contrast-enhanced MRI information (e.g. on perfusion and blood flow) can be used in 
the pharmacokinetic modelling of the PET data, resulting in an improvement in PET 
reconstruction and data analysis.
 - Better localization of the PET signal within soft tissues. 
 - No radiation burden from the MRI part. 
 - Better application of the one-stop-shop principle for simultaneous diagnostic-quality 
acquisition of nuclear medicine and radiological images. 
 - More structural, functional and molecular imaging at the same time.
On the other hand, compared to PET/CT, PET/MRI examinations may result in a lower 
compliance by the patient, because of long examination times and noise. Furthermore, 
MRI cannot image all body parts at once (different body parts may require different MR 
acquisition sequences and probes). This new hybrid technique requires collaboration between 
radiologists and nuclear medicine physicians for image interpretation and might be more 
expensive than PET/ CT scans (both capital and running costs). It is therefore of economical 
and clinical importance to correctly identify the possible fields of relevance of PET/MRI over 
other imaging techniques, especially PET/CT and stand-alone MRI. 
 
Until recently, functional imaging of inflammation and infection was mainly restricted to planar 
imaging and SPECT. More and more PET radiopharmaceuticals have now become available 
allowing more sensitive detection and quantification of specific aspects of inflammatory 
processes. There is substantial potential in the application of hybrid whole-body PET/MRI to 
the investigation of infectious and inflammatory diseases. PET can give functional information 
about the target organ, including disease activity, release of cytokines and infiltration of 
specific immune cell populations. However, PET does not provide anatomical information, 
which can seriously hamper accurate diagnosis. The use of hybrid PET/CT is of limited added 
value in most cases of inflammation, since it lacks good soft-tissue contrast. MRI offers better 
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overcome these shortcomings by providing quantitative molecular functional information 
concerning the inflammatory lesion, and accurate localization as well as anatomical changes 
with motion correction. This could improve differential diagnosis and guide anti-inflammatory 
treatment strategies, resulting in better medical care. 
The combination of PET radiopharmaceuticals and PET/MRI imaging could significantly 
improve the sensitivity and specificity of the diagnosis and follow-up treatment of infectious 
and inflammatory diseases. It would allow more accurate assessment of the extent and exact 
localization of inflammatory lesions than PET alone or PET/CT, especially in soft tissues that are 
prone to movement artefacts, for example in vascular and cardiac infections, inflammatory 
bowel disease (IBD) and diabetes. MRI now offers more than just anatomical information. For 
example, brain function can be measured by functional MRI (fMRI) including diffusion-weighted 
imaging (DWI), magnetic resonance spectroscopy (MRS) and perfusion imaging. There have 
also been improvements in MRI contrast agents which can be used with radiolabelled probes 
that may lead to even more insights into the dynamics and characteristics of the inflammatory 
process. A third interesting feature of PET/MRI is motion correction based on MRI, which 
would allow more accurate quantification of PET data, leading to better treatment monitoring 
and the possibility of earlier response evaluation. 
Indeed, there are some relevant infectious and inflammatory diseases in which a clinical 
impact of PET/MRI is foreseen. In insulin dependent (type 1) diabetes mellitus, PET/MRI may 
provide the opportunity to visualize the cell-mediated autoimmune destruction of beta cells 
of the pancreas (insulitis) at an early stage, may quantify insulitis at an early stage, and may 
accurately diagnose insulitis and routinely follow-up diabetic patients.
In spondylodiscitis, MRI has advantages over CT because it can better distinguish bone marrow, 
vertebra and intervertebral disc, and is better able to evaluate the neural structures (including 
the spinal cord, epidural space and peripheral soft tissue). The main goals in PET/MRI imaging 
are to assess if sensitivity and specificity of the diagnosis will improve by combining PET and 
MRI simultaneously, and to assess if this hybrid imaging technique could be used for follow-up 
during treatment.
In inflammatory bowel diseases (IBD), MRI has shown a higher sensitivity in detecting signs 
of intestinal and mesenteric inflammation, and has an intrinsically higher soft-tissue contrast 
and sensitivity for inflammatory abdominal tissues (20). Moreover, signs of inflammation can 
be detected and analyzed using different MRI parameters. Huge advantages from the use of 
hybrid PET/MRI systems in IBD may be expected. Cells can be labelled with radionuclides, with 
fluorescent or bioluminescent markers (optical imaging) intra-operatively or with MRI contrast 
agents. The combined use of nuclear medicine techniques (PET for imaging cells and molecular 
events involved in the disease) and MRI (for morphological definition of affected bowel 
segments) is the key for the future approach to IBD. The main goal for PET/MRI in IBD therefore 
should be to assess if combined PET/MRI using targeted molecular imaging and different MRI 
techniques (MRS, DWI) is able to detect IBD with high accuracy. Moreover, patients with IBD 
have to undergo follow-up studies (CT, colonoscopy) routinely each year. PET/MRI could be 







Infections of the diabetic foot are difficult to detect. MRI is able to differentiate between 
osteomyelitis and soft tissue infection, but the specificity is reduced if bony destruction, 
dislocation, marrow edema, synovial effusion and loss of bone and joint limits are present. 
White blood cell scintigraphy is at this moment the nuclear medicine imaging technique of 
choice (Chapter 4 of this thesis) as the sensitivity of 18F-FDG-PET alone is not high enough. 
However, hybrid PET/MRI imaging could improve accuracy in the diagnosis of diabetic foot 
infection and improve differentiation of osteomyelitis, the neuropathic Charcot’s joint, and 
soft tissue infection.
Other future PET/MRI applications could be the use in inflammatory diseases in children. In 
dermatomyositis, as well as in polymyositis and scleroderma, MRI is the first radiological 
imaging technique of choice, but lacks the possibility to monitor therapy correctly. In these 
patient groups, PET/MRI is preferable to PET/CT imaging, since there is no radiation burden 
of the MRI part, of particular importance in young patients with regular follow-up scans. An 
example of PET/MRI imaging in myositis in a young patient is shown in Figure 2.
Figure 2
Example of the use of 18F-FDG-PET and MRI in a young patient with myositis. Left image: Coronal MIP image of 
18F-FDG-PET showing slightly elevated uptake in the knee joints and lateral of the hip joints. At the right side; 
upper images: coronal MRI and coronal PET-MRI software fusion image, middle images: transversal PET/MRI 
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4. THE DEVELOPMENT OF DIAGNOSTIC PATHWAYS
After the successful development and implementation of guidelines for white blood cell 
scintigraphy and 18F-FDG-PET/CT imaging, we can move forward to increase the visibility of 
nuclear medicine. To achieve this, the Infection and Inflammation Committee of the EANM 
organized a workshop with lectures from nuclear medicine physicians, radiologists and 
clinicians. The EANM Infection and Inflammation Committee has now started collaboration with 
several other European societies to discuss and develop common diagnostic flow charts. This is 
of major importance for the future of nuclear medicine. The nuclear medicine community has 
to state clearly what we can offer at which time point in the diagnostic work-up of a patient. 
As an example of this process, this concept will be further explained in the patient with a 
suspected prosthetic joint infection (PJI): Imaging is mandatory in patients with a symptomatic 
prosthesis and suspicion of a “delayed” (between 3 months and 2 years after surgery) or 
“late” (more than 2 years after surgery) infection. However, for diagnosis of an “early” (first 3 
months after surgery) infection, imaging is often not necessary, since this is mostly a clinical 
diagnosis. The white blood cell scan can be performed in patients with or without antibiotic 
therapy. Some authors suggested that the diagnostic accuracy of the exam increases if the 
patient is off-therapy for 2 weeks despite no clear data have been published supporting this 
theory. In Figure 3, we propose a diagnostic pathway for imaging PJI. Different pathways are 
proposed depending on the age of prosthesis and the probability of infection. 
More debated is the timing of a control scan after antibiotic therapy and the timing of a control 
scan after removal of an infected prosthesis with position of a temporary spacer, to verify the 
absence of residual infection before re-implanting a new prosthesis. These timings really 
depend also on the clinical organization and local experience. Some orthopedic surgeons re-
implant a new prosthesis as soon as 2 weeks after explant of the infected prosthesis to limit 
the period of patient inability, without performing any control scan; more frequently, others 
perform a standard antibiotic therapy for 2 or 4 weeks and then wait and watch the patient for 
additional 2-4 weeks before re-implant, without performing any control scan; finally, others 
wait for a negative control scan before re-implanting a new prosthesis. In the latter case, 
to avoid performing unnecessary scans, it is suggested that the control scan is performed 
after an adequate antibiotic treatment and when clinical and laboratory parameters become 
negative. 
Our proposed diagnostic flow chart for the proven infected prosthesis is shown in Figure 4. 
Certainly, this is the suggested approach from the nuclear medicine point of view, but no data 
exist in literature to support this flow chart, neither are there published studies comparing 
the different approaches to patient management. However, it is a matter of fact that the 
incidence of infection after re-implant of a prosthesis is 10 times, or more, higher than for the 
first implant and no satisfactory surveillance is performed in these patients, nor are enough 








Schematic diagnostic pathway for imaging PJI. There is a different pathway depending on the age of 
prosthesis and the probability of infection. 
*An 18F-FDG-PET scan can be performed in patients with low probability of infection (normal WBC counts, or 
ESR, or CRP) due to the high sensitivity of this technique. 
**In patients with a suspected chronic infection the scan with anti-granulocyte MoAb has been reported to be 
slightly more accurate than WBC scan. 
***In patients with an equivocal WBC or anti-granulocyte scan, particularly if SPECT-CT is not available or 
doubt consists in differential diagnosis between osteomyelitis and soft tissue infection, 18F-FDG-PET may 
be useful due to its high special resolution and sensitivity. By contrast, if differential diagnosis is between 
osteomyelitis and bone marrow expansion, the gold standard technique is to combine a bone marrow scan 
with radiolabelled colloids. 
PJI = prosthetic joint infection, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, WBC = white 
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Figure 4
Proposed diagnostic flow chart for the proven infected prosthesis. In this proposal, WBC scintigraphy is used 
in the flow diagram to support decision-making (continue or stop antibiotic treatment, time-point for re-
implantation).
W&w = wait and watch, WBC = white blood cells
These flow-charts, as proposed here in case of a patient with a suspected prosthetic joint 
infection, are being discussed with the societies of the orthopaedics, infectiologists, and 
radiologists to develop commonly agreed and supported guidelines, useful in clinical practice.
Several more collaborations have to be started, many guidelines have to be developed and 
introduced for various infectious and inflammatory diseases (inflammatory bowel diseases, the 
diabetic foot, osteomyelitis, vascular graft infections, endocarditis etc.). This is a tremendous 








1. Blockmans D, De Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 
18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 
patients. Arthritis Rheum 2006; 55:131-137
2. Bertagna F, Bosio G, Caobelli F, Motta F, Biasiotto G, Giubbini R. Role of 18F-fluorodeoxyglucose positron 
emission tomography/computed tomography for therapy evaluation of patients with large-vessel vasculitis. 
Jpn J Radiol 2010; 28:199-204
3. Henes JC, Mueller M, Pfannenberg C, Kanz L, Koetter I. Cyclophosphamide for large vessel vasculitis: 
assessment of response by PET/CT. Clin Exp Rheumatol 2011; 29:S43-S48
4. Aide N, Allouache D, Ollivier Y, de RS, Switsers O, Bardet S. Early 2’-deoxy-2’-[18F]fluoro-D-glucose PET 
metabolic response after corticosteroid therapy to differentiate cancer from sarcoidosis and sarcoid-like 
lesions. Mol Imaging Biol 2009; 11:224-228
5. Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W, Alavi A. Functional imaging of inflammatory 
diseases using nuclear medicine techniques. Semin Nucl Med 2009; 39:124-145
6. Braun JJ, Kessler R, Constantinesco A, Imperiale A. 18F-FDG PET/CT in sarcoidosis management: review 
and report of 20 cases. Eur J Nucl Med Mol Imaging 2008; 35:1537-1543
7. Imperiale A, Riehm S, Veillon F, Namer IJ, Braun JJ. FDG PET coregistered to MRI for diagnosis and 
monitoring of therapeutic response in aggressive phenotype of sarcoidosis. Eur J Nucl Med Mol Imaging 
2011; 38:983-984
8. Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC. 18F-FDG PET in sarcoidosis: 
an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008; 
25:143-149
9. Ito K, Kubota K, Morooka M, Hasuo K, Kuroki H, Mimori A. Clinical impact of (18)F-FDG PET/CT on the 
management and diagnosis of infectious spondylitis. Nucl Med Commun 2010; 31:691-698
10. Warmann SW, Dittmann H, Seitz G, Bares R, Fuchs J, Schafer JF. Follow-up of acute osteomyelitis in 
children: the possible role of PET/CT in selected cases. J Pediatr Surg 2011; 46:1550-1556
11. Goerres GW, Forster A, Uebelhart D, Seifert B, Treyer V, Michel B, et al. F-18 FDG whole-body PET for the 
assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med 2006; 31:386-390
12. Elzinga EH, van der Laken CJ, Comans EF, Boellaard R, Hoekstra OS, Dijkmans BA, et al. 18F-FDG PET as 
a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. 
J Nucl Med 2011; 52:77-80
13. Spier BJ, Perlman SB, Jaskowiak CJ, Reichelderfer M. PET/CT in the evaluation of inflammatory bowel 
disease: studies in patients before and after treatment. Mol Imaging Biol 2010; 12:85-88
14. Lee TY, Kim MH, Park dH, Seo DW, Lee SK, Kim JS, et al. Utility of 18F-FDG PET/CT for differentiation 







Conclusions and future perspectives
198
15. Shigekawa M, Yamao K, Sawaki A, Hara K, Takagi T, Bhatia V, et al. Is (18)F-fluorodeoxyglucose 
positron emission tomography meaningful for estimating the efficacy of corticosteroid therapy in patients 
with autoimmune pancreatitis? J Hepatobiliary Pancreat Sci 2010; 17:269-274
16. Basu S, Saboury B, Werner T, Alavi A. Clinical utility of FDG-PET and PET/CT in non-malignant thoracic 
disorders. Mol Imaging Biol 2011; 13:1051-1060
17. Franzius C, Biermann M, Hulskamp G, Frosch M, Roth J, Sciuk J, et al. Therapy monitoring in aspergillosis 
using F-18 FDG positron emission tomography. Clin Nucl Med 2001; 26:232-233
18. Xu B, Shi P, Wu H, Guo X, Wang Q, Zhou S. Utility of FDG PET/CT in guiding antifungal therapy in acute 
leukemia patients with chronic disseminated candidiasis. Clin Nucl Med 2010; 35:567-570
19. Conti F, Priori R, Chimenti MS, Coari G, Annovazzi A, Valezini G, et al. Succesful treatment with 
intraarticular infliximab for resistant knee monoarthritis in a patient with spondylarthropathy – a role for 
scintigraphy with 99mTc-infliximab. Arthritis Rheum 2005; 52:1224-1226
20. Malviya G, Conti F, Chianelli M, Scopinaro F, Dierckx RA, Signore A. Molecular imaging of rheumatoid 
arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies. Eur 










Infectious and inflammatory diseases are a heterogeneous class of diseases that can be 
localized or systemic and may be divided into infection, acute inflammation and chronic 
inflammation, each of them with specific characteristics. In the clinical setting, it is very 
important to diagnose early occult infections and to differentiate between infection and 
sterile inflammation.
Nuclear medicine is able to image infection and inflammation by specifically targeting 
the involved cells, molecules, and mediators of infection and inflammation. Some 
radiopharmaceuticals exist already for many years. However, the progress in our understanding 
and knowledge of the pathophysiology of infectious and inflammatory diseases has led to 
the development of several new and specific tracers that are useful to diagnose infection 
and inflammation and can help to differentiate between the two entities. Moreover, nuclear 
medicine techniques may offer the unique possibility to evaluate disease activity and efficacy 
of therapy, and may have a role in monitoring relapse of disease.
This thesis aims to give more insights in how to perform diagnostic procedures in infection 
and inflammation, compares different nuclear medicine techniques with each other and 
with conventional radiological imaging techniques, evaluates specific tracers for specific 
diseases, and tries to develop future concepts and new strategies when to use which nuclear 
medicine technique in which part of the diagnostic pathway. It comprises two parts. After 
the introduction chapter, the first part (chapter 2-5) consists of nuclear imaging methods in 
infectious diseases. The second part (chapter 6-8) addresses the use of nuclear techniques in 
inflammatory diseases. The last chapter emphasizes four important concepts that are worth 
to investigate in the future.
Chapter 1 provides an overview of the pathophysiology of infection, acute inflammation 
and chronic inflammation, the diseases belonging to each of them and the available 
radiopharmaceuticals to image them. The most commonly used tracers are discussed more 
extensively: the labelled autologous white blood cells (with 99mTc, 111In, and 18F-FDG ), the 
labelled antigranulocyte monoclonal antibodies (Scintimun®, LeuTech®, and LeukoScan®), 
18F-FDG, and labelled interleukin-2. The acquisition modes, image interpretation criteria, 
indications and clinical examples are provided for each of these tracers. Furthermore, the few 















Already for many years, white blood cell (WBC) scintigraphy is considered the best nuclear 
imaging technique to diagnose infections in the bone and soft tissue (except spondylodiscitis). 
However, reported diagnostic accuracies are variable, due to variations in labelling procedures, 
differences in acquisition protocols and differences in interpretation criteria. Guidelines for WBC 
labelling, quality controls, and safety procedures are available, but guidelines that describe 
the correct image acquisition protocols and interpretation criteria do not exist. Therefore, we 
decided to compare different acquisition methods and different interpretation methods to 
see which methods achieved the highest diagnostic accuracy. The main aim was to provide a 
foundation for consensus within the nuclear community which acquisition protocol and which 
interpretation criteria have to be followed to correctly perform WBC scintigraphy, thereby 
making comparisons between publications from different centers worldwide possible. 
Chapter 2 describes the retrospective analysis of 297 WBC scans performed in the University 
Medical Center Groningen between 2009 and 2012. All patients were checked for infection 
parameters in the blood and medication use at time of scintigraphy. Final diagnosis of an 
infection was based on pathological and microbiological reports, or clinical follow-up for at 
least 6 months. Two different dual time point acquisition protocols, (the fixed-time acquisition 
with late images acquired with a standard acquisition time of 10 min (n=80), and the time 
decay-corrected acquisition with late images acquired with acquisition times corrected tor 
decay (n=217)) and five image interpretation criteria (visually and semiquantitatively with 
four different reference regions of interest) were evaluated. In the scans with time decay-
corrected acquisition the images were displayed with the number of counts and with the 
same intensity scale, thereby making comparisons between the images possible without 
observer bias.
Time decay-corrected acquisition was found the best acquisition protocol (diagnostic accuracy 
94.5% vs 82.5% for fixed-time acquisition). Visual analysis was found the best interpretation 
method with a diagnostic accuracy (in all patients) of 91.9%. However, when having equivocal 
scans by visual analysis, semiquantitative analysis may be helpful. Best reference tissue was 
the contralateral side, except for osteomyelitis and infected osteosynthesis. In these groups 
the contralateral bone marrow has to be taken as reference tissue. No statistical differences 
were found between infection parameters in the blood and the scan results, nor between 
patients under medication at time of the scan and patients without medication.
Based on these results we proposed a diagnostic flow chart for the correct analysis of WBC 
scintigraphy in musculoskeletal infections. A dual acquisition protocol at 3-4 h and at 20-24 
h after injection has to be performed, and the acquisition times of the scans have to be 
corrected for decay. Visual analysis is in most patients enough, leading to a high diagnostic 
accuracy. When interpretation by visual analysis is inconclusive, semiquantititative analysis 
increases diagnostic accuracy. When performing WBC scintigraphy, it is not necessary to stop 
medical treatment.
In Chapter 3, the image acquisition and interpretation criteria for WBC scintigraphy were 
retrospectively analyzed in a multicenter setting. In three centers (University Medical Center 







with suspected osteomyelitis, suspected prosthesis infection and suspected soft tissue infection 
were analyzed. Fixed-time acquisition was acquired in 105 patients, and time decay-corrected 
acquisition in 130 patients. SPECT/CT was performed, if necessary, for precise location of the 
infectious focus. Interpretation by visual analysis gave the same results as in Chapter 2. For 
semiquantitative analysis, presumed normal reference tissue was used as background and 
images were classified using different thresholds of increasing ratios over time.
In patients with suspected osteomyelitis or suspected prosthesis infection, time decay-
corrected acquisition was also found the best acquisition method in this study, however with 
smaller differences compared to the study described in Chapter 2. The sensitivity, diagnostic 
accuracy and positive predictive value were slightly better in the time decay-corrected 
acquisition. For the semiquantitative analysis, best accuracy and sensitivity were found when 
considering any percentage of increase of radioactivity in the suspected lesion over time, 
for both acquisition protocols. Interobserver agreement scores were higher for time decay-
corrected acquisition.
In patients with soft tissue infections, the advantage of time decay-corrected acquisition was 
not evident. This may be caused by different kinetics of migration of radiolabelled WBC in 
bone and soft tissues. Additionally, the soft tissue infection group in this study population 
was very heterogeneous with possible different behavior in terms of leukocyte recruitment. 
Consequently, this population may need “ad hoc” interpretation criteria.
Overall, it is clear that dual time point imaging is necessary, one at 3-4 hours (delayed images) 
and one at 20-24 hours (late images) after injection, and acquisition times of the scans have 
to be corrected for decay, thereby avoiding operator dependence and bias that can strongly 
affect the results of fixed-time acquired images. Any percentage of radioactivity increase over 
time may be defined as positive for an infection. SPECT/CT images may be used to better 
localize the site and extent of an infection, and is especially recommended in indications 
where the need of anatomical landmarks is relevant (endocarditis, cardiac devices, vascular 
prosthesis infections, and the diabetic foot).
The nuclear medicine community is still in debate about which imaging technique is best 
suitable to diagnose infections in the diabetic foot. WBC scintigraphy was the gold standard 
for years, but in recently published studies 18F-FDG-PET/CT was also found to be a specific 
imaging modality, complementary with MRI. In Chapter 4, WBC scintigraphy and 18F-FDG-
PET/CT were evaluated in 13 patients with clinically suspected infections in a diabetic foot. 
Furthermore, the role of sequential 18F-FDG-PET/CT (with acquisition times at 10 min, 1 h, 
and 2 h) was evaluated to define objective interpretation criteria to be compared with WBC 
scintigraphy (with acquisition times 30 min, 3 h, and 20 h). 
After biopsy or cultures, osteomyelitis was proven in 7 patients and soft tissue infection 
without bone involvement in 2. For WBC scintigraphy, the best interpretation criterion found 
was target-to-background ratio > 2.0 at the late images and increasing with time, leading 
to a diagnostic accuracy of 92%. For 18F-FDG-PET/CT, the best interpretation criterion was a 
maximal standardized uptake value (SUVmax) > 2.0 at 1 h and at 2 h and increasing with 
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time, leading to a diagnostic accuracy of only 54%. 18F-FDG-PET/CT at 10 min was not useful. 
The combination of 18F-FDG-PET at 1 h and CT was best to differentiate between osteomyelitis 
and soft tissue infection. Interobserver agreement between 3 independent nuclear medicine 
physicians was excellent.
Based on these results, we think that there is no role for 18F-FDG-PET/CT imaging, even not 
with sequential scanning, in the infected diabetic foot. At this time point, WBC scintigraphy 
remains the gold standard nuclear imaging method with high diagnostic accuracy.
One of the most serious complications after a vascular prosthetic graft replacement is an 
infection. The incidence is low, but if a vascular prosthetic graft is infected it could lead to 
life or limb loss in > 50% of the patients. The predictive value of clinical signs, measurement 
of infection parameters, CT, and MRI, is relatively low. Chapter 5 evaluated the diagnostic 
accuracy of single 18F-FDG-PET, single CT, and fused 18F-FDG-PET/CT, and the agreement in 
reading between different observers in diagnosing vascular prosthetic graft infections.
In 25 patients with suspected vascular prosthetic graft infection, CT angiography and 18F-FDG-
PET was performed. The CT scans were assessed by two radiologists using a probability 
score based on literature reports. 18F-FDG-PET scans were assessed by two nuclear medicine 
physicians using a visual grading score and by calculation of SUVmax and tissue-to-background 
ratios. The fused 18F-FDG-PET/CT images were subsequently assessed by one radiologist and 
one nuclear medicine physician.
The sensitivity and specificity of 18F-FDG-PET was 93% and 70%, respectively and was found 
higher than CT (56% and 57%, respectively). The interobserver agreements were found to be 
good (kappa-value 0.63) between the radiologists and excellent (kappa-value 1.00) between 
the nuclear medicine physicians. With fused 18F-FDG-PET/CT, a difference was found between 
sensitivity and specificity rates, when judged by a nuclear medicine physician (93% and 70%, 
respectively), compared to the judgement of a radiologist (73% and 60%, respectively). The 
concordance between the radiologist and the nuclear medicine physician reached a high level, 
with agreement in 21 of 25 cases (84%).
This study showed that in vascular prosthetic graft infection, 18F-FDG-PET has a higher accuracy 
compared with CT. After fusion of both modalities, a high concordance was found in findings. 
Fused 18F-FDG-PET/CT is the imaging modality of choice in patients with a suspected vascular 
prosthetic graft infection.
The second part (inflammatory diseases) of this thesis starts with a short description of 
the possibilities nuclear medicine offers for diagnosing the atherosclerotic plaque. Recent 
advances in basic science established a fundamental role for inflammation in all stages of 
atherosclerosis from initiation through progression and vulnerability leading to thrombotic 
complications. Intermezzo 1 describes the molecular events in atherosclerosis and provides 
an overview of the available tracers to image different targets in the development of 
atherosclerosis: the atherosclerotic lesion components, inflammation, thrombosis, and 







The prominent role of inflammatory cells in the transformation of a stable plaque into a 
vulnerable one forms the basis of the research study in Chapter 6. Since lymphocytes are 
a significant cell population and constitute at least 20% of infiltrating cells in vulnerable 
plaques, the interleukin-2 receptor (over expressed on activated T-lymphocytes) may present 
an attractive biomarker for detection of vulnerable plaques. Imaging with radiolabelled 
interleukin-2 (IL2) may therefore provide useful information for the selection of infiltrated 
vulnerable plaques at risk of rupture and hence of patients at risk for clinical events. In this 
study, we evaluate in vivo and ex vivo if 99mTc-hynic-IL2 is able to detect lymphocytic infiltration 
in vulnerable atherosclerotic plaques of the carotid artery.
For the in vivo study, 99mTc-hynic-IL2 scintigraphy was performed in 10 symptomatic patients 
scheduled for carotid endarterectomy. The images were analyzed visually on planar and 
SPECT/CT images and semiquantitatively by calculating target-to-background ratios. After 
surgery, immunomorphology and immunophenotype was determined on plaque slides. Visual 
analysis demonstrated clear 99mTc-hynic-IL2 uptake in 7 out of the 10 symptomatic plaques by 
planar imaging, and in 8 out of 10 by SPECT/CT. A significant correlation was found between 
the uptake and the number of CD25 positive lymphocytes and the total number of CD25 
positive cells. Furthermore, uptake in the 10 symptomatic plaques was significantly higher 
than in 8 contralateral asymptomatic plaques.
For the ex vivo studies, 4 additional patients were included and, after in vitro incubation of 
the removed plaques with 99mTc-hynic-IL2, autoradiography and microSPECT imaging were 
performed. MicroSPECT showed clear uptake within the plaque wall, but not in the lipidic core. 
With autoradiography, only CD3 positive lymphocytes were found to be labelled.
This study clearly confirmed the specificity of 99mTc-hynic-IL2 for imaging activated 
T-lymphocytes in carotid plaques. 99mTc-hynic-IL2 was found a true marker for the inflamed 
plaque and therefore of plaque stability. However, we also found several issues to solve. A 
cut-off value for positivity regarding the uptake still has to be defined and the low spatial 
resolution of the gamma camera, especially in such small objects as plaques in the carotid 
artery, decreases the diagnostic value of the technique. The recently developed PET tracer for 
imaging activated lymphocytes, 18F-FB-IL2, could maybe overcome these limitations and may 
be an even more promising radiopharmaceutical for human atherosclerotic plaque imaging.
The last inflammatory disease described and investigated is amyloidosis, a group of diseases 
characterized by extracellular tissue deposition of fibrils composed of low molecular weight 
subunits of a variety of serum proteins (amyloid). Depositions of amyloid can be localized 
(produced in and limited to one organ or site of the body) or systemic (deposition in various 
organs and tissues throughout the body). Amyloid deposition in organs and tissues causes 
prominent swelling of the affected organ and tissue and results in loss of function, eventually 
leading to death of the patient. Intermezzo 2 describes the different types of systemic and 
localized amyloidosis, the clinical evaluation of a patient with (suspected) amyloidosis, and 
the nuclear medicine radiopharmaceuticals that are available for the clinical evaluation of the 








the deposition of amyloid in the heart. Cardiac amyloidosis may lead to systolic or diastolic 
dysfunction and symptoms of heart failure, dysrhythmias, electromechanical dysfunction, 
thromboembolism, and even to cardiac death. An overview is provided of the nuclear medicine 
possibilities to image cardiac amyloidosis.
In patients with suspected amyloidosis, it is important to establish whether the amyloid 
deposits are localized or systemic, since prognosis and therapy regimen is different between 
the two types. Localized amyloidosis differs from systemic amyloidosis by the local presence 
of clonal plasma cells and giant cells. It is hypothesized that in localized amyloidosis giant 
cells are involved in the production of amyloid. Because of this presence of giant cells, we 
investigated if 18F-FDG-PET/CT could help to differentiate between localized and systemic 
amyloidosis. Chapter 7 describes the 18F-FDG-PET/CT findings in 21 patients with histologically 
proven systemic or localized amyloidosis. Twenty patients also underwent 123I-SAP scintigraphy. 
Indeed, 10 out of 11 patients with localized amyloidosis showed markedly increased FDG 
uptake at the amyloid site, whereas one showed slightly increased FDG uptake. In ten 
patients with systemic amyloidosis, increased FDG uptake was not found in any affected 
organ containing amyloid. 123I-SAP scintigraphy was not able to differentiate. In 10 patients 
with localized amyloidosis, the SAP scan was positive in three at the amyloid site and in one 
patient a weakly positive spleen was found. In 9 out of 10 patients with systemic amyloidosis, 
123I-SAP scintigraphy was positive for specific organ involvement, in agreement with literature 
results.
In localized amyloidosis, giant cells are thought to be present because of their role in the 
production of amyloid. Indeed, 8 out of 11 patients with localized disease showed giant cells 
in their biopsy material. In systemic amyloidosis, giant cells are thought to be unnecessary 
for the formation and deposition of amyloid. This was also in agreement with the biopsy 
results: giant cells were not present in any of the patients with systemic amyloidosis. This 
absence of giant cells and inflammation is a stable feature of systemic amyloidosis due to the 
accumulation of SAP in amyloid deposits, probably acting as a kind of camouflage and thereby 
protecting these deposits from recognition and clearance by giant cells.
So, 18F-FDG-PET/CT may be helpful in differentiating systemic amyloidosis (no increased 
FDG uptake at the amyloid site) from localized amyloidosis (increased FDG uptake at the 
amyloid site). Apart from diagnosis, this may also have potential clinical application in therapy 
evaluation and follow-up.
In patients with a specific type of systemic amyloidosis, ATTR amyloidosis, myocardial 
involvement is frequently seen and it is characterized by a restrictive cardiomyopathy due 
to amyloid deposition in both myocardial tissue and atrioventricular conduction system. ATTR 
amyloidosis may be hereditary (caused by a mutation of the precursor protein transthyretin) 
or age-related (when normal transthyretin behaves as a ‘wild type’). Diagnosing ATTR 
amyloidosis and typing with confidence is challenging. In the hereditary type, liver 
transplantation is the only effective way to get rid of the mutated protein as treatment for 
the disease. Echocardiography, ECG, and MRI are not able to differentiate between amyloid 







amyloidosis. Furthermore, these techniques have only limited diagnostic utility in the early 
phase of the disease. Recently, bone scintigraphy with radiolabelled diphosphonate was found 
to be a new diagnostic tool to define the type of amyloid cardiomyopathy, since high uptake 
was found in ATTR type whereas absent of weak uptake was found in AL (immunoglobulin 
light chain-derived) amyloid cardiomyopathy.
Chapter 8 further assesses the usefulness of bone scintigraphy for cardiac involvement in 
a group of 41 patients with ATTR amyloidosis in different phases of their disease (mutation 
carriers (n=11), ATTR patients without signs of cardiomyopathy (n=19), and ATTR patients 
with cardiomyopathy (n=11)), correlates the cardiac uptake on bone scintigraphy with 
echocardiographic findings, ECG characteristics, and cardiac biomarkers, and evaluates 
different scintigraphic imaging techniques and calculation methods for quantification of the 
cardiac uptake.
All patients with ATTR and cardiomyopathy showed high cardiac uptake on bone scintigraphy. 
However, 8 out of the 19 patients without cardiomyopathy also showed high cardiac uptake, 
probably suggesting that these patients also are developing cardiomyopathy. High correlations 
were found between planar bone scintigraphy and troponin T and left ventricular mass index. 
Concerning scintigraphy, visual analysis and calculation of heart-to-skull ratio at planar images 
performed best. SPECT/CT had no added value.
We also searched for differences between patients with the most common mutation type 
(Val30Met) and all other gene mutations (non-Val30Met), and found that patients with 
Val30Met mutation had lower cardiac uptake scores, whereas most patients with non-
Val30Met mutation had high uptake scores. This is in agreement with literature, since patients 
with a non-Val30Met mutation type are known to have a worse prognosis.
Bone scintigraphy was found to identify cardiac involvement in patients with ATTR amyloidosis, 
and probably even before it can be diagnosed using echocardiography. Cardiac uptake on bone 
scintigraphy correlated well with the severity of cardiac involvement using echocardiography, 
ECG, and cardiac biomarkers.
The last chapter, Chapter 9, of this thesis focuses on four important concepts that deserve to 
be investigated in the forthcoming years. The first concept described is the potential role of 
18F-FDG-PET/CT in therapy evaluation. For vasculitis, sarcoidosis, and echinococcosis, enough 
evidence is available for the clinical usefulness of 18F-FDG-PET/CT in therapy evaluation. For 
other diseases however (osteomyelitis, rheumatoid arthritis, inflammatory bowel diseases, 
autoimmune pancreatitis, etc.) we still have to develop evidence. Other applications, both 
for diagnosis and therapy evaluation, that have to be evaluated in the near future, are fungal 
infections and inflammatory diseases in children, such as polymyositis, dermatomyositis, and 
sclerodermia.
Secondly, we have to focus on targeting of specific disease characteristics and personalized 
medicine. Nuclear medicine techniques offer the unique possibility to target cells and 








patients for specific targeted therapy, to predict their response to therapy, and to follow-up 
the therapy response. All this information is more and more useful to clinicians to define a 
personalized tailored therapy and to follow up its efficacy.
Thirdly, we have to look to new applications provided by new hybrid imaging techniques, 
especially the simultaneous PET/MRI system. This combination of PET radiopharmaceuticals 
and PET/MRI imaging could significantly improve the sensitivity and specificity of the diagnosis 
and follow-up of treatment of infectious and inflammatory diseases. A clinical impact of PET/
MRI is foreseen in insulin dependent diabetes mellitus, in inflammatory bowel diseases, and in 
the diabetic foot. Furthermore, future PET/MRI applications could be the use of inflammatory 
diseases in children. In these patient groups, PET/MRI is preferable to PET/CT imaging, since 
there is no radiation burden of the MRI part, of particular importance in young patients with 
regular follow-up scans.
The last concept described, is the collaboration with other societies to develop commonly 
diagnostic and therapeutic flowcharts. The nuclear medicine community has to state clearly 
what we can offer at which time point in the diagnostic work-up of a patient. Several 
collaborations have to be started, many guidelines have to be developed and introduced for 
various infectious and inflammatory diseases (prosthetic joint infection, inflammatory bowel 
diseases, the diabetic foot, osteomyelitis, vascular graft infections, endocarditis etc.). This is a 









WAT IS NUCLEAIRE GENEESKUNDE?
Nucleaire geneeskunde is een medisch specialisme dat gebruikt maakt van radioactieve 
stoffen voor de diagnostiek en de behandeling van een grote verscheidenheid aan ziekten. 
Radioactieve atoomkernen (radionucliden of radio-isotopen) zijn kernen die instabiel zijn en 
onder het uitzenden van straling (radioactief verval) overgaan naar een stabiele status. Door 
deze radioactieve isotopen te koppelen aan bijvoorbeeld een medicijn, of een antilichaam, 
of een (bloed)cel, is het mogelijk om op moleculair niveau af te beelden welk (ziekte)proces 
aanwezig en actief is in het lichaam. De combinatie van een radioactief isotoop aan een 
specifieke marker voor een ziekteproces noemen we een radiofarmacon of een tracer. Het 
afbeelden van een (ziekte)proces op celniveau noemen we moleculaire beeldvorming. 
Radioactieve isotopen kunnen verschillende soorten straling uitzenden tijdens het vervallen tot 
een stabiele kern. Zo bestaan er radionucliden die gammastraling uitzenden, en radionucliden 
die bètastraling uitzenden, maar er zijn ook radionucliden die zowel gamma- als bètastraling 
uitstralen. Gammastraling kan worden opgevangen en afgebeeld met een gammacamera. 
Bètastraling wordt slechts over een zeer geringe afstand uitgezonden en wordt gebruikt voor 
therapiedoeleinden. Sommige radionucliden zenden positronen (positief geladen elektronen) 
uit. Deze radionucliden worden gebruikt in de positronemissietomografie (PET).
Het transformatieproces van instabiele naar stabiele kern noemen we het radioactieve verval. 
De snelheid waarmee dit verval plaatsvindt wordt gemeten in het aantal desintegraties per 
seconden, ook wel Becquerel (Bq) genoemd, de eenheid van straling. Elk radionuclide heeft 
zijn eigen unieke vervalconstante, ook wel de halfwaardetijd genoemd. Dit is de tijd die 
noodzakelijk is voor het vervallen van de helft van de stralingsactiviteit van het radionuclide. 
Dit is uitermate belangrijk in de nucleaire geneeskunde, aangezien deze halfwaardetijd 
bepaalt wanneer het beste de beeldvorming (de plaatjes) kan plaatsvinden.
Nucleaire beeldvorming van gammastraling uitzendende tracers vindt plaats met behulp 
van de gammacamera. Hiermee kan een tweedimensionaal plaatje van het lichaam worden 
gemaakt. Omdat hierbij structuren (organen) over elkaar heen geprojecteerd kunnen worden 
kan het soms moeilijk zijn om deze organen apart van elkaar te herkennen. Dit kan echter 
verbeterd worden door verschillende opnamen te maken vanuit verschillende hoeken in 








Tomography, oftewel SPECT. Hiermee zijn driedimensionale afbeeldingen te verkrijgen van 
delen van het menselijk lichaam. De resolutie van een gammacamera ligt rond de 8 mm.
Positron uitzendende tracers worden afgebeeld door middel van een PET camera. Hiermee 
kan een driedimensionale afbeelding van het hele lichaam gemaakt worden in een kort 
tijdsbestek. De intrinsieke eigenschappen van de PET camera en de eigenschappen van de 
positronen maken het zelfs mogelijk om afwijkingen vanaf 4 mm af te beelden.
Zowel de gammacamera als de PET camera zijn tegenwoordig vrijwel allemaal gecombineerd 
met een CT camera. SPECT-CT en PET-CT opnamen worden gemaakt in exact dezelfde houding 
van de patiënt, waardoor het afgebeelde (ziekte)proces van het nucleaire deel gecombineerd 
kan worden met de anatomische informatie van de CT scan. Exacte lokalisatie van het aanwezige 
proces is op deze manier mogelijk en leidt tot betere diagnostische mogelijkheden voor de 
patiënt. De gecombineerde camera’s bieden duidelijke voordelen: het is kosteneffectief, 
patiënten hoeven niet apart onderzoeken te ondergaan op 2 locaties (nucleaire geneeskunde 
en radiologie), wachtlijsten en wachttijden worden korter, en uitslagen en conclusies worden 
gecombineerd aangeleverd aan de aanvrager (de behandelend arts) en de patiënt. Een PET-CT 
onderzoek wordt uitgevoerd in ongeveer 20 minuten.
De nucleaire geneeskunde speelt een rol in een grote verscheidenheid aan ziekten, in 
verschillende orgaansystemen en in verschillende delen van het lichaam. Kennis van anatomie 
en fysiologie van het hele lichaam is daarom uitermate belangrijk, evenals de samenwerking 
met de aanvragers van de onderzoeken en allerlei vakgebieden binnen het ziekenhuis. 
Met de komst van de PET camera in de jaren negentig van de vorige eeuw, en de gecombineerde 
SPECT-CT en PET-CT camera’s in de afgelopen tien jaar heeft de nucleaire geneeskunde 
een grote sprong voorwaarts gemaakt. Bij vele oncologische ziekten speelt de nucleaire 
geneeskunde een voorname rol: in diagnostiek, voor het bepalen van het stadium van de 
ziekte, voor de prognose voor de patiënt, voor het aantonen of uitsluiten van teruggekeerde 
ziekte, voor het bepalen van de beste therapie voor de individuele patiënt en voor follow-up 
en evaluatie van deze therapie. De afgelopen jaren is er eveneens een duidelijke uitbreiding 
qua mogelijkheden en belangstelling voor het afbeelden van infectieziekten, het deel binnen 
de nucleaire geneeskunde waarover dit proefschrift gaat en waarin ik mijn expertise de 
afgelopen jaren heb uitgebreid.
INFECTIE EN ONTSTEKING
Infectie en ontsteking worden vaak door elkaar gehaald, maar zijn twee verschillende 
processen, die echter wel gelijktijdig kunnen voorkomen. Een infectie wordt veroorzaakt 
door een micro-organisme, het pathogeen, dat het lichaam van een levend wezen is 
binnengedrongen en daar schade aanricht. Een pathogeen is bijvoorbeeld een bacterie, 
een virus, een schimmel of een parasiet. Een ontsteking is een reactie van het lichaam op 
beschadiging van weefsels of op prikkels van buiten. Dit kan dus zijn als gevolg van een 







het lichaam. Een ontsteking, ook wel inflammatie genoemd, heeft als doel het verwijderen 
van het schadelijke pathogeen en het herstellen van schade. Een infectie heeft vaak een 
inflammatie als gevolg. Maar lang niet alle infecties gaan gepaard met inflammatie en lang 
niet alle ontstekingen worden veroorzaakt door een infectie. Zowel infectie als inflammatie 
kunnen locaal (gelokaliseerd in één orgaan) of systemisch (meerdere organen verspreid in 
het lichaam) aanwezig zijn.
In de kliniek is het uitermate belangrijk om onderscheid te kunnen maken tussen een infectie 
en inflammatie. De behandeling kan immers verschillen. De clinicus wil graag van de nucleair 
geneeskundige weten of er een infectie of een inflammatie is, waar die zich bevindt en 
hoe groot die is, of er meer infectieuze of inflammatoire haarden zijn, en of de therapie 
gecontinueerd (is er nog steeds een infectie?) of gestopt (is de infectie weg?) kan worden.
Nucleaire geneeskunde speelt een voorname rol in het bepalen of er een infectie of een 
inflammatie is en hoe uitgebreid die is. Veel tracers zijn beschikbaar die aangrijpen op 
verschillende cellen of receptoren die betrokken zijn bij de ontwikkeling van een infectie of 
ontsteking. Kennis en begrip van het ontstaan van een inflammatoire ziekte zijn de laatste 
jaren steeds groter geworden. Hierdoor zijn ook weer andere tracers ontwikkeld, die gebruikt 
kunnen worden om de vragen van de clinicus te beantwoorden.
DIT PROEFSCHRIFT
Dit proefschrift tracht meer inzicht te verschaffen wat de beste manier is om nucleair 
geneeskundige diagnostische technieken te gebruiken in infectieuze en inflammatoire 
ziekten. Het vergelijkt nucleaire technieken met radiologische technieken en evalueert de 
diagnostische mogelijkheden van specifiek ontwikkelde tracers voor specifieke ziekten. 
Daarnaast beschrijft het toekomstmogelijkheden en nieuwe strategieën, zoals hoe en wanneer 
onze technieken zouden moeten worden ingezet in de diagnostische en therapeutische route 
die een patiënt in zijn of haar ziekteproces ondergaat. Het proefschrift is onderverdeeld in 2 
delen. Na de introductie (hoofdstuk 1), worden in de hoofdstukken 2 tot en met 5 nucleair 
geneeskundige methoden bij infectieuze ziekten behandeld. De hoofdstukken 6 tot en met 
8 gaan dieper in op het gebruik van onze technieken bij inflammatoire ziekten. Hoofdstuk 9, 
het laatste hoofdstuk, legt de nadruk op vier belangrijke concepten die onderzocht dienen te 
worden in de toekomst.
Hoofdstuk 1, de introductie, geeft een overzicht van de pathofysiologie van een infectie, 
acute inflammatie en chronische inflammatie, de verschillende ziektebeelden die hierbij 
horen en de beschikbare tracers om deze ziekten af te beelden. De meest gebruikte tracers 
binnen de kliniek worden meer uitgebreid besproken: de gelabelde witte bloedcellen/
leukocyten (met 99mTc, 111In, en 18F-FDG), de gelabelde monoclonale antilichamen tegen 
granulocyten (Scintimun®, LeuTech®, and LeukoScan®), 18F-fluorodeoxyglucose (18F-FDG, 
gelabeld glucosederivaat), en het gelabelde interleukine-2. De werkingsmechanismen, 
de optimale scan uitvoeringen (acquisities), criteria voor een goede interpretatie van de 
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deze tracers. Vervolgens worden de spaarzame beschikbare richtlijnen voor het afbeelden van 
infectieuze en inflammatoire ziekten beschreven.
Al jarenlang wordt de leukocytenscan beschouwd als de beste nucleair geneeskundige 
techniek om infecties in het skelet (met uitzondering van spondylodiscitis) of in de weke 
delen af te beelden. De diagnostische accuraatheid verschilt echter in literatuurstudies, als 
gevolg van variaties in labelling procedures, verschillen in scan acquisities en verschillen in de 
interpretatie van scans. Richtlijnen voor de labelling van de leukocyten, voor kwaliteitscontrole 
en voor veiligheidsvoorschriften rondom de labelling zijn beschikbaar, maar richtlijnen die de 
correcte scan acquisitie en interpretatie criteria beschrijven bestaan tot op heden niet. Dit is 
de reden dat wij besloten om verschillende scan acquisities en verschillende interpretatie 
methoden met elkaar te vergelijken en te bepalen welke methode heeft geleid tot de 
beste diagnostische accuraatheid. Het belangrijkste doel dat we nastreefden was om een 
duidelijk raamwerk te verschaffen om uiteindelijk tot consensus te komen binnen de nucleair 
geneeskundige gemeenschap hoe de scan acquisitie en scan interpretatie correct uitgevoerd 
dienen te worden. Deze consensus zou moeten leiden tot duidelijke richtlijnen waardoor 
studies uitgevoerd in verschillende centra eenduidig zijn en goed met elkaar vergeleken 
kunnen worden.
 
In hoofdstuk 2 onderzochten we retrospectief 297 leukocytenscans die uitgevoerd werden 
in het Universitair Medisch Centrum Groningen tussen 2009 en 2012. Bij alle patiënten 
werd gekeken naar beschikbare infectieparameters in het bloed en naar medicatiegebruik 
gedurende de uitvoering van de scans. De uiteindelijke diagnose of er wel of niet een infectie 
was, werd gebaseerd op uitslagen van pathologie en microbiologie, of door klinische follow-
up voor ten minste 6 maanden. Twee verschillende acquisitie protocollen, beide met scan 
acquisitie op 2 verschillende tijdstippen (na 3-4 uur en na 20-24 uur), maar met verschillende 
scan acquisitie parameters bij de scan na 20-24 uur werden met elkaar vergeleken. Bij de 
fixed-time acquisitie werden de late scans verkregen met een standaard acquisitie tijd van 
10 minuten (bij 80 patiënten); bij de time decay-corrected acquisitie werden de late scans 
verkregen met een acquisitie tijd die gecorrigeerd werd voor het radioactief verval (bij 217 
patiënten). De time decay-corrected acquisitie maakt het mogelijk de verkregen beelden te 
bekijken met hetzelfde aantal counts en dezelfde intensiteitsschaal, waardoor de interpretatie 
niet meer afhankelijk is van hoe hoog de intensiteit gezet wordt door degene die de beelden 
moet interpreteren. Tevens werden er 5 interpretatie mogelijkheden met elkaar vergeleken: 
1 visuele en 4 semikwantitatieve met 4 verschillende gebieden als achtergrondopname ter 
vergelijking. Bij de visuele analyse werd een scan positief beschouwd indien er toename 
van stapeling of toename in grootte van de stapeling was gedurende de tijd. Bij de 
semikwantitatieve analyse werd een scan positief beschouwd indien de ratio tussen het 
infectiefocus en het achtergrondgebied toenam in de tijd.
De beste acquisitie methode was de time decay-corrected acquisitie met een diagnostische 
accuraatheid van 94.5% (tegenover 82.5% bij de fixed-time acquisitie). Visuele analyse van 
de scans bleek de beste interpretatie methode met een diagnostische accuraatheid van 91.9% 
bij alle patiënten gezamenlijk. Echter, wanneer bij visuele analyse de scan niet duidelijk te 







om tot een uiteindelijke conclusie te komen of er wel of niet sprake was van een infectie. Als 
beste achtergrondgebied werd bij bijna alle infectiegroepen de contralaterale zijde gevonden. 
Alleen bij de groepen osteomyelitis en mogelijk geïnfecteerd osteosynthesemateriaal kwam 
het contralaterale beenmerg als beste referentiegebied naar voren. Er waren geen statistische 
verschillen tussen het resultaat van de scans en infectieparameters in het bloed en tussen 
patiënten met of zonder medicatiegebruik ten tijde van de scan.
Naar aanleiding van deze gevonden resultaten werd een diagnostische strategie voorgesteld 
voor het correct uitvoeren en interpreteren van de leukocytenscan bij infecties in het skelet 
en in de weke delen. De scan acquisitie dient te worden uitgevoerd op 2 tijdstippen na de 
reïnjectie (na 3-4 uur en na 20-24 uur) waarbij de acquisitietijden van de scans gecorrigeerd 
moeten worden voor het radioactief verval. Visuele analyse van de scans is bij de meeste 
patiënten genoeg en leidt tot een hoge diagnostische accuraatheid. Indien de interpretatie 
van de scan bij visuele analyse niet conclusief is, verhoogt semikwantitatieve analyse de 
diagnostische accuraatheid. Uit ons onderzoek is tevens gebleken dat het niet noodzakelijk is 
dat medicijnen tijdens de scan gestopt worden.
Het bereiken van consensus over hoe de leukocytenscans correct uitgevoerd en beoordeeld 
dienen te worden was ook het doel van een volgende studie, die werd uitgevoerd in 3 centra: 
het Universitair Medisch Centrum Groningen, de University of Pisa Medical School en de 
Sapienza University in Rome. Dit multicenter onderzoek wordt beschreven in hoofdstuk 3. 
In totaal werden 235 patiënten met verdenking op osteomyelitis, geïnfecteerde prothese en 
weke delen infectie geanalyseerd. In 105 patiënten werd gebruikt gemaakt van de fixed-time 
acquisitie en in 130 patiënten van de time decay-corrected acquisitie. In sommige gevallen 
werd de SPECT-CT gebruikt voor exacte localisatie van het verdachte geïnfecteerde gebied. De 
interpretatie van de scans met behulp van de visuele analyse gaf hetzelfde resultaat als bij de 
vorige studie. Bij de semikwantitatieve analyse werd als referentiegebied een gebied zonder 
verhoogde opname genomen (contralateraal, ipsilateraal, beenmerg) waarbij toenemende 
opname ratio’s geclassificeerd werden in groepen met verschillende afkapwaarden.
Bij patiënten met verdenking op een osteomyelitis of een geïnfecteerde prothese werden 
ook in deze studie betere resultaten gevonden bij een time decay-corrected acquisitie. Het 
verschil tussen beide acquisitiemethoden was echter wel minder groot dan bij de studie 
die beschreven is in het vorige hoofdstuk. De sensitiviteit, diagnostische accuraatheid en 
positief voorspellende waarde waren hoger bij de time decay-corrected acquisitie. Bij de 
semikwantitatieve analyse werd de beste sensitiviteit en diagnostische accuraatheid 
gevonden indien als afkapwaarde elk percentage toename in ratio in de tijd werd genomen. 
De overeenkomst tussen de verschillende beoordelaars was hoger bij de time decay-corrected 
acquisitie, wat ook te verwachten was: de beoordeling van de scan is immers niet meer 
afhankelijk van hoe de intensiteit wordt ingesteld door degene die de scan analyseert.
Bij patiënten met een weke delen infectie was er geen duidelijk voordeel van de time decay-
corrected acquisitie. De oorzaak hiervan is dat er mogelijk een verschil is in de migratie van de 
leukocyten tussen infecties in het skelet en in de weke delen. Verder was ook de groep met 
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heeft geleid tot een ander gedrag van de leukocyten. Als gevolg hiervan zal nog wel bepaald 
dienen te worden of deze populatie andere interpretatiecriteria behoeft.
Wat zeker duidelijk is geworden uit beide studies is dat er op 2 tijdstippen gescand moet 
worden, het liefst 3-4 uur en 20-24 uur na reïnjectie, en dat de acquisitietijden gecorrigeerd 
dienen te worden voor het radioactief verval van het gebruikte radionuclide. Met deze methode 
wordt vermeden dat de schaling van de intensiteit en daardoor de uitslag afhankelijk is van 
degene die de scans bekijkt, iets wat zeker het geval is bij de fixed-time acquisitie. Iedere 
toename van radioactiviteit gedurende de tijd kan beschouwd worden als een positieve 
uitslag voor een infectie. SPECT/CT kan gebruikt worden voor exacte localisatie en uitbreiding 
van de infectie en wordt zeker aanbevolen in indicaties waarbij de anatomie van groot belang 
is (endocarditis, geïnfecteerde vaatprothese en de geïnfecteerde diabetische voet).
Binnen de nucleair geneeskundige gemeenschap is men het er nog steeds niet over eens wat 
nu de beste techniek is om infecties in de diabetische voet aan te tonen. Jarenlang gold de 
leukocytenscan als de standaard nucleair geneeskundige techniek, maar in recente publicaties 
is ook duidelijk geworden dat 18F-FDG-PET/CT een goede modaliteit is met hoge accuraatheid, 
zeker in combinatie met de MRI. In hoofdstuk 4 worden beide modaliteiten met elkaar 
vergeleken in 13 patiënten met een klinische verdenking op infecties in een diabetische 
voet. Tevens werd er gekeken of sequentiële 18F-FDG-PET opnamen (met acquisitietijden 10 
minuten, 1 uur en 2 uur na de toediening) zinvol waren en leidden tot objectieve criteria om 
de scans te interpreteren. Deze 18F-FDG-PET data werden vergeleken met de leukocytenscan 
met acquisitietijden 30 minuten, 3 uur en 20 uur na de reïnjectie.
Bij 7 patiënten werd, na biopsie of kweken, een osteomyelitis gevonden en bij 2 patiënten een 
weke delen infectie zonder betrokkenheid van het skelet. Een ratio > 2.0 tussen infectiefocus 
en de achtergrond op de late opname en toename in de tijd leidde bij de leukocytenscan 
tot de beste diagnostische accuraatheid (92%). De beste resultaten bij 18F-FDG-PET werden 
bereikt bij een maximaal gestandaardiseerde opnamewaarde (SUVmax) >2.0 bij de opnamen 
na 1 en 2 uur met toename in de tijd. Dit leidde echter tot een diagnostische accuraatheid 
van slechts 54%. Een acquisitie 10 minuten na de toediening van 18F-FDG bleek vanwege de 
overmatige bloodpool activiteit niet zinvol. 18F-FDG-PET na 1 uur, gecombineerd met CT, was 
de beste methode om te differentiëren tussen osteomyelitis en weke delen infectie. Met 
gebruik van deze criteria was de consensus tussen 3 verschillende nucleair geneeskundigen 
uitstekend.
Gebaseerd op deze resultaten is er naar onze mening geen rol voor het gebruik van 18F-FDG-
PET/CT bij patiënten met verdenking op een geïnfecteerde diabetische voet, ook niet met 
scanacquisitie op verschillende tijdstippen. De leukocytenscan blijft bij deze patiëntengroep 
de beste nucleair geneeskundige scantechniek met een hoge diagnostische accuraatheid.
Eén van de meest ernstige complicaties na plaatsing van een vaatprothese is een infectie. 
De incidentie hiervan is laag, maar als een vaatprothese geïnfecteerd raakt kan dit leiden 
tot verlies van een ledemaat of zelfs tot sterfte in meer dan 50% van de patiënten. De 







is laag. In hoofdstuk 5 wordt de diagnostische accuraatheid bekeken van 18F-FDG-PET, CT, en 
gefuseerde 18F-FDG-PET/CT bij patiënten met verdenking op een geïnfecteerde vaatprothese. 
Tevens wordt bekeken hoe goed de scaninterpretatie tussen verschillende beoordelaars 
overeenkomt.
CT angiografie en 18F-FDG-PET werden uitgevoerd in 25 patiënten met een verdenking op 
een geïnfecteerde vaatprothese. De CT scans werden beoordeeld door 2 radiologen met 
gebruik van een scoringssysteem gebaseerd op eerdere literatuurstudies. De 18F-FDG-PET 
scans werden beoordeeld door 2 nucleair geneeskundigen, die gebruik maakten van een 
visueel scoringssysteem en van het berekenen van SUVmax en ratio’s tussen het infectiefocus 
en de achtergrond (v. cava inferior). De gefuseerde 18F-FDG-PET/CT data werden vervolgens 
nogmaals beoordeeld door 1 radioloog en 1 nucleair geneeskundige.
De berekende sensitiviteit en specificiteit van de 18F-FDG-PET was 93% en 70% en dit was 
duidelijk hoger dan bij de CT (56% en 57%). De overeenkomst tussen de verschillende 
beoordelaars was goed (kappa-waarde 0.63) tussen de radiologen en uitstekend tussen de 
nucleair geneeskundigen (kappa-waarde 1.00). Met de gefuseerde 18F-FDG-PET/CT werd 
er een duidelijk verschil gevonden tussen sensitiviteit en specificiteit wanneer de beelden 
bekeken werden door een nucleair geneeskundige (93% en 70%) of door een radioloog 
(73% en 60%). Wel was er in de overgrote meerderheid van de gevallen (21 van de 25) 
een overeenkomstige uitslag door de radioloog en de nucleair geneeskundige. Er werd geen 
verband gevonden tussen de scanresultaten en het tijdsinterval tussen de plaatsing van de 
prothese en de scan. 
Deze studie laat zien dat bij vaatprothese infecties de accuraatheid van de 18F-FDG-PET duidelijk 
hoger is dan van de CT. Na fusie van beide modaliteiten was er een goede overeenkomst 
tussen de verschillende beoordelaars. Gefuseerde 18F-FDG-PET/CT is de eerste diagnostische 
modaliteit van keuze bij patiënten met een verdenking op een geïnfecteerde vaatprothese.
Het tweede deel van dit proefschrift (nucleair geneeskundige technieken in inflammatoire 
ziekten) start met een korte beschrijving van de mogelijkheden die de nucleaire geneeskunde 
biedt voor het diagnosticeren van de atherosclerotische plaque. Recente medisch-
wetenschappelijke ontwikkelingen hebben aangetoond dat inflammatie een belangrijke 
rol speelt in alle fases van atherosclerose (in het ontstaan van atherosclerose, in de groei 
van de plaque, in de ontwikkeling van vulnerabiliteit van de plaque en in het ontstaan 
van thrombotische complicaties). Intermezzo 1 beschrijft de belangrijkste moleculaire 
gebeurtenissen in atherosclerose en geeft een overzicht van de beschikbare radiofarmaca 
waarmee verschillende targets die een rol spelen bij de ontwikkeling van atherosclerose 
kunnen worden afgebeeld: de componenten waaruit de atherosclerose bestaat, inflammatie, 
thrombosis en apoptosis. De tracers 99mTc-interleukine-2 en 18F-FDG worden meer uitvoerig 
beschreven.
De belangrijke rol die inflammatoire cellen spelen bij de transformatie van een stabiele naar een 
vulnerabele plaque vormt de basis voor het onderzoek dat beschreven wordt in hoofdstuk 6. 
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cellen) in de vulnerabele plaque, mag verwacht worden dat de interleukine-2 receptor (die 
immers verhoogd tot expressie komt bij geactiveerde T lymfocyten) een attractieve biomarker 
is om een vulnerabele plaque te detecteren. Het afbeelden van deze receptor met behulp van 
radioactief gelabeld interleukine-2 (IL2) zou daardoor bruikbare informatie kunnen opleveren 
voor de selectie van een geïnfiltreerde vulnerabele plaque met een verhoogd risico op een 
ruptuur met allerlei complicaties voor de patiënt als gevolg. Het doel van deze studie is om 
te bewijzen in vivo en ex vivo dat 99mTc-hynic-IL2 in staat is om T lymfocyten te detecteren in 
vulnerabele atherosclerotische plaques in de a. carotis.
Bij de in vivo studie werd een 99mTc-hynic-IL2 scintigrafie verricht bij 10 symptomatische 
patiënten die gepland werden voor een carotis endarterectomie (CEA). De planaire en 
SPECT/CT beelden werden visueel en semikwantitatief geanalyseerd. Na de CEA werd 
immunomorfologie en immunofenotypering bepaald op de plaques. 
Op de planaire beelden werd bij 7 van de 10 patiënten duidelijk 99mTc-hynic-IL2 opname 
gezien. Met behulp van de SPECT/CT beelden was dit bij 8 van de 10 patiënten het geval. Een 
significante correlatie werd aangetoond tussen de traceropname en het aantal CD25 positieve 
lymfocyten en het totale aantal CD25 positieve cellen. De opname in de 10 symptomatische 
plaques was significant hoger dan in 8 contralaterale asymptomatische plaques.
Bij de ex vivo studie werden nog eens 4 patiënten geïncludeerd. Autoradiografie en microSPECT 
werd uitgevoerd na in vitro incubatie van de operatief verwijderde plaques met 99mTc-hynic-
IL2. MicroSPECT toonde een duidelijke opname van de tracer in de wanden van de plaque, 
maar niet in de lipide kern. Autoradiografie toonde aan dat 99mTc-hynic-IL2 alleen significant 
opgenomen werd in CD3 positieve lymfocyten en niet in macrofagen, gladde spiercellen of 
CD3 negatieve lymfocyten. 
De hierboven vermelde resultaten bevestigen dat 99mTc-hynic-IL2 een specifieke tracer is voor 
het zichtbaar maken van de infiltratie van T lymfocyten in de plaque en daarmee voor het 
aantonen van plaque instabiliteit. Wel moet er nog een aantal problemen opgelost worden. 
Er dient een drempelwaarde bepaald te worden waarboven de opname van 99mTc-hynic-IL2 
in de plaque met zekerheid als positief beschouwd mag worden. Bovendien verlaagt de lage 
spatiële resolutie van de gammacamera, zeker in kleine gebieden zoals de plaques in de a. 
carotis, de diagnostische waarde van deze techniek. Kortgeleden is er een PET radiofarmacon 
ontwikkeld die mogelijk geactiveerde lymfocyten kan afbeelden. Dit radiofarmacon, 18F-FB-
IL2, is misschien in staat deze beperkingen te overwinnen. Voor de toekomst verwachten we 
veel van deze tracer in het afbeelden van die ziektebeelden waarbij de lymfocytaire infiltratie 
een rol speelt. 
Amyloidose is de verzamelnaam voor een groep van ziekten die gekarakteriseerd worden door 
abnormale stapeling van eiwitten (amyloid) in weefsels en organen. Deze amyloidstapeling 
kan locaal zijn (geproduceerd in en beperkt tot een enkel orgaan of weefsel in het lichaam) 
of systemisch (stapeling in meerdere organen en weefsels in het lichaam). Amyloidstapeling 
in organen en weefsels veroorzaakt groei/vergroting van het aangedane orgaan en leidt 







verschillen tussen locale en systemische amyloidose, de belangrijkste systemische types, de 
klinische evaluatie van een patiënt met (verdenking op) amyloidose en geeft een overzicht 
van de nucleair geneeskundige mogelijkheden die beschikbaar zijn: 123I-Serum Amyloid P 
component (123I-SAP)-SPECT/CT en 18F-FDG-PET/CT. Hierna wordt in dit proefschrift de nadruk 
gelegd op amyloidstapeling in het hart. Cardiale amyloidose kan leiden tot diastolische 
dysfunctie, hartfalen, ritmestoornissen, electromechanische dysfunctie, thrombo-embolieën, 
en zelfs uiteindelijk tot sterfte. Een overzicht wordt gegeven van de nucleair geneeskundigee 
mogelijkheden om cardiale amyloidose af te beelden.
In patiënten met (verdenking op) amyloidose is het belangrijk om vast te stellen of de 
amyloidstapeling locaal of systemisch is. De prognose en behandeling verschillen immers 
tussen beide vormen. Locale amyloidose wordt gekarakteriseerd door de locale aanwezigheid 
van clonale plasmacellen en reuscellen. Waarschijnlijk zijn deze reuscellen betrokken bij de 
productie van amyloid. Omdat 18F-FDG wordt opgenomen in onder andere reuscellen, hebben 
we bekeken of 18F-FDG-PET/CT kon helpen in de differentiatie tussen locale en systemische 
amyloidose. Hoofdstuk 7 beschrijft de 18F-FDG-PET/CT bevindingen bij 21 patiënten met 
histologisch bewezen systemische of locale amyloidose. Bij 20 patiënten werd ook een 
123I-SAP scintigrafie verricht.
Zoals verwacht lieten 10 van de 11 patiënten met locale amyloidose duidelijk verhoogde 
opname van 18F-FDG zien op de locatie van de amyloidstapeling. De 11e patiënt liet slechts 
gering verhoogde opname zien. Bij geen van de 10 patiënten met systemische amyloidose 
was er verhoogde 18F-FDG opname in de aangedane organen met amyloid. 123I-SAP 
scintigrafie was niet in staat om te differentiëren. Bij 10 patiënten met locale amyloidose 
was er slechts opname bij 3 patiënten op de locatie van het locale amyloid. Bij 9 van de 10 
patiënten met systemische amyloidose was er opname van 123I-SAP in de betrokken organen, 
overeenkomend met bekende resultaten uit de literatuur.
Bij 8 van de 11 patiënten met locale amyloidose liet de biopsie aanwezigheid van reuscellen 
zien. Bij geen van de patiënten met systemische amyloidose werden reuscellen aangetroffen. 
Deze afwezigheid van reuscellen en inflammatie is een duidelijk kenmerk van systemische 
amyloidose. De ophoping van SAP camoufleert waarschijnlijk de neerslag van amyloid 
waardoor deze amyloidstapelingen niet herkend en opgeruimd worden door de reuscellen.
Geconcludeerd mag worden dat 18F-FDG-PET/CT kan differentiëren tussen systemische (geen 
18F-FDG opname) en locale (wel 18F-FDG opname) amyloidose. In de toekomst kan deze 
bevinding mogelijk ook een rol spelen bij de evaluatie van therapie en de follow-up.
Bij patiënten met een specifiek type systemische amyloidose, de ATTR amyloidose, 
wordt hartbetrokkenheid vaak gezien. Dit wordt gekarakteriseerd door een restrictieve 
cardiomyopathie als gevolg van amyloidstapeling in zowel myocardweefsel als in het 
atrioventriculaire geleidingssysteem. ATTR amyloidose kan erfelijk zijn (mutatie van het 
precursor eiwit transthyretine) of ontstaan op hoge leeftijd als het normale transthyretine 
zich “wild” gaat gedragen. Het diagnosticeren van ATTR amyloidose en typering hiervan is 
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af te komen van het gemuteerde eiwit. Echocardiografie, ECG en MRI zijn niet in staat om 
te differentiëren tussen amyloid cardiomyopathie en andere vormen van cardiomyopathie. 
Deze technieken zijn ook niet in staat om het type amyloid vast te stellen en hebben een 
beperkte diagnostische waarde in een vroeg stadium van de ziekte. Kortgeleden bleek 
de skeletscintigrafie met radioactief gelabelde difosfonaten een nieuwe diagnostische 
mogelijkheid te zijn om het type amyloid vast te stellen. Hoge opname in het hart werd 
gevonden bij het ATTR type, terwijl er geen of zeer lage opname werd gevonden in andere 
vormen van amyloidose. 
In hoofdstuk 8 werd de toegevoegde waarde van de botscan voor cardiale betrokkenheid 
van amyloid verder onderzocht bij 41 patiënten met bewezen ATTR amyloidose in 
verschillende fasen van de ziekte (11 carriers van de mutatie, 19 ATTR patiënten zonder 
tekenen van cardiomyopathie en 11 ATTR patiënten met echocardiografisch aanwijzingen voor 
cardiomyopathie). De cardiale opname op de botscan werd vergeleken met echocardiografische 
bevindingen, ECG karakteristieken en cardiale biomarkers in het bloed (NT-proBNP en 
troponine T). Verder werden ook verschillende scintigrafische afbeeldingstechnieken met 
elkaar vergeleken.  
Alle patiënten met ATTR en cardiomyopathie lieten hoge cardiale opname zien op de botscan. 
Echter, ook 8 van de 19 patiënten zonder cardiomyopathie lieten verhoogde opname zien. 
Waarschijnlijk zijn deze patiënten ook cardiomyopathie aan het ontwikkelen, maar was dit 
nog niet zichtbaar op de echocardiografie. Goede correlaties werden gevonden tussen de 
cardiale opname op planaire beelden met troponine T en met de linkerventrikelmassa. Wat 
betreft de scintigrafische techniek bleek visuele analyse en berekening van de hart-schedel 
ratio op de planaire opnamen het best te correleren met echocardiografie en biomarkers. Het 
uitvoeren van SPECT-CT bleek geen toegevoegde waarde op te leveren.
Er werd verder ook gekeken naar verschillen tussen patiënten met het meest voorkomende 
mutatie type (Val30Met) en alle andere genmutaties (non-Val30Met). Patiënten met een 
non-Val30Met mutatie hadden hogere cardiale opname dan patiënten met een Val30Met 
mutatie. Dit komt overeen met literatuurgegevens. Patiënten met een non-Val30Met mutatie 
hebben in het algemeen een slechtere prognose.
De resultaten van deze studie laten zien dat de botscan cardiale betrokkenheid bij patiënten 
met ATTR amyloidose kan detecteren. Skeletscintigrafie met 99mTc-HDP is in staat om cardiale 
betrokkenheid aan te tonen voordat er echocardiografisch bewijs wordt gevonden. De cardiale 
opname op de botscan correleert goed met de mate van hartbetrokkenheid op basis van 
echocardiografie, ECG en cardiale biomarkers.
Het laatste hoofdstuk van dit proefschrift, hoofdstuk 9, richt zich op vier belangrijke 
toekomstmogelijkheden die de nucleaire geneeskunde biedt voor het afbeelden van 
infectieziekten en inflammatoire ziekten. 
Het eerste concept dat beschreven wordt is de belangrijke rol die 18F-FDG-PET/CT kan gaan 







ziektebeelden vasculitis, sarcoidosis en echinococcosis is er al voldoende bewijs aanwezig 
dat 18F-FDG-PET/CT klinisch waardevol is voor therapie evaluatie. Voor andere ziektebeelden 
(osteomyelitis, rheumatoide arthritis, inflammatoire darmziekten, autoimmuun pancreatitis, 
etc.) is hier echter nog niet voldoende bewijsvoering voor. Dit zullen we de komende 
jaren echt moeten zien te bereiken. Andere indicaties die, zowel voor diagnose(stelling) 
als voor evaluatie van therapie, onderzocht moeten worden in de nabije toekomst zijn 
schimmelinfecties en inflammatoire ziekten bij kinderen zoals polymyositis, dermatomyositis 
en sclerodermie. Vooral voor de evaluatie van de behandeling bij schimmelinfecties voorzie 
ik een grote toekomstige rol voor de 18F-FDG-PET/CT.
Ten tweede moeten we grote nadruk leggen op het afbeelden van specifieke targets voor 
specifieke ziekten en daaraan gekoppeld de gepersonaliseerde behandeling, d.w.z. de juiste 
behandeling voor de individuele patiënt. Dit wordt nu al toegepast in de oncologie, zoals bij 
patiënten met een mammacarcinoom, maar ook voor infectieziekten moet bekeken worden 
of dit kan worden toegepast. Nucleaire geneeskunde biedt de unieke mogelijkheid om die 
cellen af te beelden die betrokken zijn bij het infectieuze of inflammatoire proces. We zijn in 
staat om patiënten te selecteren voor een specifieke therapie, te voorspellen hoe patiënten 
op deze therapie zullen reageren, en de respons op de ingestelde therapie te volgen. Al deze 
informatie komt steeds uitgebreider beschikbaar en biedt mogelijkheden voor de clinici om 
therapie aan te passen aan de individuele patiënt en om de effectiviteit van de therapie te 
volgen.
Als derde dienen we de nieuwe mogelijkheden die geboden worden door nieuwe hybride 
camerasystemen goed te onderzoeken voor hun belang bij infecties en inflammatoire ziekten. 
Vooral de simultane PET/MRI biedt mogelijkheden op de korte termijn. De combinatie van PET 
radiofarmaca en PET/MRI zou de sensitiviteit en specificiteit voor de diagnosestelling en voor 
de evaluatie van therapie (significant) kunnen verbeteren. Klinische toepassingsgebieden 
van de PET/MRI zijn de insuline afhankelijke diabetes mellitus, inflammatoire darmziekten 
en de diabetische voet. Andere mogelijkheden die de PET/MRI biedt is het gebruik ervan 
bij inflammatoire ziekten in kinderen. Bij kinderen is er een sterke voorkeur voor PET/MRI 
boven de PET/CT, aangezien kinderen van de MRI component geen straling ontvangen, in 
tegenstelling tot de CT component. Dit kan zeker van belang zijn indien jonge kinderen 
meerdere malen gescand dienen te worden.
Het laatste belangrijke concept dat beschreven wordt, betreft de samenwerking met 
andere vakgebieden en verenigingen voor de ontwikkeling van gezamenlijk diagnostische 
en therapeutische stroomdiagrammen. De nucleair geneeskundige gemeenschap moet 
duidelijk maken wat we kunnen bieden op welk tijdstip van de ziekte. Samenwerkingen 
met andere verenigingen moeten opgestart worden en richtlijnen moeten ontwikkeld en 
geïntroduceerd worden voor meerdere infectieuze en inflammatoire ziekten, zoals bij infecties 
van gewrichtsprothesen, inflammatoire darmziekten, de diabetische voet, osteomyelitis, 
vaatprothese infecties, endocarditis, etc. Dit is een enorme taak die voor ons ligt en grote 
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Daar zijn we dan … het dankwoord. Het voor velen favoriete deel van het proefschrift, maar 
voor mij het lastigste. Je zult maar iemand vergeten….
Met veel plezier heb ik aan dit promotieonderzoek gewerkt. Ik voel me bevoorrecht dat ik 
deel uitmaak van een zeer vooruitstrevende afdeling met ambitieuze, gedreven en gezellige 
collega’s, waarvan velen ook buiten het werk echte vrienden geworden zijn. Een afdeling met 
vele samenwerkingsprojecten binnen het ziekenhuis en ook ver daarbuiten. Hieraan heb ik 
uiteindelijk dit boekje te danken. Dank jullie allen hiervoor! 
My first promoter, Prof. dr. A. Signore. 
Dear Alberto, what a great opportunity you provided me when you involved me in the world 
of infection and inflammation. You explained me about all the possibilities in this area and 
that a big future was to be expected. I learned a lot working with you scientifically and 
professionally, you are really a true mentor for me. And what a large number of papers we 
published together. Thank you also for helping me to become a member of the EANM Infection 
and Inflammation Committee. This is really a good committee to be part of with enthusiastic 
and devoted people. I will never forget how you’re always taking care of me and be there for 
me during my visits to Rome (especially when I couldn’t go home during the volcano burst…). 
You also learned me perseverance while looking together at plaque histology for 2 days 
thereby creating the possibility to continue with the paper! Alberto, thanks for your guidance, 
positivity and friendship. I am sure we will continue working together for a long time.
Mijn tweede promotor en mijn afdelingshoofd, Prof. dr. R.A.J.O. Dierckx. 
Beste Rudi, wat ben ik nog steeds blij dat je me (op advies van Prof. dr. P.P. van Rijk, waarvoor 
dank Peter) tijdens de laatste maanden van mijn opleiding belde om eens een kijkje in 
het hoge noorden te komen nemen. Het bleek een schot in de roos te zijn. Alles wat je 
toen beloofde heb je waargemaakt zoals je alles weet te bereiken wat je in gedachten 
hebt. Natuurlijk mijn dank dat je me in staat stelde het gebied van de infectieziekten en 
de inflammatie te ontdekken, te onderzoeken en verder in kaart te brengen. Volgens mij 
zijn we daarin geslaagd en liggen er nog vele mooie mogelijkheden op dit gebied voor ons 
in de toekomst. En ook al schiet de gezamenlijke cappuccino er door je drukke bezigheden 
vaak bij in de laatste tijd, we vinden vast ook in de toekomst genoeg tijd om belangrijke 
afdelingszaken samen door te nemen. En als Philip een keer raad nodig heeft van (de véél 
oudere en dus wijzere) Mats weet je ons te vinden.
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En dan mijn drie copromotoren. Alle drie totaal verschillend, maar alle drie met een zeer 
wezenlijke bijdrage aan dit promotieboekje.
Dr. E.F.J. de Vries. 
Beste Erik, bij jou kan iedereen altijd terecht en ik dus ook. Fijn dat je immer bereid bent om te 
luisteren en te helpen. Wanneer het onderzoek eens een keertje vastliep, de tracerproductie 
mislukte of de patiënteninclusie weer eens te traag naar mijn zin verliep, verzon je altijd weer 
een oplossing. Je kritische en wetenschappelijke blik bracht de manuscripten telkens weer 
op een hoger niveau. Altijd op papier, met een hoop correcties (al verzekerde je me dat het 
bij anderen nog veel erger was) en binnen een paar dagen. Dank voor de samenwerking bij 
dit proefschrift. Ik reken op continuering van de samenwerking in de toekomst gezien onze 
wederzijdse interesses op wetenschappelijk gebied. Fijn ook dat ik jouw werk in het EANM 
Comité mag voorzetten. 
Dr. B.P.C. Hazenberg. 
Beste Bouke, wat ben je toch een bijzondere man. De patiënten zijn altijd zo positief over je. 
Ik sta er nog steeds versteld van dat als je een scan ziet je precies weet welke patiënt het 
betreft, de gehele voorgeschiedenis uit je hoofd kent, de hoogte van de labwaarden, zijn/
haar verjaardag, de namen van de kinderen, en nog veel meer wat van elke patiënt een 
mens maakt. Voor mij was het geweldig leerzaam om met zo’n autoriteit op het gebied van 
amyloidose samen te werken. Ik zal ook nooit vergeten hoe je me geleerd hebt om ‘data te 
masseren’, reviewers tegemoet te komen en hoe je met een kam door een manuscript heen 
moet vlooien om het nog perfecter te maken.
Dr. R.H.J.A. Slart. 
Tja, Riemer... Over jou zou ik een heel promotieboek vol kunnen schrijven…Vanaf de allereerste 
dag dat ik op deze afdeling kwam werken, klikte het tussen ons. Je bent inmiddels een goede 
vriend geworden! Soms ben je onnavolgbaar wanneer je al je wetenschappelijke ideeën 
opdreunt en ik ken niemand die zo snel kan denken als jij. We hebben elkaar gevonden, 
op afdelingsgebied, op wetenschappelijk gebied, en op vriendschappelijk gebied. Hopelijk 
blijven we nog heel lang zo samenwerken. Riemer, dank voor je wetenschappelijke inbreng, je 
snelle reacties en je vriendschap. En voor de andere collega’s: dat dagelijkse kopje cappuccino 
(of 2) hebben we allebei nodig. Niet alleen voor de cafeïne, maar vooral om de dagelijkse 
persoonlijke zaken en afdelingsperikelen door te nemen. Bovendien ontstaat daar vaak weer 







De leden van de beoordelingscommissie. 
Prof. dr. M. Sathekge, Prof. dr. F. Jamar en Prof. dr. A.W. Friedrich. Dear Mike, dear François, 
dear Alexander, many thanks for your willingness to be members of the reading committee 
and share your expert opinions about this thesis with me.
Walter Noordzij en Ronald van Rheenen. 
Niet alleen paranimfen, maar ook directe stafcollega’s en goede vrienden. Dank voor jullie 
bereidheid mij bij te staan bij de verdediging van dit proefschrift en voor het regelen van 
een feestje. Fijn dat onze artsengroep met jullie twee kon worden uitgebreid. Het maakt 
het werken nog gezelliger en aangenamer. Hopelijk kunnen jullie op korte termijn ook zo’n 
boekje produceren! We zullen elkaar nog veel zien de komende jaren, niet alleen tijdens het 
werk, maar ook privé met al onze kids in dezelfde leeftijdsgroepen.
Alle co-auteurs. 
Al diegenen die een rol hebben gespeeld in de totstandkoming van de artikelen dank ik van 
harte voor de prettige samenwerking. Een kleine greep hieruit: de nucleaire geneeskundige 
afdelingen van Rome (Sapienza University) en Pisa (University of Pisa Medical School), de 
afdeling pathologie van Tor Vergata in Rome (thanks Elena!), en de afdelingen vaatchirurgie 
(dank Clark!), cardiologie (dank Maarten!) en reumatologie & klinische immunologie (dank 
Bouke!) van het UMCG.
Marie-josé de Ruyter.
Wat fijn dat ik een zus heb die mensen kent die zulke fantastische covers kunnen maken. Het 
heeft mijn verwachtingen overtroffen. Marie-josé, dank voor de prachtige vormgeving!
De afdeling Nucleaire Geneeskunde en Moleculaire Beeldvorming van het Universitair 
Medisch Centrum Groningen. 
Een lange titel voor een afdeling met een lange historie. Fijn om deel uit te maken van zo’n 
geweldige afdeling, die landelijk en wereldwijd bekend is, excellentie nastreeft en op vele 
gebieden een voorloper is. Maar we zijn met velen en ik hoop dat ik niemand vergeet…..
Eerst natuurlijk Sarita, want dat heb ik haar beloofd. Dankjewel voor al je geregel rondom 
mijn promotie en alle andere zaken die je voor me afhandelt. 
Annegrit (en daarvoor Annie) bedankt voor de financiële ondersteuning van de vele projecten 
waaraan we werken.
Een speciaal bedankje voor Gert en Hendrikus, die ondanks alle drukke GMP-bezigheden 
toch altijd bereid waren om weer naar IL2 te kijken…of weer een andere tracer in te plannen 
als ik daarom vroeg. En natuurlijk dank Michel (Koole) voor al je berekeningen die me verder 
hielpen. Verder uiteraard alle andere stafleden (Adrienne, Anne, Antoon, Aren, Fons, Jan, 
Janine, Johan, Marjolijn en Philip): bedankt voor de samenwerking, collegialiteit, discussie 
en gezelligheid. 
De medisch nucleair werkers: altijd bereid om een extra scan te verrichten, of om een 
programma om te gooien, of om mee te denken hoe een onderzoek het best te verrichten. 








van zo’n ‘ouwe’ gezellige rot in het vak als jij), Aafke, Anja, Annemieke, Eelco, Hedy, 
Johan, Jose, Leonie, Marijke, Remko, Sieneke, Yvonne (van der Eide) en Yvonne (van 
der Knaap).
De dames van de zorgadministratie (Erna, Rika, Klara, en natuurlijk ook nog – tijdje geleden – 
Ilse en Arja): dank voor het regelen van weer een scanplekje voor één van mijn onderzoeken. 
Jitze! Bedankt dat mijn hersenen nu in kwaliteit denken! Op naar de EFQM! 
Klaas-Willem: bedankt voor je hulp als ik weer eens problemen had met mijn computer of 
als het niet lukte om op mijn kamer de Tour de France te kijken.
Jurgen: veel heb ik niet met dierexperimenten, maar toch: dank voor de paar plaques die we 
beneden gescand hebben. 
Dank ook alle dames en heren van het lab. Wat moet onze afdeling zonder jullie? Geen 
tracers = geen afdeling. Dank Bram, Chantal, Esther, Hans Pol, Hilde, Hugo, Janet, Joost, 
Marianne, Marissa, Michèl, Petra, Rianne, Rolf en Vanathee.
Thanks to all PhD’s and postdocs connected currently and in the past to our department. Enjoy 
your time here, it’s a special department! Special thanks to Gaurav and Valentina. Our work 
is linked to each other and hopefully we can continue working together!
En dan natuurlijk alle AIOS (Silvia, Niels, Klaas-Pieter, Leo, Elise, Brian, Gilles, Eef, Sharon) 
met wie ik sinds ik in Groningen ben, heb samengewerkt. Velen al lang klaar met hun 
opleiding en inmiddels werkzaam op een mooie positie elders in het land. Anderen nog in 
hun opleiding met een prachtige toekomst in het vooruitzicht. Wat een mooi vak hebben wij! 
Laten wij er met z’n allen voor zorgen dat het ook in de toekomst een fantastisch vak blijft. 
Een excuus aan jullie is ook op z’n plaats, voor de momenten dat ik weer eens bezig was met 
het schrijven van één of ander artikel en wederom geen tijd had om uitgebreid de kliniek te 









Lieve mama, wat had je dit graag willen meemaken. Wat kan het leven hard zijn. Vier jaar 
geleden inmiddels al weer, wat gaat het snel. Het zal me mijn hele leven lang verdriet doen 
dat je mijn kinderen nooit hebt kunnen zien. Bedankt voor alles, je was een topmoeder.
Lieve papa, wat fijn dat jij dit nog wel kunt meemaken. Wat ben je sterk doorgegaan zonder 
mama. En wat zijn de kinderen gek op je. Blijf nog lang bij ons komen in Groningen! Dank voor 
alles wat je voor me gedaan hebt en nog steeds doet. Wat heb ik geluk met zulke ouders!
Lieve Anouk en Jurgen. Anouk, fijn dat ik je kan bedanken via dit boekje. Een betere grote 
zus kan ik me niet wensen. Jullie hebben me een fantastische neef en twee nichtjes bezorgd. 
Perle, Elard en Malin: wij zullen er altijd zijn voor jullie! Veel succes in jullie leven.
En dan natuurlijk mijn lieve Marieke. We leerden elkaar kennen op een studentenkamer in 
Nijmegen, lang geleden. Sindsdien zijn we onafscheidelijk. Een grote stap samen richting 
Groningen, maar wat hebben we het daar goed. Groningen heeft ons gegrepen. Getrouwd 
in het Groninger Museum in 2009, zo ingeburgerd waren we al na een jaar Groningen. Wat 
een topdag was dat. Voorlopig gaan we zeker niet meer weg; we hebben het veel te gezellig 
samen in het hoge noorden.
Inmiddels met z’n viertjes. Lieve Mats en Line, het is geweldig jullie vader te zijn en jullie te 
zien opgroeien. Ik geniet elke dag van jullie en probeer er zoveel mogelijk voor jullie te zijn. 















Adrianus (Andor) Waltherus Johannes Maria Glaudemans werd geboren in ’s-Hertogenbosch 
op 19 mei 1976. Na het behalen van het gymnasium bèta diploma aan het Jeroen Bosch 
College begon hij in 1993 met de studie Geneeskunde aan de Radboud Universiteit Nijmegen. 
In 1999 behaalde hij het artsexamen. 
De eerste 4 jaren als arts werkte Andor als ANIOS Algemene Heelkunde in het Viecuri Medisch 
Centrum te Venlo (2000-2001) en als ANIOS en AIOS Algemene Heelkunde in het Universitair 
Medisch Centrum St. Radboud in Nijmegen (2002-2004). Tijdens de jaren Algemene 
Heelkunde ontstond de liefde voor de beeldvorming en in 2004 koos hij voor de richting van 
de Nucleaire Geneeskunde. De opleiding Nucleaire Geneeskunde doorliep hij van 2004 tot 
2008 in het Universitair Medisch Centrum Utrecht onder leiding van Prof. dr. P.P. van Rijk en dr. 
H. van Isselt. Tijdens de opleiding liep hij een aantal maanden stage in het Meander Medisch 
Centrum Amersfoort en in De Gelderse Vallei in Ede. In februari 2008 rondde hij de opleiding 
tot nucleair geneeskundige af waarna hij verhuisde naar Groningen. 
Sinds februari 2008 is hij nucleair geneeskundige en staflid bij de afdeling Nucleaire 
Geneeskunde en Moleculaire Beeldvorming van het Universitair Medisch Centrum 
Groningen met als afdelingshoofd Prof. dr. R.A.J.O. Dierckx. Andors aandachtsgebied betreft 
infectie en inflammatie (dit proefschrift). Andere interessegebieden zijn: oncologische 
ziekten, hematologische ziekten, afbeelden van hormoonreceptoren (18F-FES en 18F-FDHT), 
sportgeneeskunde en radio-isotopentherapie. 
Sinds 2009 is Andor Glaudemans redactielid bij het Tijdschrift voor Nucleaire Geneeskunde en 
sinds 2012 lid van het EANM Comité voor Infectie en Inflammatie. Inmiddels heeft hij al vele 
publicaties in nationale en internationale vakbladen.
Andor trouwde in 2009 met Marieke Smit. Samen hebben ze twee kinderen: Mats (2010) en 
Line (2012).
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